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Abstract
Measurement of the cerebral metabolite y-aminobutyric acid (GABA) has been performed on
clinical MRI scanners using a variety of magnetic resonance spectroscopy (MRS)
techniques. MRS studies of GABA are difficult, especially at 1.5T due to low in-vivo
concentrations and overlapping of higher concentration metabolites. Unlike spectral editing
methods, two-dimensional (2D) MRS allows the simultaneous measurement of GABA and
other, more traditional metabolites. This work evaluates three implementations of 2D MRS
for both in-vitro and in-vivo GABA measurement on a clinical MRI scanner.
Existing spectroscopy sequences were used to develop a protocol for performing 2D J-
resolved MRS without a dedicated sequence. GABA was measured in-vitro at
concentrations approaching normal physiological levels and volunteer results allowed
assignment of the 3.01ppm GABA resonance at its J-coupling frequency (7.4Hz). However,
the prolonged scan time of over two hours prevented practical application of this approach.
A far more efficient method of acquiring 2D J-resolved spectra is achieved with a dedicated
2D J-resolved sequence. An optimised set of acquisition parameters was produced to allow
GABA measurement with maximum SNR, and without macromolecule contamination, in 35
minutes. Since the reproducibility of the sequence must be sufficient to detect physiological
changes, a formal reproducibility study was performed acquiring three measures of
reproducibility at six concentrations of GABA, using a standard volume head coil, 3"- and
5"- surface coils. To our knowledge, this is the first such reproducibility study dedicated to
2D J-resolved GABA measurement, and as such, could have significant implications on the
interpretation of in-vivo results. In-vivo 2D J-resolved spectra were acquired and compared
well to the published results, allowing assignment of the 3.0Ippm GABA (plus
macromolecule) peak (J = 7.4Hz). In the first reported 2D J-resolved spectra specifically
designed to reduce the macromolecule contribution by optimising the echo time range,
assignment of the in-vivo 3.01 ppm GABA peak was less convincing.
As an alternative to 2D J-resolved spectroscopy, preliminary testing of 2D correlation
spectroscopy (COSY) showed that it was not as sensitive or robust for either in-vitro or in-
vivo GABA measurement. Although provisional assignment of the 3.01 ppm GABA peak
was made, in their current form, neither technique is suitable for pure GABA measurement
at 1.5T.
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GABA (y-aminobutyric acid) is the major inhibitory transmitter in the mammalian
brain (1) and changes in concentration of this metabolite have been associated with
several neuropsychiatric disorders (2-5). Normal physiological cerebral
concentrations ofGABA are low and reported to be in the range of 0.8mM - 1,9mM
(6,7). In a study of depressed patients, Sanacora et al found a 52% reduction in the
GABA levels of depressed patients compared to a group of non-depressed controls
using a spectral editing method on a 2.IT system (8). Abnormal GABA
concentrations have also been observed in women with pre-menstrual dysphoric
disorder (a severe form of pre-menstrual syndrome) compared to a group of healthy
controls (9).
With such results from in-vivo GABA measurements being increasingly reported, the
incentive behind the work presented in this thesis was the study of GABA levels in a
population of post-stroke patients. In a review by R. Robinson, the author stated that
"depression is probably the most common and most severe emotional disorder
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associated with stroke'" (10). It has been estimated that between 25% and 63% of
people will develop depression following a stroke, figures that are significantly
larger when compared to the incidence of depression in a general, elderly population.
Patients suffering from post-stroke depression will experience impaired physical and
cognitive recovery, and their chances of surviving the first two years post stroke will
be dramatically reduced when compared to a similar population of non-depressed
stroke patients. Ultimately, it is hoped that results from magnetic resonance
spectroscopy (MRS) could aid the management of such patients, with decreases in
cortical GABA levels providing a predictive marker for depression.
Recent advances in MR methods have made it possible to measure GABA non-
invasively, in-vivo (8,9,11,12). However, the application of such methods at 1.5T is
very difficult: The low normal physiological concentrations of GABA means that it
is on the threshold of detection using clinical MRI scanners. At clinical field
strengths, GABA is strongly J-coupled, giving rise to complex resonance patterns.
To further complicate the matter, GABA is extensively overlapped by higher
concentration metabolites, which means that conventional ID spectroscopy
techniques are unable to resolve multiplets at any of its chemical shift frequencies, at
1.5T. Despite this, GABA measurements at 1.5T using a variety of techniques have
been published, including spectral editing (13-16), double quantum filters (17-19),
2D correlated spectroscopy (COSY) (20,21) and 2D J-resolved MRS (22-27).
Unlike the spectral editing methods, 2D spectroscopy is not as susceptible to
complications caused by patient motion and allows for the simultaneous
measurement ofGABA and other metabolites.
1.2 Aims
The main aim of this work is to evaluate two methods of two-dimensional
spectroscopy and to assess their suitability for in-vivo GABA measurement at 1.5T.
This will include extensive in-vitro experimental work to validate the techniques,
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optimise acquisition protocols and establish the reproducibility of the methods before
evaluating their performance in healthy volunteers.
1.3 Outline of chapters
The background to the work in this thesis is provided in two theoretical chapters. It
is assumed that the readers of this thesis will have a basic understanding ofmagnetic
resonance, and so a detailed description of the physical basis of the technique is not
included. However, it is acknowledged that this experience may not extend to
magnetic resonance spectroscopy. For this reason, Chapter 2 introduces MRS as it is
currently applied on clinical MRI scanners. This includes a brief history ofMRS, an
outline of the background theory and a description of the cerebral metabolites studied
using this non-invasive technique.
Since the focus of this work is on GABA measurement using MRS, chapter 3
provides a review of the MRS methods currently applied for GABA detection at
1.5T. These techniques are critically assessed in terms of the quality and type of
metabolite information acquired and ease of application on a clinical MRI scanner.
Two-dimensional MRS has the advantage of providing information on all of the
metabolites within the sample, and from the encouraging GABA-related results
identified in this review, was chosen as the most efficient method of evaluating the
complete biochemical status of the individual.
Each of the experimental chapters lists the materials and methods employed, and
then presents and discusses the results from each series of experiments. In the first
of these chapters, chapter 4 presents the work performed investigating the application
of the standard PRESS sequence to perform 2D J-resolved MRS. The results from
the preliminary in-vitro experiments are presented, including the general
reproducibility of the scanning and post-processing protocol, and the sensitivity of
this method to GABA measurement. The chapter concludes with the results from the
application of this technique in-vivo.
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Practical work using 2D J-resolved MRS continued with the evaluation of a
dedicated 2D J-resolved MRS sequence. This sequence provides an automated
method of acquiring the same data as obtained using a protocol of 64 individual
PRESS sequences. However, a difference in the data acquired during prescan
necessitated a change to the post-processing, the results of which are presented in
chapter 5. This chapter also contains the results from the initial in-vitro practical
work to re-evaluate 2D J-resolved MRS using automated acquisition of the raw data.
By performing a similar series of experiments to those presented in chapter 4, the
results from the two scanning protocols can be directly compared.
To address the specific application of GABA measurement using 2D J-resolved
MRS, practical work was performed to optimise the scanning protocol. These results
are presented in chapter 6 and include investigation of different coil arrangements,
spectroscopy voxel sizes and acquisition parameters. The results from testing the
optimised protocol on a phantom containing physiological concentrations of all the
common cerebral metabolites are also shown.
The final stage before acquiring in-vivo data was to establish the reproducibility of
the scanning and post-processing protocol. Despite the increasing interest in GABA
measurement using a variety of MRS methods, as described in chapter 3, there have
been few studies specifically addressing the reliability of these measurements, and
none using 2D J-resolved MRS. Therefore, chapter 7 presents the results from
formal investigation into the reproducibility of 2D J-resolved GABA measurement,
as recorded in phantoms and using different coil arrangements.
Completion of evaluation of 2D J-resolved MRS in-vitro allowed application of the
technique in-vivo. The 2D J-resolved spectra acquired from healthy volunteers,
using the optimised protocol, are presented in chapter 8.
As an alternative method for in-vivo GABA measurement, chapter 9 presents the
initial practical work performed to evaluate a dedicated 2D L-COSY sequence. To
allow comparison between these results and those using 2D J-resolved MRS, a
Page 4
Introduction
similar series of in-vitro experiments were performed as those described in chapters
4 and 5, to establish the reliability of the technique in both general terms and
specifically for GABA measurement. The chapter concludes by presenting the
results from the acquisition of 2D L-COSY spectra in-vivo.
Finally, chapter 10 presents the conclusions drawn from this work, and offers
suggestions for future work.
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2 Introduction to Magnetic Resonance Spectroscopy
2.1 Introduction
Since its introduction into the clinical environment in 1981 (28), MRS has been an
extremely useful tool for studying the biochemistry of different living tissues non-
invasively (29). In doing so, MRS has been able to provide insight into different
disease courses and their response to treatment (30). Although it is somewhat
restricted by a limited chemical shift range and overwhelming water peak (31), 'H
MRS has been applied extensively to evaluate brain metabolism in different disease
states including stroke (32), tumours (33), Alzheimer's disease (34) and head injury
(35).
The aim of this chapter is to quickly bring the reader up to speed with the current
state of clinical MRS, and use this as a foundation on which to build-up to the non¬
standard, research MRS techniques described in later chapters. To help achieve this,
a brief history of MRS is provided in §2.2 to illustrate the significant developments
accomplished in this field over such a short time.
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For a complete understanding of the technique, an appreciation of the physical basis
of magnetic resonance (MR) is required. This is not a new discipline and so it is
beyond the scope of this thesis to provide a thorough description of MR from first
principles — there are many texts with excellent descriptions of the physics behind
magnetic resonance imaging (MRI) and MRS. However, a quick overview ofMR is
included in §2.3, with appropriate references to guide the reader in obtaining a more
comprehensive understanding of the subject.
The focus of this thesis is the application ofMRS to identify and quantify GABA in-
vivo, and so GABA and some of the other cerebral metabolites studied in-vivo using
MRS are introduced in this chapter. This is also an appropriate place to mention
alternative techniques for GABA measurement, and at the same time, stress the
advantages of using MRS. §2.4 not only describes these metabolites, but also
includes any effect their presence may have on GABA measurement.
Building on the physical basis of MR, §2.6 describes clinical MRS as currently
applied at 1.5T. It is important to appreciate the role and limits of conventional, one-
dimensional (ID) spectroscopy before introducing two-dimensional (2D) MRS in
§2.7. It should be noted that where ID MRS is still establishing its role in clinical
practice, 2D MRS remains very much in the research domain.
2.2 History of Magnetic Resonance Spectroscopy
In 1946, two independent scientists published their results regarding the " Nuclear
Magnetic Resonance (NMR) phenomenon". Bloch led one group at Stanford
University and received acclaim for their work into "Nuclear Induction" (36). This
pioneering work involved superimposing a small gradient over a main static
magnetic field to produce tiny variations in the Larmor frequency of the protons in
the water sample. By placing a coil with its axis in the same direction as the applied
gradient, Bloch et al were able to record a signal from the sample. This technique
was to form the basis of spatial encoding.
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At the same time, Purcell and his group, at the Massachusetts Institute of Technology
(37), employed similar methods to determine the Larmor frequency of paraffin. At a
time where the concept of "spin-lattice relaxation" was known and accepted, results
from this group revealed relaxation times far shorter than those expected from
consideration of only longitudinal relaxation. It was such observations that led to the
definition of spin-spin (T2) relaxation time.
Both Bloch and Purcell were awarded the Nobel Prize in 1952 for their
achievements, and their work formed the platform on which the technique of
magnetic resonance has evolved into the spectrum of applications that exists today.
In one of the first practical applications ofMRS, Shaw and Elsken used the so called
"Nuclear absorption phenomenon" to investigate the peak intensity of the water
signal in a selection of organic samples, including apples, potatoes and maple wood
(38). Measurements taken during controlled dehydration of the samples showed a
linear relationship between the peak intensity of the absorption signal and the amount
of water in the tissue. Thus, it was proposed that by recording the absorption signal
from resonating hydrogen nuclei, the water content of hygroscopic materials could
be evaluated. However, the large linewidth of the signal prevented observation of
"splitting" of the absorption curve due to the structural and chemical properties of the
samples.
A similar low-resolution technique was applied to a cohort of biological samples
including human red blood cells and rat muscle (39). Odebald and Lindstrom found
a linear relationship between the received signals and measured water content in
most of their samples. However, exceptions to this rule were found in adipose,
cartilage and fibrous tissue where the recorded signals were greater than expected
from consideration of their water content alone. It was hypothesised that this
anomaly was due to the presence of bound protons within a structured lattice or, in
the case of adipose tissue, protons bound to the carbon chains forming the fat
molecule, unable to contribute to the observed signal. In addition, it was speculated
that the binding of protons to proteins and other macromolecules caused the
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broadening of the signals. More recent work has confirmed this hypothesis, with
broad resonances from macromolecules shown to contribute to 'H MRS of the
human brain in both normal (40,41) and diseased states (42-44).
Spectral resolution was to remain an issue until the introduction of super-conducting
magnets and the application of Fourier Transform (FT) to NMR in the 1960's (31).
The first truly high resolution NMR spectra were reported by Moon and Richards,
and allowed the identification of phosphorous containing compounds in red blood
cells (45).
From the early 1970's, work focussed on the use of NMR spectroscopy to study the
major phosphorous containing compounds. In 1974, Floult et al obtained the first
reported spectrum of this type on intact muscle taken from the hind leg of a dead rat
(46). Their measurements allowed the identification of a number of phosphate
compounds and these were related to tissue metabolism immediately prior to death.
A few years later, Dawson et al acquired spectra from frog skeletal muscle in
different metabolic states: rest, contraction and recovery (47). Of particular
importance, the MRS results in this work were confirmed by similar results obtained
using the more traditional chemical analysis techniques on extracted and frozen
samples, and consequently furthered the understanding of metabolic changes in
muscle.
An increase in the available bore size of the NMR spectrometer facilitated the study
of larger organs, and one of the first to exploit this technology were Garlick et al
(48). Using specially designed apparatus, 31P MRS was used to measure pFI and
obtain indications of tissue metabolism from the concentrations of phosphorous
containing compounds, from isolated rat hearts under normal and ischaemic
conditions.
The introduction of surface coils to provide basic spatial localisation permitted the
31
study of tissue in-situ. Ackerman et al used surface coils to acquire P MR spectra
31from the brain and muscle of an anaesthetised rat (49). Consequently, P NMR was
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able to provide information about phosphorous containing compounds non-invasively
for the first time. In addition to providing localisation of the MRS signal from within
a volume, this technique had the added advantage of improving the signal to noise
ratio (SNR) by eliminating the acquisition of noise from outside the volume of
interest (VOI).
Construction of high field, horizontal, homogenous magnets, large enough for human
study, prompted the first non-invasive, biochemical studies of human disease. The
very first application of MRS to confirm a clinical diagnosis was in a patient with
T 1
McArdle's syndrome (28). Results from P MRS of the forearm of the patient
showed differences in muscle metabolism and a consistently higher intracellular pH
when compared to normal control subjects.
The first in-vivo studies of the human brain were performed on newborn babies
(50,51). 3IP MRS showed abnormal changes in phosphorous containing compounds
when, at the same time as MRS was performed, both neurological and ultrasound
examinations were normal. Consequently, it was suggested that MRS had predictive
value in detecting metabolic changes before the observation of structural
abnormalities, and as such, could influence treatment management. The predictive
value of MRS was later confirmed in the follow up of severely hypoxic newborn
babies in a 31P / *H MRS study (51). In three of the infants studied, their PCr/Pi ratio
3]
improved with their clinical condition and in another, the abnormal P MR spectrum
in one hemisphere was related to tissue loss as later shown on ultrasound.
With developments of large bore magnets and improvements in image quality, MRI
became established as a clinical tool in the 1980's with the acquisition of whole body
images based on the mapping of water protons (52). However, up to this point, MR
imaging and MR spectroscopy had effectively been considered as two different
modalities using different nuclei: 31P (or 13C) for spectroscopy and *H for imaging.
]H MRS was complicated by the need to suppress the much higher concentration
water signal to detect the lower concentration metabolites, and by the comparatively
small chemical shift range of the metabolites of interest: lOppm in *H MRS and
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40ppm in 31P MRS. Despite these limitations, Behar et al were able to obtain high
resolution 'H MRS spectra from a rat brain in-vivo (53). The cerebral metabolites N-
acetyl aspartate (NAA), phosphocreatine and creatine were identified, in addition to
lactate under hypoxic conditions.
The advent of strong magnetic field gradients allowed MRS (31P and l3C) to be
performed using the same instrumentation as 'H MRI, to obtain both anatomical and
biochemical information of the human head in the same examination (54,55). Using
hardware that would not seem out of place in a modern clinical setting, a 1.5T
superconducting magnet with lm bore, Bottomley et al acquired 4mm thick
3113
transverse whole brain images, as well as P and C spectra from a volume using
surface coil localisation. In addition to performing imaging and spectroscopy on the
same MR system, this work was the first to acquire high resolution 'H MR images of
the human brain, and in doing so, set the course for clinical MR imaging as applied
today.
To overcome contamination of spectra by signals from the tissue surface due to the
use of surface coils, localisation techniques using radiofrequency (RF) pulses and
magnetic field gradients were developed. Bottomley was among the first with this
approach and he developed a simple, single pulse sequence known as Depth-
REsolved Surface coil Spectroscopy (DRESS) to excite the sample away from the
high sensitivity region at the tissue surface (56). Using DRESS, it was possible to
excite only the nuclei in a rectangular plane parallel to the surface coil, and by
varying the frequency of the excitation pulse, the depth of the region of interest
(ROI) with respect to the surface coil could be altered.
Localisation pulse sequences quickly advanced to provide 3D localisation without
the need of a surface coil. Point RESolved Spectroscopy (PRESS), for example, uses
three RF pulses and three magnetic field gradients to excite the volume at the
intersection of the three orthogonal gradients (57). So in addition to being able to
use a standard imaging coil for spectroscopy, PRESS also allows finer control of the
shape and location of the excited volume.
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Methods for biochemical imaging evolved from the multidimensional techniques
used in high resolution, organic chemistry NMR (58) to obtain a matrix of spatially
localised spectra (59). Selective post-processing of the data allows the spectra to be
quantified at a specific chemical shift frequency, to produce an image displaying the
distribution of chemicals, within the localised volume, resonating at that frequency.
Images of the different chemicals within the sample are obtained by varying the
selection frequency, and this technique of processing MRS data to indicate the spatial
distribution of a specific chemical eventually led to the technique "metabolite
mapping" or "chemical shift imaging" (CSI).
By the mid-1990's, both single-voxel (SV) and CSI techniques were being applied to
an increasing variety of clinical conditions, particularly in the human brain
(30,31,60-63). With the increased use of 'H MRI in clinical imaging, !H MRS
became the MRS method of choice for gaining measures of brain metabolism with
the detection of the cerebral metabolites NAA, choline and total creatine (63).
Recent advances in MRS research have concentrated on identifying strongly
overlapping resonances such as glutamate, glutamine and GABA, and it is to this
problem that the attention of this thesis is focused.
2.3 Physical basis of 1H MRS
To any reader familiar with MR imaging and / or spectroscopy, the physics
underlying both techniques will be well understood, and any further discussion in
this thesis quite unnecessary. However, it is appreciated that scientists new to this
field may require a basic grounding in the physical principles under-pinning
magnetic resonance. For a complete and thorough description of the physics relating
to MR, it is highly recommended that the reader study one of the many available
texts or publications, for example (52,64-67). As a very brief introduction to *H
magnetic resonance spectroscopy and its clinical relevance, the remainder of this
section will provide a quick overview of the topic. It is emphasised that the
following paragraphs offer only a short summary and far more comprehensive
descriptions can be found in the published literature.
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By mass, the human body is made up of about 60% water (68). Every molecule of
water, as its chemical name H20 implies, contains one oxygen atom and two
hydrogen atoms, thus making hydrogen one of the most abundant elements in the
human body (69).
The magnetic properties of any atom are defined by the spin and charge distributions
of the neutrons and protons within the atom's nucleus. The positively charged
proton gives rise to a magnetic field, and when combined with the inherent spin of
the nucleus, produces a magnetic dipole. Since the resulting dipole has both
magnitude and direction, it is often presented in vector form, with the strength and
orientation defining its magnetic moment.
The hydrogen nucleus, containing a single proton surrounded by a single orbiting
electron, has the largest magnetic moment of any biologically occurring element
(65). This makes the proton the most MR sensitive stable nucleus, and combined
with its natural abundance, has made'l l MRS a clinically useful tool (61).
Hydrogen, like most biologically relevant nuclei, possesses a quantum spin number
of Vi, which means that it can exist in two different orientations relative to an
arbitrary axis (31). When a hydrogen nucleus is placed into a static magnetic field,
its magnetic moment is forced to align itself either with or against the direction of the
field. Both classical and quantum models exist to describe this interaction and the
reader is directed to the literature for a full description of these models (e.g.
(64,65,67,70)). In a sample containing many millions of protons, such as the human
body, then a proportion of the protons will align themselves with the field (in the
lower energy state) and the remainder against (in the higher energy state) according
to the Boltzman law. The difference in spin population between the two states is
known as the "net magnetisation" and it has two components: A component aligned
parallel with the field, known as longitudinal magnetisation, and a second aligned at
90° from the external field known as transverse magnetisation. In the presence of a
static magnetic field, the number of protons aligning themselves with the field is
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slightly greater than those against, leading to an excess of spins in the lower energy
state.
For a proton with only two possible energy levels, the ratio of the number of protons
in the higher energy level («/,) compared to the lower energy level (n/) is given by
Equation 2.1. At room temperatures and clinical magnetic field strengths, the excess
population in the lower energy state is less than 1 in 105 (67). Since an MR signal is
only detected from this excess of lower energy nuclei, it makes MRS a low







Equation 2.1 Boltzman distribution where («/,) = number of nuclei in the higher energy level, (/»/)
= number of nuclei in the lower energy level, y = gyromagnetic ratio, h = Plank's constant, B0 =
applied magnetic field, k = Boltzman constant and T= temperature (Kelvin) (71).
The static magnetic field has a second effect on the spinning protons. Interactions
between the magnetic fields of individual protons and the much larger external field,
generate a force on the protons causing them to rotate, or precess, about their own
axis. The frequency at which the protons precess is proportional to the strength of
the applied magnetic field in a relationship described by the Larmor equation,
Equation 2.2.
coL = yB0
Equation 2.2: The Larmor equation stating that the applied frequency, coL is proportional to the
static external field B0; the constant of proportionality is y, the gyromagnetic ratio (65).
MR experiments are composed of a series of RF pulses applied with specific local
variations in the magnetic field, known as magnetic field gradients. Without
application of RF pulses or changes in the local magnetic field, the sample will
remain in equilibrium. In this position, the longitudinal magnetisation is maximal
and there is zero magnetisation in the transverse direction, resulting in no signal.
The sample leaves its equilibrium position when it is excited by RF radiation. The
frequency of the radiation must be exactly matched to the difference between the
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energy levels and if this condition is met, resonance occurs. The amplitude and
duration of the RF pulse determines the number of nuclei that make the transition
between the lower to higher energy state (70). Resonance can also be described
using both quantum physical or classical models and again, the reader is directed to
suitable texts to study both approaches, e.g. (64,65).
Once the spins have been excited and the RF pulse switched off, a signal can be
detected as the spins return to equilibrium. This is a sinusoidally varying signal,
whose envelope decays due to the spin-spin and spin-lattice interactions, and is
known as a Free Induction Decay (FID). The length of the recorded FID depends on
the relaxation parameters of the spins within the sample and its amplitude on the spin
density, and so exactly reflects the tissue structure and composition of the sample. A
signal will only be recorded from a coil in the transverse plane while the precessing
spins are also in the transverse plane and maintain their phase coherence.
In order for the spins to return to their equilibrium position, they must give up the
energy acquired to obtain resonance, and this is achieved through two relaxation
mechanisms. Immediately after the RF pulse is removed and as the spins continue to
precess, they start to interact with one another, causing tiny changes in the magnetic
fields surrounding each of the protons, causing them to precess at slightly different
frequencies. This is known as spin-spin interaction, or spin-spin relaxation (T2), and
is responsible for the loss of phase coherence in the sample, leading to the
exponential loss of the MR signal. T2* relaxation takes into account the intrinsic
inhomogeneities of the applied magnetic field and is therefore much faster than T2.
In order for the spins to return to the equilibrium position, the individual protons
must give up their energy to the surrounding tissue (historically known as the
"lattice"). This again is an exponential process and the efficiency of the spins in
giving up their energy is determined by the nature of the interaction of the nuclei
with the surrounding environment. This interaction is known as spin-lattice (Ti)
relaxation.
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However, in a uniform magnetic field, all protons within the sample in that field are
excited by the same frequency RF pulse, and since they are all precessing at the same
rate, they all contribute to the recorded signal. In most clinical applications, where
often the whole body is in the magnet, this would not be particularly useful.
Localisation of the signal is achieved using magnetic field gradients (61). These are
applied in conjunction with the RF pulses to influence the spins in a pre-determined
manner. The gradients have both positive and negative maxima, and the
combination of these gradients with the main magnetic field produces a linear
variation in the magnetic field experienced by the protons across a set field of view
(FOV). Thus, according to the Larmor equation, Equation 2.2, the frequency of
precession of the protons will vary in a uniform and predicable manner across the
FOV. Consequently, the frequency and bandwidth of the RF pulses can be selected
to excite a specific volume of protons in a particular location within the sample.
Three orthogonal gradients exist in the main body of the magnet to allow localisation
in any direction. The order and duration of the gradients in the MR pulse sequence
defines its exact mechanism of localisation and the reader is referred to §2.6.2 or
published text, e.g. (56,72,73), for further details on VOI definition.
MR imaging provides high-resolution, anatomical images. Using the local gradients,
frequency information is used to determine the spatial location of the MRI signal. In
MR spectroscopy, the frequencies obtained are determined by the exact chemical
environment of the sample, thus allowing identification of the molecules by their
unique Larmor frequencies. The electrons surrounding each nucleus shield it from
the external magnetic field, causing very local and very specific differences in the
resulting field experienced by the nucleus. These minute changes in magnetic field
produce proportional variations in the Larmor frequency of the nuclei, and since the
variations are due to the chemical environment of the nuclei, a chemical shift
(frequency) scale is adopted. Therefore, the end result of an MRS experiment is a
series of peaks at different chemical shift locations and intensities (60). These peaks
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can be exactly related to the concentration, couplings and relaxation properties of the
molecules in the sample, thus making MRS an extremely useful tool.
2.4 Reading a 1H MR spectrum
2.4.1 Introduction
Clinical MRS has focussed on using 31P and *H although MRS using nuclei such as
19F, l3C and l5N is available (30). However, in most clinical MR systems where, by
convention, the resulting images are maps of the protons arising from water and fat,
the associated RF hardware is all tuned to protons. Therefore, 'H MRS is the most
readily available MRS technique (74). The practical work in this thesis is based
entirely on MRS and so the discussion of MRS using any other nuclei is not
included.
As shown in Figure 2.1, an MR spectrum comprises a series of peaks whose
positions are defined in terms of the chemical shifts and couplings of the molecules
in the sample. The intensity of these peaks is proportional to the number of nuclei
resonating at that frequency, and so integration of the peak areas can allow a measure
of the metabolite concentration to be derived (75). To understand the significance of
the appearance of these spectral peaks, the remainder of this introductory section will
discuss chemical shift and scalar coupling.
NAA
5 4 3 2 1
ppm
Figure 2.1 Long echo time (TE) (TE = 135ms) in-vivo ID MR spectrum identifying the
metabolites choline (ch), creatine (cr) and NAA.
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2.4.2 Chemical Shift
In the discussion thus far, it has been assumed that every proton experiences the
same magnetic field, from the applied field, B0. If this were true, then the same MR
signal would be recorded from every proton and, as stated very nicely by Derek
Shaw in his book, "n.m.r. would be a very dull and not useful technique" (67)! The
beauty ofMRS is that the acquired signals differ according to the type of nucleus and
its surrounding environment i.e. the other atoms forming the molecule in which it
resides (70).
When a molecule is placed in a magnetic field, its magnetic moment precesses
around the nucleus in the direction of the field, giving rise to a small magnetic field
at the nucleus. This opposes the applied magnetic field (Bo), and effectively shields
the nucleus from the main field, Equation 2.3. The extent to which the field is
perturbed at the nucleus is dependent on the applied magnetic field strength, the
specific nuclei under investigation and its chemical environment. This is known as
the chemical shift phenomenon (5) and is defined by Equation 2.4.
~ Bo (1 — cr)
Equation 2.3 Definition of the effective magnetic field (Beff) at the nucleus, where B0 = main
magnetic field and o is the screening constant, (67).
Equation 2.4 Basic definition of chemical shift (8) in ppm, where os is the resonant frequency of
the nuclei of interest and i)R is the resonant frequency of the chosen reference nuclei. (70).
According to the Larmor equation, Equation 2.2, the differences in magnetic field
will be observed as changes in the resonant frequencies of the nuclei in different
chemical environments. Thus, each line (or peak) in the spectrum corresponds to the
resonant frequency of one nuclei within the molecule, hence the term "resonant line"
is sometimes used. The exception to this general rule is when studying molecules
with chemically equivalent protons, where each experiences the same chemical
environment, or screening factor as described in Equation 2.4, and so has the same
resonant frequency. Therefore, at clinical field strengths, such protons will occupy
the same chemical shift position.
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For example, the differences in nuclei shielding due to the changing number of
electrons, will force the methine (CH), methylene (CFF) and methyl (CH3) chemical
groups to resonate at slightly different frequencies, and so occupy different chemical
shift positions on the MR spectrum. Since more electrons shield the methyl group,
the effective field sensed by the protons will be less than that experienced by any of
the other groups, and it will resonate at a lower frequency. However, when the
protons in each of the methylene and methyl groups are chemically equivalent (e.g.
ethanol), only one resonant line per chemical group is observed on the spectrum.
Since the resonant frequency of the metabolites is a function of the effective
magnetic field, the spectrum of the same metabolite at different field strengths will
vary with B0. However, by expressing the chemical shift frequency of the metabolite
of interest as a fraction of a reference compound frequency (e.g. tetramethylsilane
(TMS) in *H MRS), the chemical shift will always have a constant value,
independent of Bo (64). This scale has units of parts per million (ppm) and is
extremely useful in allowing metabolites to be identified at the same ppm position,
regardless of the magnetic field strength. Thus, GABA will always have multiplets
at 1.89ppm, 2.28ppm and 3.01ppm (7). It should be noted, however, that the
resonant frequency of the water is temperature dependant and so a shift to the right of
approximately 0.1 ppm is observed in spectra from room temperature phantoms (52).
The chemical shift range of the common proton-containing compounds is lOppm,
resulting in a highly overlapped spectrum of peaks at clinical field strengths. The
spectrum is further complicated by scalar coupling, a concept that is discussed in the
next section.
2.4.3 Scalar (J) coupling
Scalar, or J-, coupling refers to the interaction of nuclei as transmitted through the
electrons in the outer "shells" or orbits of the nuclei (67). At high fields, the effect of
scalar coupling can be observed as the splitting of the resonant line into a multiplet of
lines, occurring in a well-defined pattern, at different frequencies along the chemical
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shift axis. This leads to an inherent loss in SNR since the proton signal is split into
multiplets. An example of the complex coupling pattern ofGABA is given in Figure
2.2. The J-coupling ofGABA will be considered in detail in §3.3.2.
1500
1000
4.0 3.0 2.0 1.0
Figure 2.2 Modelled ID spectrum of GABA (TE = 35ms, TR = 2000ms, B0= 1.5T) to
demonstrate the complex splitting pattern of the metabolite resonances, (135).
J-coupling is a fixed property of the molecule, and so is independent of the applied
magnetic field (76). The strength of the interaction is given by the scalar coupling
constant Jab, where a and b denote the two nuclei coupled by the bond, with its
magnitude expressed in Hertz (77).
The effect of these interactions can most easily be explained using a two-spin,
weakly coupled system. By convention, the spins are designated I and S where S is
the spin to be studied. Spins are considered to be weakly coupled if the difference in
their precessional frequencies is much greater than the coupling frequency (76).
Assuming that in the presence of a magnetic field, each spin has two equilibrium
states corresponding to the magnetic quantum number, m = ± 14 , then the complete
two-spin system can be described by four possible states, Table 2.1.
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In the absence of any scalar coupling, the energy for each of these states is the sum
of the energies of each spin, Table 2.2.
Table 2.2 Description of the four possible energy levels of an uncoupled, two-spin system, where
V] and vs are the Larmor frequencies of the two spins. By convention, the spin-state aligned
parallel with the magnetic field (m = + Z2) is designated a, and the spin-state aligned anti-
parallel (m = - 'A) (3.
I s Energy level
P P E4 = + Vz V| + Vz Vs
P a e3 = + v> V| — y2 vs
a P E2 = -1/4 V| + Vz vs
a a E-| = -1/4 V| — Vz vs
In terms of transition between the energy levels, only those that obey the selection
rule Am = ±1 are allowed, leading to four possible transitions, Figure 2.3 and Table
2.3.
Table 2.3 Possible energy transitions of a two spin, uncoupled system
I S Energy Total magnetic quantum
number (m)
Allowable transition to state
(Am = +1):
P P E4 = + Vz V| + Vz v$ +1 None
(highest energy state)
P a E3 = + /4 V| — Vz vs 0 4
a P E2 = -1/4 V| + 1A vs 0 4
a a Ei = -1/4 V| - Vz vs -1 2 or 3
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Figure 2.3 Energy level diagram for an uncoupled two-spin system
Since the transitions are due to changes in the I spin or the S spin, the resulting
spectrum will consist of two lines, one at each of the chemical shift frequencies for I







Figure 2.4 Resulting spectrum from a hypothetical, uncoupled two-spin system.
line represents the change in spin state of spin I at V| or spin S at
Each resonance
tvs.
The resulting MR spectrum is modified if the two spins I and S are coupled: The
presence of spin I causes spin S to experience a tiny magnetic field at the site of S.
This additional field will be positive or negative, depending on the orientation of I to
the B0 (parallel or anti-parallel), and on the sign of the coupling constant Jis-
Consequently, the resultant field at S will either be reinforced or diminished, Table
2.4.
Table 2.4 Description of a coupled, two-spin system.
I S Energy
p P E4 = + 1/2 V| + Vl Vs + V2 J |S
p a E3 = + V2 V| — 1/2 Vs - 1/2 J is
a P E2 = - % V| + 1/2 Vs - Vz J is
a a E1 — - V2 V| — 1/2 Vs + 1/2 J is
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Thus, the transitional changes are not only determined by changes in the I or S spin,
but also on scalar coupling between the spins, Jis- Therefore, the resulting spectrum
consists of four lines, whereby the resonant frequency of S will be split into a doublet
at the frequency Jis Hz and likewise, spin S will have a similar effect on spin I,
Figure 2.5. Consequently, the resulting spectrum will contain the resonances of I and
S at their chemical shifts, each one split into doublets by J-coupling interactions.
This description of a weakly coupled system is a valid approximation for the
metabolite lactate, and will be given further consideration in §2.6.4.
Energy transitions: 3-4 1-2 2-4 1-3
v, vs
Figure 2.5 Resulting spectrum from a hypothetical, coupled two-spin system now consisting of
four lines: Two centred around the transition frequency of Spin S , <os , and separated by 2n J,s ;
Two more centred around the transition frequency of Spin I, cc»i, also separated by 271 JiS.
In conventional ID spectroscopy, the spectra are complicated by the splitting of
molecules due to their J-couplings, causing further overlapping of the molecular
resonances and, in some cases, preventing the identification and quantification of
individual chemical shifts. Therefore, complex editing or 2D techniques are
employed to aid detection of these chemicals.
2.5 Metabolites detected using 1H MRS
2.5.1 Introduction
MR neuro-spectroscopy is not a new field (54), and throughout its history, the
number of metabolites identified using this non-invasive technique has increased.
Fundamental to reading any MR spectrum is knowing which metabolites are likely to
be present, where they exist on the spectrum and the range of values constituting
"normal physiological" concentrations. Consequently, this section will briefly
Page 23
Introduction to Magnetic Resonance Spectroscopy
introduce some of the metabolites more commonly studied using ]H MRS, as well as
those of significant interest to the work in this thesis.
2.5.2 N-Acetyl Aspartate
The most prominent peak in any normal, ID MR spectrum is that from the three
protons in the N-Acetyl Aspartate (NAA) methyl group, Figure 2.6. NAA is
believed to provide a marker for neuronal density with decreases in its concentration
observed with degenerative diseases such as multiple sclerosis (7).
In an MR spectrum, the NAA singlet exists at 2.01ppm, and due to the broad base of
this peak, plus the smaller contributions from N-Acetlyaspartylglutamate (NAAG),
the peak overlaps GABA at its 1.89ppm resonance. Since NAA is normally present
in much larger concentrations than GABA (~ xlO greater (7)), GABA is virtually
invisible in both ID and 2D spectra at this chemical shift frequency. Consequently,











Figure 2.6 Short-echo time (TE = 35ms) 'H spectrum acquired from a phantom containing N-
Acetyl Aspartate (NAA), choline, creatine, glutamate, myo-inositol and lactate at 1.5T.
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2.5.3 Choline
The most prominent signal from choline exists at 3.2ppm, Figure 2.7, and is due to
the nine magnetically equivalent protons on the trimethylamine group. Normal
physiological concentrations of choline are in the range 0.9mM - 2.5mM (7). In-
vivo, this peak also contains contributions from glycerophosphorylcholine and
phosphorylcholine, so it is more accurate to refer to the singlet as "total choline".
Changes in the concentration of choline have been observed in cancer, Alzheimer's
disease and stroke, which has led to its association with membrane integrity (7) and
as an indicator ofmyelination (60).
0
Figure 2.7 Short TE (35ms) spectrum from a phantom containing 2.5mM choline (with all peaks
shifted by ~ O.lppm in the room temperature phantom).
In normal ID MR spectra, the total choline singlet is sufficiently distant from all the
GABA resonances to prevent overlap, although in white matter where it exists at
higher concentrations, there may be some "bleed" from the choline obscuring the
3.01ppm GABA multiplet.
2.5.4 Creatine and phosphocreatine
The methyl protons of creatine and phosphocreatine are observed as a singlet at
3.03ppm. With normal physiological concentrations of creatine between 5.1mM -
10.6mM (7), this peak significantly overlaps the lower concentration 3.01ppm
GABA resonance in ID spectra. However, creatine exhibits no J-coupling, whereas
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GABA shows complex J-coupling patterns between each of its methyl groups.
Therefore, it is possible to separate the metabolites from one another on the basis of
their J-coupling properties using a 2D J-resolved MRS technique.
Creatine is believed to be an indicator of brain metabolism (62) and decreased levels
of Cr and PCr have been recorded in low-energy tumours with reduced glycolysis
rates (63). Reduced total creatine levels have also been shown in cerebral ischaemia
although the significance of this is unclear since some researchers use total creatine




4.0 3.0 2.0 1.0 PPm
Figure 2.8 Short TE (35ms) spectrum from a phantom containing 9mM creatine (with all peaks
shifted by~0.1ppm in the room temperature phantom).
2.5.5 Glutamate and glutamine
The excitatory neurotransmitter glutamate is found in the human brain in
concentrations of the range 6.0mM - 12.5mM (7). The strongly coupled methine
and two methylene groups form a complex series of multiplets distributed over the
2.04ppm - 2.35ppm range, with an additional doublet-of-doublet centred at 3.74ppm
arising from the proton on the methine group. Figure 2.9.
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4.0 3.0 2.0 1.0 ppm
Figure 2.9 Short TE (35ms) spectrum from a phantom containing 12mM glutamate (with all
peaks shifted by ~ 0.1 ppm in the room temperature phantom).
As its precursor, glutamine is very similar to glutamate, both in terms of its structure
and J-coupling. The four protons in the two glutamine methylene groups have
resonances grouped across 2.12ppm - 2.46ppm, with an additional triplet centred at
3.75ppm due to the methine proton, Figure 2.10. With normal concentrations





-500 1 1 ; 1
4.0 3.0 2.0 1.0 ppm
Figure 2.10 Short TE (35ms) spectrum from a phantom containing 2.5mM glutamine (with all
peaks shifted by ~ 0.1 ppm in the room temperature phantom).
Using clinical MR scanners, it is very difficult to resolve glutamate from glutamine
using conventional ID techniques, and so the complex multiplet arising from both in
the 2.04ppm - 2.46ppm range is referred to as the "Glx" contribution. In patients
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with severe liver damage causing chronic hepatic encephalopathy, elevated levels of
Glx have been reported (61). Due to the enormous spread of these metabolite
resonances in the MR spectrum, the Glx contribution overlaps the GABA resonances
at both 1.89ppm and 2.28ppm. With similar J-coupling frequencies, it is also very
difficult to separate the metabolites from each other using 2D J-resolved methods.
Consequently, approaches have been adopted targeting the 3.01ppm GABA
resonance, which is free from the complex overlapping of Glx.
2.5.6 /Wyo-inositol
Myo-inositol is a cyclic sugar alcohol, and has six protons giving rise to four
multiplets centred at 3.27ppm, 3.52ppm, 3.61ppm and 4.05ppm, Figure 2.11.
Normal physiological concentrations of this metabolite vary between 4mM - 8mM
(7). In a conventional ID MR spectrum, myo-inositol is not easily detected due to
overlap of higher concentration metabolites, although contributions may be identified
at very short TEs. In respect to GABA detection, the myo-inositol resonances are




-500 i — 1 '
4.0 3.0 2.0 1.0 ppm
Figure 2.11 Short TE (35ms) spectrum from a phantom containing 8mM myo-inositol (with all
peaks shifted by ~ O.lppm in the room temperature phantom).
Increases in the ratio of myo-inositol to creatine have been observed immediately
following clinical diagnosis of ischaemic stroke, suggesting cell swelling due to an
osmotic imbalance (32).
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2.5.7 Lactate
As a product of anaerobic glycolysis, the presence of lactate is highly significant in
conditions such as stroke (42). If present, the lactate methyl group is observed as a
doublet centred at 1.31ppm, Figure 2.12, and so is distant enough from all the GABA
resonances so as not to complicate GABA detection. Nevertheless, since the target
population of this work is in patients following stroke, an awareness of this normally
very low concentration metabolite (0.4mM (7)) is required.
Figure 2.12 Short TE (35ms) spectrum from a phantom containing 5mM lactate (with all peaks
shifted by — O.lppm in the room temperature phantom).
2.5.8 Y-Aminobutyric acid
Of primary interest to this thesis is the study of y-aminobutyric acid (GABA), Figure
2.13. GABA is found extensively throughout the different brain regions, and it is the
main inhibitory transmitter of the central nervous system (16). It acts by increasing
the permeability of the postsynaptic membranes to chloride ions (78) or potassium
ions (68), resulting in an increase in the threshold required for triggering an action
potential. Consequently, the membrane remains stabilised in its hyperpolarised state.
Early studies have shown that a deficit of GABA in the hypothalamus, which is
partially responsible for the regulation of food intake, could lead to hyperphagia
(excessive over-eating) or anorexia (79). In the same paper, it was reported that a
defect in GABA functions in the retina might affect visual perception and
integration. In addition, it was found that GABA-ergic dysregulation in layer IV
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neurons of the motor cortex may result in an increased susceptibility to grand mal
seizures. Through such mechanisms, GABAergic neurons are thought to play a
significant role at all levels.
H3N+ - 4CH2 - 3CH2 - 2CH2 - 'COO-
Figure 2.13 Chemical structure of gamma aminobutyric acid, taken from (7)
The change ofGABA levels in humans has been studied in numerous ways including
peripheral measures of plasma and cerebral spinal fluid (CSF) concentrations, in
addition to neuroimaging studies such as positron emission tomography (PET),
single photon emission computed tomography (SPECT) and MRS. Decreases in the
mean plasma GABA levels were observed in a group of patients with mood disorders
when compared to another group of healthy controls (80), but the extent to which
GABA brain activity is reflected by GABA plasma levels remains unclear.
Reductions of CSF GABA levels have also been shown in depressed patients in a
number of studies and have so far provided the most convincing evidence of the link
between dysfunction of the GABAergic system and depression (3). In terms of
routine assessment of GABA levels, these invasive, laboratory techniques are
unlikely to obtain popularity, where other non-invasive methods can be reliably
applied.
Nuclear medicine techniques such and PET and SPECT have been applied to
neuropsychiatric disorders such as anxiety and panic attacks, to image the
distribution of binding sites most frequency associated with GABAa receptors (3).
(It is to this type ofGABA receptor that anti-anxiety drugs bind to enhance the effect
of GABA in the CNS.) In epileptic patients, PET has also been used to monitor the
response of GABAa receptors to treatment with GABA-increasing medication (16).
Specifically to post-stroke depression, results from PET imaging studies have been
used to establish a relationship between serotonin receptor binding and the severity
of symptoms of depression (81-83). However, to date, no work imaging GABA
receptors in patients with post-stroke depression has been reported.
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In a clinical environment however, one of the major advantages of using MRS over
PET or SPECT is that MRS can be performed as part of the standard MR
examination, without needing another piece of equipment, often necessitating return
to the hospital at a different time (30). In addition, biochemical information is
obtained using MRS without the need to inject radioactive tracers. In terms of the
interpretation of the resulting data, MRS has another advantage over PET: In MRS
the magnitude of the recorded peak is proportional to the concentration of the
metabolite from which it arose, thus allowing it to be quantified (using either relative
or absolute values). Although PET is able to quantify processes related to
metabolites, such as metabolism and receptor binding, it is unable to quantify the
actual concentration of the metabolite present. SPECT is able to produce colour
maps displaying uptake of a specific tracer in respect to a reference region, but due to
the inherent problems of the technique, such as scatter and attenuation, these results
are not quantitative.
Recent MRS evidence has been acquired linking GABA dysfunction with major
depression. Animal models have shown decreases in the levels of GABA with
depression, a finding that has been replicated in human studies (3). In a study by
Sanacora et al, SV MRS methods were used to quantify GABA concentrations in the
occipital cortex of medication-free depressed patients and healthy volunteers (8).
The findings demonstrated a 52% decrease in the measured levels of GABA in the
depressed patients when compared to the normal healthy volunteers, and
demonstrated the diffuse nature of the dysfunction.
However, the actual mechanisms underlying the reduction in GABA levels
associated with mood disorders is not well understood and caution has been
recommended in assuming that abnormally functioning GABAergic neurones have a
causative role in depressive disorders (1). In cortical biopsies taken from patients
undergoing surgery, reduction in GABA levels were correlated with severity of
depressive mood disorders among the patients studied (84). This finding has not
been replicated in post mortem results, but may be due to variation in biopsy material
due to differences in the temperature of the brain at death, the cooling rate of the
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brain after death, the time between death and biopsy as well as complications of
death (e.g. cardiac, respiratory) and prescribed drugs (85).
Understanding the role of GABA dysfunction in mood disorders has been further
complicated by the results of depression-related pharmacological animal studies. In
the studies reviewed by Sanacora et al, treatment of depression using a variety of
anti-depressants saw hugely variable results (including increases, decreases and no
measured change in the GABA levels) suggesting no consistent pattern of response
(3).
In MR spectra, GABA exhibits three resonances, due to the three methylene groups,
Figure 2.13, with multiplets centred at 1.89ppm, 2.28ppm and 3.01ppm, Figure 2.14.
Despite its prominent role in maintaining normal brain activity, GABA is only
present in the brain in concentrations of 1.3mM - 1.9mM (7). At high field
strengths, with larger chemical shift resolution, it is possible to observe GABA using
a numerically optimised, "single-shot" pulse sequence (12). Using an editing
sequence at 7T, Terpstra et al identified GABA in 14 normal volunteers, at
1
concentrations in agreement with previously published C MRS results (11).
However, at 1.5T, GABA is extensively overlapped by other metabolites.
Therefore, editing methods, or techniques exploiting differences other than chemical
shift (such as J-coupling) have to be applied. These sequences are often more
complicated than the standard clinical spectroscopy sequences and extensive post¬
processing is essential. Consequently, such sequences are not routinely applied. A
review of the MR methods for detecting GABA is provided in §3.
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1.04.0 3.0 2.0 ppm
Figure 2.14 Short TE (35ms) spectrum from a phantom containing lOmM GABA (with all peaks
shifted by ~ 0.1 ppm in the room temperature phantom).
2.5.9 Macromolecules
Macromolecules are large organic molecules with a molecular weight greater than
3500 Dalton (42). They are detected in MRS as broad resonances appearing below
metabolites of smaller molecular weight. At short echo times, macromolecule
contributions exist across the entire frequency range (0.6ppm - 4.4ppm)
complicating accurate quantification of all the metabolites of interest, including
GABA (86). It is possible to separate macromolecules from the low molecular
weight metabolites on the basis of their different Ti relaxation times: Metabolites
have longer Ti's than the macromolecules, which means that the macromolecules
will recover their longitudinal magnetisation before the metabolites (44). Therefore,
by using an inversion recovery (IR) pulse, with an inversion time (TI) equal to the
time taken for the longitudinal magnetisation of the metabolites to reach zero, only
the magnetisation from the macromolecules will be excited producing a metabolite-
free spectrum. Such IR techniques have been used to eliminate macromolecules
from the metabolite spectra (41,44,87). However, analysis of the macromolecule
baseline is starting to provide clinical information, with differences in the observed
baseline attributed to cerebral location and age (86), and pathologies such as stroke
(42,43)
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2.5.10 Other GABA contaminating resonances
It is clear from the discussion in the preceding sections how the overlapping of
higher concentration metabolites complicates the detection of GABA at 1.5T. In
addition to these commonly studied metabolites, contributions from glutathione
(GSH) and homocarnosine can contaminate GABA resonances. GSH is normally
present in-vivo at concentrations between 2mM and 3mM, with multiplets occurring
across the spectrum in the range 2.15ppm to 4.56ppm (7). Of particular concern to
this work, this tripeptide has two doublets of doublet centred at 2.93ppm and 2.98pm,
very close to the 3.01ppm GABA multiplet. Homocarnosine exists at much smaller
concentrations of between 0.3mM to 0.6mM, but also has a multiplet group close to
that of 3.01ppm GABA at 2.96ppm (7). The constituents of this dipeptide include
GABA, so it is no surprise that the protons in its three methylene groups are similar
to those of GABA. Although normally at such low concentrations as to remain
undetectable in-vivo at 1.5T, elevated levels have be reported in epileptic treatment
using vigabatrin (88), ensuring that its presence in an MR spectrum cannot be
entirely discounted.
2.6 Conventional, one-dimensional spectroscopy
2.6.1 Introduction
Although the focus of this thesis is the use of 2D spectroscopy techniques, a short
section on conventional, ID methods is included to demonstrate how MRS is
currently applied on clinical MR scanners.
In theory, it is possible to acquire MR spectra from all body regions, but clinical use
of the technique has concentrated on MRS of specific organs, such as the brain, and
specific disorders within those organs (62). Since this work is concerned only with
the application of MRS in the brain, discussion of its use in other organs will be
omitted.
A common protocol for MR spectroscopy exists, independent of the exact technique
adopted. This comprises of localisation and shimming of the VOI followed by
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suppression of the water signal, and each of these processes will be discussed in turn.
In addition, a description of the effects of changing some of the acquisition timing
parameters will also be included.
2.6.2 Localisation
The aim ofMRS is to obtain chemical information from a specific anatomical region
and so accurate localisation of a VOI is essential. Ideally, perfect localisation would
allow measurement of 100% of the available signal within the VOI while
suppressing all other signals from outside the volume (89). In early MRS
experiments, localisation was achieved using a surface coil (49). However, this type
of localisation alone is not sufficient for in-vivo MRS of the brain due to
contaminating resonances from the layer of fat within the scalp of the subject (61)
and obtaining only poor definition of the VOIs (52).
Similar to conventional MRI, localisation in MRS is achieved using a specific series
of RF pulses in the presence of slice selection gradients. However, unlike
localisation in MRI, acquisition of the FID must occur in the absence of any gradient
in order to maintain the chemical shift information. Using this combination of
switched magnetic field and RF pulses, it is possible to acquire signals from a single
voxel or simultaneously from a number of voxels to form low resolution, chemical
shift images (61).
2.6.2.1 Single Voxel Spectroscopy
As the name implies, MR signals from a single volume of interest are acquired using
single-voxel (SV) spectroscopy. Localisation is achieved using three slice-selective
gradients, applied in orthogonal directions, and the MRS signal is recorded from the
intersection of these three planes (57).
In clinical, single-voxel spectroscopy, the most commonly used localisation
techniques are Point RESolved Spectroscopy (PRESS) and Stimulated Echo
Acquisition Mode (STEAM) (61,89). Both sequences achieve accurate 3D
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localisation using three RF pulses (90). PRESS consists of a 90° excitation pulse
followed by two 180° refocusing pulses, all in the presence of mutually orthogonal
gradients, after which a full spin-echo is acquired in the VOI (61). STEAM consists
of three 90° excitation pulses resulting in a stimulated echo, which at maximum, is
only half the signal of a full-echo. Since several 2D sequences have been based on
PRESS (22-24), it is appropriate that this sequence is studied in more detail.
As mentioned above, PRESS consists of an excitation pulse followed by two
refocusing pulses, Figure 2.15. When the 90° RF pulse is applied at the same time as
the X magnet field gradient, the spins in the YZ plane are excited. By the same
argument, it is clear that when the Y gradient is applied at the same time as the first
re-focussing pulse, then the spins located in the XZ plane are refocused, Figure 2.15
(b). The resulting echo is then refocused by the second 180° pulse in the presence of
the Z gradient, and a second spin echo formed at TE including the spins excited in
the XY plane. Therefore, the recorded echo contains data from the spins in the
intersection of all three planes (90). Spoiler gradients are also applied to prevent the
detection of signals experiencing only one or two of the three RF pulses (52).
The actual size of the intersection of the three planes, or the VOI, can be changed by
altering the strength of the applied gradients (61). Consequently, the dimensions of
the VOI can be identical for all MRS experiments. The situation is more
complicated when defining the actual spatial location of the VOI. Differences in
chemical shift between the metabolites result in the generation of voxels - of the
dimensions as defined by the gradients - for each of the resonances within the
sample. The effective VOI for each metabolite peak will be displaced from the next
according to the chemical shift separation of the resonances. The recorded spin-echo
will only contain information from the overlapping voxels, which due to the
chemical shift displacement, may not contain 100% of the metabolite signal (90).
This chemical shift artefact is particularly important when applying PRESS to
coupled systems, and will be discussed further in §3.
Page 36
Introduction to Magnetic Resonance Spectroscopy
The timings between each of the pulses and before spin-echo acquisition are
carefully controlled. Examination of the PRESS sequence software listing, e.g. on
the 1.5T GE Signa Horizon scanner used for all experimental work in this thesis,
allows definition of each of the time intervals as shown in Figure 2.15. These are
listed in Table 2.5. It is important to note that the actual numerical value stated for
TE is split equally across the last refocusing pulse - the relevance of which will
become apparent in the examination of 2D J-resolved MRS in §3.





Figure 2.15 RF pulse and gradient sequence for PRESS localisation (spoiler gradients not
shown), (a), (b) and (c) show the planes of excitation following application of an RF pulse in
each of the three gradient directions, resulting in a signal recorded from the excited spins in the
intersection of the planes.
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Although the PRESS sequence is very successful in allowing a signal to be recorded
from a well-defined voxel, the minimum echo time (TEmjn) is larger than the TEmin
permitted using STEAM localisation. In PRESS, the TE has to be long enough to
allow all three RF pulses to be played out including the formation of two spin-echoes
and allow sufficient time for application of the spoiler gradients. These are
necessary to eliminate signals excited from outside the VOI so that only the second
spin echo arising from all three RF pulses at the intersection of all three planes is
recorded
Table 2.5. Description of the timing parameters used in the GE PRESS spectroscopy sequence
Time Description Value
t_st1 time from start to centre of pulse 1 Fixed at 2.548ms
t 12 time from centre of pulse 1 to centre of
pulse 2
Fixed at 9.392 ms
t 23 time from centre of pulse 2 to centre of
pulse 3
Varies according to t -te-23
2
t 3r time from centre of pulse 3 to centre of
the echo (when acquisition starts)
Varies according to t ir=--t 12
PRESS is less sensitive to motion than STEAM and so signals from diffusing
metabolites are less attenuated using PRESS (61). However, better water
suppression can be achieved with STEAM compared to PRESS localisation, due to
the additional water suppression pulse between the last two RF pulses. Immediately
after the second 90° pulse (in STEAM), the magnetisation is along the z-axis and so
is unaffected by variations in the magnetic field gradients, thus allowing another
water suppression pulse without compromising the recorded signal.
Despite these drawbacks, PRESS has become the localisation technique of choice for
in-vivo MRS since it records the maximum available signal from uncoupled
resonances (91). This is a considerable advantage when acquiring signals from low
concentration metabolites.
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2.6.2.2 Chemical shift imaging
As with conventional MR imaging, localisation in 'H chemical shift imaging (CSI) is
achieved after the 90° excitation pulse, using phase encoding gradients in three
dimensions to spatially encode the metabolite information (61). A 180° refocusing
pulse is then applied to produce a spin echo. By varying the gradient from a
minimum (negative) value in a step-wise manner to the set maximum (positive)
value, then a series of spin-echoes are recorded allowing reconstruction of the
metabolite information across the whole CSI slice.
Although in theory, distinct FIDs are recorded from each voxel in an n x n
spectroscopy matrix, the true spatial sensitivity of each is more akin to a point-spread
function, with maximum sensitivity in the centre of the voxel and oscillating side¬
bands spreading outwards. This gives rise to the main disadvantage of CSI, so called
"Fourier Bleed", where signals contribute to FIDs both within and outside the voxel
from which they arose, due to the side-bands extending out of the voxel from which
they were generated (61). In clinical applications, the CSI matrix size is small
compared to that required for MR imaging purposes, and so signals arising from
Fourier Bleed that contaminate adjoining voxels have a much larger influence over
the spectroscopic image. Fourier bleed can be reduced with post-processing
methods, e.g. by extrapolating the lipid k-space region to reduce the ringing artefacts,
or using rapid acquisition sequences to prevent loss of SNR of the metabolites of
interest (92). In addition, PRESS and STEAM localisation can be incorporated into
CSI to improve localisation and prevent contamination from lipids present in the
scalp, bone marrow or white matter myelin.
In diseases with extensive patterns of brain abnormality, such as stroke (63) or
gliomas (93), CSI is able to provide information about both diseased and normally
appearing brain matter across whole brain slices. This multi-voxel spectroscopy data
can be compiled into chemical-specific colour maps overlaid onto anatomical images
of the same slice, to allow immediate comparison between structural and functional
information.
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CSI lies outside the scope of this thesis, but is included here to complete the
discussion on ID MRS techniques. Readers particularly interested in ID MRS
methods are directed towards the published literature (for example (60,61,94,95)) for
further details.
2.6.3 Shimming and water suppression
Precise localisation is essential in 'H MRS to prevent contamination of the spectra
from scalp lipids that may obscure the signals from the metabolites of interest. In
addition, effective suppression of the water signal is required for the acquisition of
well resolved spectra (90).
Shimming is the process by which the homogeneity of the static magnetic field is
improved by manipulating the electrical currents in the gradient coils (64). Clinical
MR scanners have an automated shimming procedure that adjusts the shim currents
in the gradient coils until the FID of the water signal is optimised. Successful
shimming produces a slowly decaying FID which, when Fourier Transformed,
results in a high intensity water peak with a narrow linewidth. Without satisfactory
shimming, the natural inhomogeneity in the magnetic field would prevent the
detection of the very small chemical differences of the metabolites, thereby
producing very low-resolution spectra. For clinical MRS at 1.5T, the homogeneity
needs to be less than the desired resolution of measurement (O.lppm) over the VOI,
which practically is better than five parts in 108 to achieve linewidths of 3Hz (52).
In terms of spectroscopy, and specifically spectroscopy of the brain, the chemicals of
interest are contained within the intracellular water compartment. Since intracellular
water accounts for 85% of brain water (60), water is the main signal in any 'H MR
spectrum, and without water suppression, would be the only visible signal.
Most spectroscopy sequences use a CFIEmical Shift Selection (CHESS) pulse to
suppress the water signal. A frequency-selective 90° pulse is applied to flip the
water into the transverse plane where it is then immediately dephased by a spoiler
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gradient. Typically three CHESS pulses are required for adequate water suppression.
This allows only the magnetisation from the metabolites in the longitudinal plane
available to contribute to the FID after the specific spectroscopy sequence has been
played out (61).
2.6.4 Sequence timings
Although the number of metabolites detected using conventional, ID MRS
techniques is restricted by overlap from the highest concentration metabolites, the
appearance of the spectra can be altered to aid metabolite identification by changing
the timing parameters used at acquisition.
Spectra acquired with a short TE have a more complex appearance, Figure 2.16 (a).
This is due to the presence of short T2 metabolites such as glutamate and glutamine,
as well as those from the longer T2 metabolites such as NAA, choline and creatine.
Another characteristic of such spectra is the underlying broad resonance due to
macromolecules.
Using a longer TE to acquire MR spectra, typically TE = 125ms - 145ms, removes
all contributions from macromolecules and signals from the very short T2
metabolites. The resulting spectrum will only contain metabolites with longer T2's,
such as NAA, choline and creatine, and will therefore be much simpler to read,
Figure 2.16 (b). However, it should be noted that the magnitude of the remaining
metabolites will be reduced, also due to T2 relaxation (42).
Short TE spectra are useful for providing a more complete spectrum with
information from several cerebral metabolites. However, at longer TEs,
quantification of the metabolites can occur without complications from the
underlying macromolecules or associated very short T2 metabolites. Therefore, in
cases where the investigator / clinician is only interested in NAA, choline and
creatine, it is often more useful to collect longer TE spectra.
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Figure 2.16 (a) Short TE (35ms) in-vivo MR spectrum acquired using a volume head coil. Note
the broad macromolecule baseline underneath the metabolite spectra across the entire chemical
shift range, (b) Long TE (145ms) in-vivo MR spectrum from the same volunteer.
The choice of echo time is also very important in the detection of J-coupled
metabolites. For example, lactate, a J-coupled metabolite with the three methyl
protons, gives rise to a doublet at 1.31ppm (90). In addition, lactate has a quartet at
4.1 lppm, but this is not usually observed due to its close proximity to the water peak.
However, the difference between the chemical shift frequencies of lactate (4.1 lppm
- 1.3lppm = 2.8ppm « 180Hz) is much greater than the coupling between the
resonances (6.9Hz (7)), and so at clinical field strengths, lactate is considered a
weakly coupled spin system (76), Figure 2.17.
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Figure 2.17 Chemical structure of lactate. Weak scalar coupling occurs between 2CH and 3CH3.
As discussed in §2.5.7, lactate is not detected in normal in-vivo spectra since it is an
end product of anaerobic metabolism. However, when present in increased levels in-
vivo, or simply in-vitro, lactate is very interesting as the effect of its J-coupling
properties can be observed in routine, 1D MR spectra.
Lactate can be completely described by a A3X spin system (90). (By convention,
spin-systems described by letters that are well separated are weakly coupled, whereas
those described by adjacent letters (AB) are strongly coupled.) During the evolution
period after an excitation pulse, the individual resonances will have slightly different
resonant frequencies due to the effects of chemical shift, scalar coupling and
magnetic field inhomogeneities, and will therefore precess at a slightly different rate
in the transverse plane. Consequently, immediately before the refocusing pulse, the
resonances will have acquired slightly different phase shifts. The evolution of each
of the resonances, and therefore the end phase shift, is governed by the applied echo
time, and so the resulting spectra are characterised by pure in-phase or pure anti¬
phase magnetisation or a combination of both. Examples of the evolution of lactate,
as measured in-vitro, are shown in Figure 2.18. As a result of J-coupling, the
appearance of lactate spectra will change according to the TE used and this can be a
useful tool in differentiating coupled from uncoupled metabolites. It is this principle
that is applied to facilitate the identification of GABA using 2D J-resolved
spectroscopy as described in §3.3.2.
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Figure 2.18 J-evolution of lactate. All experiments were performed in-vitro, using a GE spectro
phantom containing 5mM lactate. Single-voxel spectroscopy was performed (TR = 2000ms,
NEX = 8, VOI = 3x3x3 cm3) with (a) TE = 35ms (~ J/4), (b) TE = 145ms (4J/4), (c) TE =
290ms (8J/4) where J = 6.9Hz.
2.7 Two-dimensional spectroscopy
Two-dimensional (2D) MRS techniques refer to the two frequency dimensions. In
conventional MR spectroscopy, there is only one frequency axis - the chemical shift
axis - and so such methods are known as one-dimensional. The other variable -
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signal amplitude - is not included in any discussion of the dimension of an
experiment (71).
The actual information on the frequency axis depends on the type of experiment
being performed, and on the interactions within (or between) the molecules of
interest. These interactions fall into three categories of (1) "through-bond coupling",
such as shift correlation (COSY) and J-resolved experiments; (2) "through-space
coupling", utilising the nuclear Overhauser effect; (3) "chemical exchange", also
utilising a technique based on the NOSEY experiment.
In general terms, the principles behind generating a second dimension follow a
similar structure, independent of the precise technique, Figure 2.19. As with
conventional, 1D spectroscopy, each 2D experiment has a preparation period, where
the spins are initially excited, and a detection period during which the FIDs are
acquired. Two additional periods are required for 2D MRS: An evolution and a
mixing period. These are introduced between the preparation and detection periods,
Figure 2.19. Crucial to all 2D experiments is a variable time delay (ti), applied in the
evolution period and uniformly increased to a set final value as the experiment
proceeds (77). At each value of ti, the same pulse sequence is repeated and an FID
recorded. As the ti time interval increases, the spectra will decay exponentially due
to T2* relaxation effects, and so spectra collected with long ti will show considerably
diminished intensities. Consequently, each signal recorded during the detection time
(t2) is modulated by the precessional time in ti. Fourier transform of the recorded
signal with respect to ti produces the frequency information appearing on the F1
dimension in the resulting 2D spectrum.
Preparation Period Evolution Period Mixing Period Detection Period




Figure 2.19 General requirements for a 2D experiment
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The mixing period is particularly important in experiments containing coupled spins,
as in any in-vivo MRS experiment of the brain. During this period, coupled spins are
able to transfer polarisation (or coherence) between two nuclei (96), which means
that magnetisation originating from one spin is transferred onto another spin.
Therefore, the frequency of the spins during ti is no longer equal to the frequency
during t2, and this property can be exploited to provide coupling information about
the spin systems. Depending on the exact nature of the 2D experiment, the mixing
period may contain one or more RF pulses and so will determine the relationship
between the two frequency dimensions. The frequency information in F2 always
corresponds to the chemical shift frequencies of the peaks, but F1 is used to display
information not normally acquired in a ID experiment, Figure 2.20. Different types









Figure 2.20 (a) General format of a 2D MR spectrum. Ft is used to display information not
resolved in ID experiments (such as J-coupling) whereas F2 shows the chemical shift
information of the peaks, analogous to a ID MRS experiment (b).
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3 GABA detection using MRS at 1.5T
3.1 Introduction
It has been established in the preceding chapter that in-vivo MR spectroscopy can
provide considerable metabolic information, particularly for the higher concentration
cerebral metabolites such as NAA, choline and creatine. However, due to its low
concentration, its complex spectrum and the overlapping of higher concentration
metabolites, GABA is not as easy to detect using conventional, 1 D-spectroscopy
methods. At very high fields, such as 11.7T, the improvement in spectral resolution
associated with the increase in Bo means that single shot sequences can be used to
identify GABA (2). However, at lower field strengths of 1.5T, simplification of the
spectrum is required to allow identification of overlapped, lower concentration
metabolites such as GABA. This can be achieved in a variety of ways, including
spectral editing and two-dimensional techniques. In this chapter, the principles
behind each of these approaches will be discussed and the application of these
methods to GABA detection at 1.5T will be examined.
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3.2 Spectral editing techniques
3.2.1 Introduction
Spectral editing exploits the J-coupling of coupled metabolites to differentiate them
from the spins in uncoupled metabolites. There are different types of spectral editing
techniques, which can simplify spectra by using differences in chemical shift,
couplings within nuclei or relaxation times (15). Methods using differences in
chemical shift are routinely used in both MRI and MRS to suppress the signal from
fat and water (75). However, for the small chemical shift range of the metabolites of
interest, this approach is not sensitive enough to discriminate adequately between the
resonances. Methods utilising changes in relaxation time are equally insensitive.
Consequently, approaches making use of differences in J-coupling have been
investigated, and this section will explore the success of two examples of such
schemes for GABA measurement: Multiple quantum filters and difference editing.
3.2.2 Difference method
3.2.2.1 Background theory
As the name suggests, spectral editing using a spectrum difference method relies on
the acquisition of two spectra, with the difference between the two providing the
edited spectrum. In its simplest form, selective 180° pulses can be used to eliminate
uncoupled resonances from the difference spectrum, Figure 3.1. The first MRS
experiment, acquired without the 180° RF pulse, results in a complete spectrum of all
the metabolite resonances. The second sequence includes the refocusing pulse. This
selective pulse affects only the coupled spins, and so the uncoupled spins remain
positive in the resulting spectrum. After subtraction of the two spectra, the
difference spectrum will only contain resonances from the targeted coupled spins.
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90° 180° (on / off)
TE/2
-> ACQUIRE
Figure 3.1 Basic pulse sequence for spectral editing based on differences in J coupling (97). The
180° pulse is designed to select one frequency component of the coupled system. A first
spectrum is acquired without the pulse and a second spectrum with the refocusing pulse on, so
that subtraction of the two spectra yields a difference with the targeted resonances.
3.2.2.2 Clinical application
To date, very little work has been published using difference editing techniques to
measure GABA at 1.5T (13,14,16). In the first of these papers, a spectral editing
sequence developed for a 2.IT system was modified for application at 1.5T (13).
The original sequence, developed by Rothman et al (98), used a Delays Alternating
with Nutation for Tailored Excitation (DANTE) inversion pulse centred on the
1.9ppm GABA resonance to induce J-modulation of the 3.01ppm GABA resonance.
The DANTE sequence is made up of a series of N hard, very short duration RF
pulses separated by regular periods for free precession of the magnetisation (76).
After each pulse, the spins are flipped through a small angle and allowed to precess,
so that the next RF pulse acts on the spins when they are in different phases of
precession. Consequently, when viewed as Cartesian vectors in the rotating frame of
reference, the spins follow a zigzag path determined by the offset from resonance
before each RF pulse. By keeping the pulse amplitude constant while varying the
pulse duration, DANTE can be used to shape pulses where amplitude modulation is
not possible, and the pulse envelope may be shaped to meet a specific design. In this
example, the DANTE pulse inverted the 1.9ppm GABA resonance and the sidebands
of the 3.01ppm GABA resonance, resulting in an edited spectrum with the removal
of all resonances not J-coupled to the 1,9ppm GABA resonance.
The application of this method at 1.5T is complicated by baseline distortions from
the incomplete subtraction of NAA and choline, which degraded the appearance of
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the difference spectrum around the 3.01ppm GABA resonance. Consequently, these
contaminating resonances influenced the accuracy of quantification contributing to
the large standard deviations (SDs) reported (46% for 8cc VOIs and 23% for 4cc
VOIs). In addition, no attempt was made to discriminate GABA from the underlying
macromolecule resonances (40), which probably contributed to the poor
reproducibility of the results. Nevertheless, a GABA "peak" was identified in the
edited spectra of all 10 normal volunteers.
As part of a study comparing techniques to identify low concentration metabolites,
Weber et al developed an editing protocol by adapting the standard PRESS
localisation sequence (15). The authors also targeted the 3.03ppm creatine peak to
resolve the underlying 3.01ppm GABA resonance. The editing sequence was tested
in five volunteers, and GABA concentrations between 0.7mM and 1.5mM were
reported, with an "uncertainty" of 0.5mM. However, from the poorly resolved in¬
vito example provided, it is difficult to see exactly what part of the GABA "peak"
would have been quantified. Again, no correction for the underlying
macromolecules was applied.
The same difference method was later applied to another set of five healthy
volunteers undergoing both MRS and PET examinations to monitor the effects of the
GABA-increasing drug vigabatrin (16). Each of the volunteers received different
doses of the drug, and a near-linear trend was observed between dose increase and
GABA measurement at low concentrations of vigabatrin. However, with only one
experiment per volunteer, the reproducibility of the measurements could not be
established. Baseline errors were less pronounced in the edited spectra presented here
than in (13), but yet again, no account was taken of contamination of the GABA
resonance from macromolecules or homocarnosine. Since earlier work by Petroff et
al (88) had shown increases in homocarnosine with vigabatrin, it is possible that
increases in this dipeptide contributed to the increased GABA measurements
reported in (16).
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Although Weber et al reported that "an adequate" SNR was acquired for all of their
GABA measurements, the GABA peak in the difference spectrum provided post-
drug administration was much more convincing that that pre-administration (16). It
should also be noted that the increases in GABA were identified as positive peaks in
the difference spectra. In a later study by the same group investigating the effects of
vigabatrin in combination with the coenzyme pyridoxal 5'-phospate (14), an increase
in the GABA+ / creatine signal was shown as a negative GABA+ resonance
(GABA+ was used to acknowledge the contribution of macromolecules and
homocarnosine to the "GABA" peak). Despite using the same acquisition protocol in
both studies, different post-processing procedures were applied: In the first study, the
difference spectra were the result of the nonedited - edited spectra (16). In this later
work, the difference spectra resulted from the edited - nonedited spectra (14). Even
with this change in analysis, the peak assignments pre-administration were again not
clear and the spectra only marginally better post-drug administration. This may
suggest that normal physiological GABA levels are just beyond the limits of
detection using this spectral editing, difference method at 1.5T.
3.2.2.3 Technical limitations
The main disadvantage of this approach is that it only provides information about a
single metabolite. In disease processes where the underlying metabolic changes are
poorly understood, it is often useful to obtain information on all cerebral metabolites.
Difference editing sequences, using specially tailored selective excitation pulses,
permit the investigation of only one metabolite at a time (99). However, the
acquisition of multiple difference editing spectra would be inefficient and with
examination times quoted of up to 90 minutes (14), totally impractical. In such
situations, it is more useful to apply a technique that allows the study of all
metabolites simultaneously.
In addition to the inefficiency of the technique, application of difference-editing
MRS relies on the acquisition of two separate spectra and this makes it extremely
sensitive to motion (97). Any patient movement between the two sequences would
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lead to subtraction errors, complicating the resulting spectra and resulting in
inaccuracies in quantification (21).
It is clear from the literature that difference-editing techniques at 1.5T are not
suitable for pure GABA measurement due to the indistinguishable J-modulations of
the resonances from homocarnosine and macromolecules at 3.0ppm (11,12).
However, from a scientific viewpoint, it is extremely interesting to evaluate new
methods of GABA detection on clinical scanners. In collaboration with Dr. N.
Sailasuta from General Electric Health Care (GEHC), a difference editing sequence
was obtained for initial testing. Since the GABA editing pulse was designed for a 3T
system, the failure of the sequence to work at 1.5T was not surprising.
The sequence provided by Dr. N. Sailasuta was based on the editing sequence by
Hetherington et al (100). The homonuclear editing sequence uses specially designed
Shinnar-Le Roux type pulses, which are polynomial in design and therefore have
more optimised shapes when compared to the more conventional sine or Gaussian
RF pulses (64). The pulse consisted of specific frequencies for inversion and
additional regions of non-inversion, to both invert the 1.9ppm macromolecule
resonance and reduce the effect of the pulse on the 1.7ppm macromolecule
resonance. Since the version of the sequence from Dr. Sailasuta was written for
frequency bandwidths on a 3T scanner, the RF pulse was far too broad when applied
at 1.5T, and so rather than refocusing only the spins of interest, the pulse wiped out
almost the entire metabolite spectrum. With an editing pulse comprising a train of 30
pulses and 29 delays, optimisation of the pulse for 1,5T would be difficult at the best
of times, and impossible without the necessary software. Even if a standard sine RF
pulse had been used for editing, production of a narrow pulse profile is not easy. To
create a discrete and uniform frequency profile, an RF pulse of infinite duration and
an infinite number of side lobes is required, which is clearly not realistic in an
imaging system. In addition, increase in the pulse duration would require an increase
in the echo time, ultimately leading to a reduction in the measured signal. DANTE
RF pulses have been proposed as a method to overcome the drop in measured signal
and deviations in the excitation profile arising from truncation artefacts. However,
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results have not been entirely successful at 1.5T with incomplete subtraction of the
metabolites close to GABA and baseline distortions (97).
3.2.3 Quantum filter techniques
3.2.3.1 Background
As described in the previous section, difference editing techniques exploit changes in
frequency, induced by RF pulses, to simplify spectra. In contrast, multiple quantum
filter methods (MQF) simplify spectra using a combination of RF pulses and
magnetic field gradients to selectively rephase only spins from a specific coherence
pathway (15). Equally important to this technique is the concept of coherence, and
more specifically, the transfer of coherence between coupled spins.
To help explain the phenomenon of coherence, consider the application of a 90°
pulse to a spin system at equilibrium. This RF pulse will force the magnetisation
into the transverse plane, and if the spin system is coupled, may be represented by a
specific number of energy level transitions as described in §2.4.3. In a conventional
MRS experiment, the magnetisation observed on the resulting spectrum arises from
the transition of spins between energy levels such that the change in magnetic
quantum number, Am = ± 1 (70). Only single-quantum coherences (SQCs) are able
to induce a voltage in the receiver coil, but this is not to say that other quantum
coherences do not exist and cannot, with some manipulation, be observed.
Multiple quantum coherences (MQCs) arise when spins states are separated by Am ^
±1, where the spins are effectively forced to absorb more than one quantum of
energy. In pulsed MR, this is achieved with application of a second RF pulse (101).
This second pulse forces the spin states to absorb another quantum of energy, and
therefore move to another energy level where the effect of this transition is no longer
observable in the MR spectrum. Flowever, the presence of these higher order
quantum coherences can be detected indirectly by converting the spin states back to a
SQC using RF pulses after manipulation of the spins by magnetic field gradients.
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After the second RF pulse, both zero quantum coherences (ZQCs) and double
quantum coherences (DQCs) are produced in equal proportions, and experience the
first magnetic field gradient. For a DQ experiment, such as the one described by
Kniittel et al (102), all coherences produced after the second RF pulse are "filtered",
using magnetic field gradients, to obtain only DQCs, Figure 3.2. The selection of
the DQ pathway leads to an automatic 50% loss in signal, since the other 50% of the
available magnetisation was converted into ZQCs.
Theoretically, both coherence orders of Am = ± 2 are possible, but practically, only
one of these pathways can be selected. Therefore, another 50% of the signal is lost.
A third selective RF pulse, applied at the same frequency as the second, converts the
DQCs into SQCs, allowing a theoretical maximum of 25% of the total magnetisation
to be recorded in the MR spectrum.
RF
90° 90° 90°






Figure 3.2 Pulse sequence (including gradients) of the DQF described in (102), where J is the
spin-spin coupling constant of the spin-system of interest. The gradients served three purposes:
slice-selection (ss), dephasing / rephasing intervals (ph) and homospoiling of the coherences (sp).
For a weakly coupled spin system (e.g. lactate), after the first RF pulse, the spins evolve under
chemical shift and spin-spin coupling interactions. The second RF pulse transfers the single
quantum coherences into multiple quantum coherences. Since only the DQC pathway is being
selected, all other pathways are dephased by the gradients in and t3. The DQCs evolve in x2
(again due to spin-spin coupling and chemical shift differences). The third RF pulse transfers
50% of the DQCs into SQCs (see text). These are refocused in the time interval t3.
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3.2.3.2 Clinical application
To date, all work using this technique at 1.5T uses DQF edited signals. Although
ZQCs would permit an additional 25% of the total magnetisation to be retained, it
has the disadvantage that uncoupled spins are not suppressed (97). During
application of the only gradient used in ZQF after the second RF pulse, any spins
from uncoupled resonances are aligned along the longitudinal axis and so do not
experience the change in Bo- Without a second gradient pulse, these unwanted
resonances are not dephased, and so remain in the recorded spectrum. This is
particularly relevant when attempting to resolve GABA from the overlying creatine
singlet.
One of the first reports specifically reporting GABA measurement using a quantum-
filter method at 1.5T, was provided by Keltner et al (17). A frequency selective
DQF pulse sequence was tuned to the 1.91ppm GABA resonance to facilitate the
transfer of magnetisation from this resonance to the 3.01ppm GABA resonance,
thereby improving its detection efficiency. In phantom work, this was cited as a
"single-shot" technique, but in-vivo, two phase-calibration pulse sequences were
required to ensure that the phase of the first 90° pulse matched that of the filter. In-
vivo, the relative phases varied with voxel size and location, thought to be due to a
transmitter delay causing a phase offset before application of the first slice-selective
pulse. Using these two calibration sequences, and the water peak as reference, the
phase was corrected prior to the DQF sequence. In all of the ten subjects scanned
using this protocol, it was reported that the 3.01ppm resonance was visible on all the
DQF spectra. (The appearance of the filtered GABA spectrum had been previously
confirmed in in-vitro studies.)
This was an encouraging result when compared to the failure of Weber et al to yield
any signal using their DQF (15). Their sequence was based on the difference editing
pulse sequence mentioned in §3.2.2.2. Two additional 90° pulses and a single
refocusing pulse were added (and additional gradients), with the timings and gradient
strengths chosen for detection of the GABA signal between 1.7ppm - 3.0ppm. In-
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vitro, the authors reported good singlet suppression and GABA identification, but
this result was not replicated in-vivo (n = 1).
A slightly different approach was taken by McLean et al in their measurement of
GABA using a localised DQF at 1.5T (19). As with (17), the DQF was based on
PRESS localisation, but in this later sequence, the hard chemical shift refocusing
pulse was removed. This, in conjunction with an increase in gradient strength,
allowed a reduction in the TM from 14ms to 6ms to maximise the GABA yield. To
avoid the additional phase calibration measurements, a series of in-vitro experiments
were performed in order to obtain the phase settings required for specific voxel sizes
and distances from the magnet isocentre. In acknowledgement of the contamination
of the GABA signal from the peptides homocarnosine and glutathione, and the
macromolecule peaks, the authors quantified "GABA+" in their resulting in-vivo
spectra. In the 15 normal volunteers scanned, it was reported that GABA+ could be
quantified in all the filtered spectra, with a repeatability of 38%.
This same DQF technique was applied by the same researchers to acquire spectra
from the occipital lobe (103) and frontal lobe (104) in both epilepsy patients and
healthy volunteers. Initial results following analysis of the occipital lobe spectra
suggested that the GABA+ measurements in the group of epileptic patients were
increased when compared to the control group, with a significant increase in the sub¬
group of patients with idiopathic generalised epilepsy (n = 15). However, after grey-
white matter segmentation, there was no significant variation in any of the groups.
No difference was observed in the GABA+ levels between the patients and healthy
controls when studying spectra from the frontal lobe either (104). This also included
a sub-group of patients with idiopathic generalised epilepsy whose mean GABA+
levels were the same as those in the control group. To date, no clinical applications
of this method have been applied outside the group who developed this version of the
DQF.
The literature thus far suggests that quantification of the results from quantum
filtering methods at 1.5T rely heavily on the post-processing techniques applied.
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Lack of spectral resolution prevents the acquisition of clear filtered GABA+ spectra,
and the end results depend greatly on the prior knowledge included in modelling
programmes, such as LCModel, (105), to extract the relevant GABA+ data from an
otherwise noisy spectrum (19,103). Application of multiple quantum filtered
techniques at higher field strengths immediately produces a discernible improvement
in resolution, providing far more convincing results and facilitating more reliable
quantification (106-110). In fact, it should be noted that at both 2.IT and 3T, CSI of
GABA is possible using multiple quantum filter techniques (111,112)!
3.2.3.3 Technical limitations
As with spectral editing techniques using selective excitation pulses, the main
limitation of this method is that it does not allow the study of multiple metabolites
without performing several quantum filter experiments. Such pulse sequences have
to be explicitly designed for each coupled spin-system under investigation, so that
the detected signal will be a function of the coherence order and the evolution time.
Thus, in order to gain a more complete biochemical description of the patient,
including GABA, multiple sequences would need to be applied. Therefore, this
inefficient approach was abandoned in preference for the more all-encompassing,
two-dimensional MRS approach.
In addition to the lack of multiple metabolite information, the signal loss associated
with the creation of the different coherence pathways is undesirable in human studies
(21), particularly when measuring the lower concentration cerebral metabolites.
Moreover, the repeatability of these techniques is non ideal, even at higher field
strengths, with the application of a doubly selective pulse sequence at 2.IT
producing a coefficient of variation of 23% for the in-vivo GABA-to-creatine ratios
(106). This is comparable to the repeatability results calculated at clinical field
strengths using spectral editing techniques, Table 7.1, suggesting that improvement
in measurement reliability is not always associated with higher field strengths.
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3.3 Two-dimensional techniques
3.3.1 2D Correlation Spectroscopy
3.3.1.1 Background
2D correlation spectroscopy (COSY) is the most widely used 2D technique, and is
more often applied in high-resolution NMR experiments to determine the fine
structure of the sample under study (113) than on clinical MRI scanners. COSY
relies on the transfer of coherence between coupled spins that occurs during the
evolution period, and since the interactions exist through the covalent bonds within
the molecule, COSY produces "through-bond coherence transfer" (77).
Unlike conventional ID MR spectra where peak assignment is made by the position
of the chemical shift peaks, in 2D COSY, metabolites are identified by the
correlation pattern arising from spins sharing a J-coupling (99). This is shown in
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Figure 3.3 (a) schematic representation of 2D L-COSY spectrum of lactate, and (b) 2DLCOSY
spectrum of a 3x3x3cml voxel from phantom containing 5.0mM lactate (pH7, with all peaks
shifted by -O.lppm in room temperature phantom).
In its most basic form, the COSY sequence comprises two 90° pulses separated by an
evolution time, tj, Figure 3.4 (76). Resuming the discussion of a weakly coupled
two-spin system first introduced in §2, and applying the concept of coherence
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transfer in §3.2.3.1, it is straightforward to see how this phenomenon is utilised in
COSY.
90c 90c
Detection period (t2) ACQUIRE
Figure 3.4 Basic COSY pulse sequence. The first pulse creates the transverse magnetisation that
then precesses during the evolution time tj. During this time, all of the individual spin
components are "labelled" with their characteristic precession frequencies. After the second 90°
pulse, the mixing pulse, transfer of magnetisation occurs between the coupled spins and they
then precess during the detection period (t2) at a new frequency.
After the first 90° pulse, the transverse magnetisation produced may be represented
by each of the transitional changes listed in Table 2.4. This information can also be
represented in terms of an energy level diagram, Figure 3.5. The SQCs from both
spins S and I will freely precess under the influence of spin-spin coupling during
time period ft. Application of a second 90° pulse transfers the coherence from I]
among the five possible transitions in the spin system (Si, S2,ft, aa - pp and ap - Pa)
leaving a proportion with ft (113). Thus coherence is transferred between I to S in
transitions Si and S2, forcing Spin S to precess at the frequency of Spin I. These
transitions correspond to SQCs and so after 2D FT, F1 ± F2, resulting in a peak that
will reside at a point corresponding to the different chemical shifts of Spin S and I.
This is away from the diagonal, hence the term "cross peak". The cross-peak
provides evidence of coupling between the spins, and is why COSY has proven to be
such a useful technique.
Figure 3.5 Energy level diagram for a coupled two-spin system IS described in Table 2.4.
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Also during the detection period (t2), the SQC remaining with spin I) or transferred to
I2 will continue to precess at its original Larmor frequency. That is, these SQC
precess at the same frequency during ti and t2, and in terms of the final 2D spectrum,
will produce a peak on the line F1 = F2. This is equivalent to the peak that would be
observed in an uncoupled spectrum, and due to its location on the 2D spectrum, is
known as a "diagonal peak".
Finally, the transfer of coherence between aa - (3p and ap - Pa result in a DQC and
ZQC respectively and will remain undetected without the addition of a third RF
pulse.
3.3.1.2 High field and clinical application
Application of 2D COSY in-vivo has not been widespread, and at the time ofwriting,
only two papers make reference to GABA measurement at 1.5T (20,21).
Consequently, it is useful to include a more general discussion of COSY, including
the development of the sequence.
As stated in the introduction, 2D COSY is more frequently applied on high
resolution NMR systems, using homogeneous samples. One of the first examples of
the acquisition of localised 2D COSY spectra from a heterogeneous sample was
provided by Cohen et al in 1989 (114). Localisation was achieved using a 2cm
diameter surface coil and used a conventional COSY sequence (90°- ti - 90° -
acquire). All experiments were performed at 4.7T on a phantom containing separate
containers of lactic acid and ethanol. Good localisation was achieved using the
surface coil, and well-resolved 2D COSY spectra were acquired.
Following these encouraging results, Barrere et al performed a series of 2D COSY
experiments on single metabolites in-vitro (phantom) and ex-vivo using rat brain
tissue (99). This work culminated in the acquisition of 2D COSY in-vivo spectra
from five rats using a 1.2cm diameter surface coil. All NMR experiments were
performed on a 400MHz spectrometer and 2D COSY spectra were acquired using a
SUPER COSY pulse sequence.
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The SUPER COSY sequence was first described by Kumar et al and incorporated
two additional time-delays around two refocusing pulses (115). These time-delays
were optimised for a specific coupling constant to prevent the signal loss of cross-
peaks associated with them being in antiphase during acquisition, as in a typical
COSY experiment. By transferring the antiphase component from the cross-peaks to
the diagonals, an increase in the intensity of the cross-peaks was observed compared
to standard COSY. This aided detection of the cross-peaks, and particularly those
close to the diagonal. The delays were also useful in suppressing the unwanted signal
from water and lipids. In addition, since the intensity of the cross-peaks was no
longer compromised, the acquisition time required for producing these peaks was
also reduced, making the technique more feasible for detecting low concentration
metabolites.
Comparison of the ID and 2D spectra from the excised rat brain demonstrated the
superior resolution of 2D COSY MRS and thus permitted the identification of
metabolites otherwise hidden in the ID spectrum (99). The results from the single
metabolite 2D COSY experiments were superimposed onto the 2D COSY spectra
from the ex-vivo and in-vivo rat brain spectra to aid metabolite identification.
However, due to interactions between the metabolites that exist in-vivo, these
reference spectra were incomplete. Despite this, GABA was identified in both 2D
COSY rat spectra using this approach. In addition, the effects of ischaemia were also
observed through the presence of lactate in the 2D COSY spectrum, and reductions
in NAA. These spectral changes may also be observed on conventional ID spectra,
but of particular interest in this work, the authors also reported an increase in analine
and GABA cross-peaks after ischaemia in all rats studied (n = 5).
Extensive pre-clinical work performed at 8.4T by Behar and Ogino permitted the
assignment of chemical shift and spin-spin coupling constants for all the common
cerebral metabolites, including GABA (116). High-resolution 2D COSY and 2D J-
resolved spectra were acquired from tissue samples of the rat brain, and these have
undoubtedly acted as an excellent source of reference for other workers in the field,
be it animal or human study.
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At the even higher field strength of 9.4T, 2D COSY was applied in conjunction with
microdialysis to monitor the effects of pharmacological inhibition of GABA-
transaminase in-vivo, in rats, leading to an increase in GABA levels (117). MRS was
performed hourly after administration of the drug diluted in NaCl solution or the
NaCl solution alone (as a control) to monitor changes in the intracellular GABA
levels. Extracellular GABA was measured via the dialysates collected at the same
time. Even before administration of the drug, the authors were able to measure
GABA using 2D COSY with a sensitivity good enough to record the changes in
intracellular GABA. Although these are exciting results, they cannot be compared
directly to clinical work: As well as the very high magnetic field strength used, the
SNR was also improved with direct contact between the rat skull and receiver coil,
made possible by surgery - clearly not acceptable in clinical work in humans!
The first in-vivo 2D COSY spectrum of the human brain was acquired by Brereton et
al in 1994 using a 2T magnet and surface coil (118). A large, 240cm3 voxel was
centred in the occipital cortex, although due to its size, it also included CSF signal
from the ventricles, and lipids from subcutaneous fat. Further improvements in the
SNR were attempted by acquiring each of the 128 increments with a NEX = 32,
producing a scanning time for 2D spectroscopy alone of 102 minutes. Due to the
short T2 of the cerebral metabolites, the authors speculated that with the reduction in
signal intensity associated with the longer TEs, the 2D experiment could be reduced
to 64 increments without signal peak loss. More recent 2D COSY experiments have
adopted this procedure, which among other factors has reduced the scanning time to
more tolerable levels. Despite these drawbacks, the experiment was a success and
peaks from aspartate, glutamate, glutamine and the a-CEl resonances of NAA were
identified on the 2D spectrum, as well as peaks from resonances normally found in
conventional ID spectroscopy.
Initial applications of a 2D COSY sequence at 1.5T did not seem very promising,
with the authors of one of the first studies concluding that the technique was "not
suitable for in-vivo work" (119). All the experiments in this study were performed
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on a phantom containing a water / ethanol mix, but it was postulated that any in-vivo
2D spectra would contain artefacts from patient motion due to the long scanning
time. This is despite the seemingly successful assignment of the CH2 and CH3
ethanol diagonal and cross-peaks. Thankfully not all research in this area was
abandoned!
Two recent studies from the lab of Thomas et al have applied 2D COSY techniques
at 1.5T for GABA measurement (20,21). Localised COSY (L-COSY) was
performed in each case, allowing volume localisation and coherence transfer in a
minimal time to prevent signal loss from the short T2 cerebral metabolites. The
sequence comprised three RF pulses (90° - 180° - ti - 90° - t2 - acquire), and novel to
this sequence, the last slice select RF pulse was dual purpose: It provided both
coherence transfer for COSY and volume localisation of the voxel (21). This
eliminated the need for additional RF pulses or gradients as described in (116,120).
Encouraging reproducibility results were obtained in-vitro, with within-run (that is,
MRS of the same VOI in the same scanning session) coefficients of variation (CVs)
for the diagonal and crosspeaks of < 2% and < 6% respectively (20). The CVs rose
to between 7% - 15% for the between-days measurements (VOIs of the same size
scanned on different days). In-vivo, the reproducibility of the higher concentration
metabolites (NAA, choline and creatine) rose to < 13%, and the reproducibility of
GABA was quoted as < 22%. These results at least suggest that in-vivo GABA
measurement using 2D L-COSY at 1.5T is viable, and as such, will form part of the
work in this thesis.
3.3.1.3 Limitations
2D COSY promises to be a useful tool for metabolite identification at 1.5T, but it is
not without its drawbacks, the main one ofwhich is the long scan time. With a TEmjn
= 30ms, TR = 2000ms, 64 At'i increments and NEX = 16/ti, a scan time of 35
minutes was quoted (21). Although comparable to some of the scan times quoted for
the spectral editing techniques (13,16), it is much longer than the time required for a
conventional ID spectrum (approximately three minutes). Therefore, it is possible
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that some patient groups will not tolerate 2D L-COSY. However, the results from
the two 1.5T studies presented suggest that with any fewer excitations, GABA is not
observed in the 2D spectrum in-vivo.
Another disadvantage of this method is the loss of sensitivity when compared to 1D
spectroscopy (121). 2D COSY relies on the transfer of coherence between different
spins, and since only part of the magnetisation is transferred onto the coupled proton,
there is a loss in the resulting signal. However, this reduction in sensitivity can be
counter-acted with optimisation of the acquisition and processing parameters.
In common with the spectral editing sequence, another limiting factor of this 2D L-
COSY is that a dedicated sequence is required, and without access to the
programming skills or appropriately compiled sequence, 2D COSY measurements
would not have been possible. Indeed, without the collaboration from Dr. M. Albert
Thomas, University of California, the 2D COSY work in this thesis would not have
been possible, and it is with thanks that the author acknowledges his assistance.
3.3.2 2D J-resolved spectroscopy
3.3.2.1 Background
J-resolved spectroscopy is another example of a "through-bond" 2D technique that
can be utilised to reduce the complexity of spectra, by separating (or resolving) the
chemical shifts of the multiplets from their scalar couplings. In doing so, it is
possible to identify multiplets of similar chemical shift that are not normally resolved
in a ID spectrum (122). Of specific interest to this work is the 'Homonuclear J-
resolved" technique where the homonuclear (usually H-H) couplings are resolved
from the chemical shift information, thus allowing measurement of these couplings
in decoupled spectra. So unlike 2D COSY spectra where both axes contain chemical
shift and J-coupling information, after post-processing, 2D J-resolved spectra
separate the J-coupling information (Fl) from the chemical shift information (F2),
Figure 3.6.
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Figure 3.6 2D J-resolved spectrum of the weakly coupled metabolite lactate. The F1 dimension
contains the J-coupling information (Hz) and the F2 dimension contains the chemical shift
information (ppm). (All peaks are shifted by -O.lppm due to room temperature phantom.)
Aue et al first pioneered 2D Homonuclear J-Resolved Spectroscopy in the mid-
1970's (58). In his communication, Aue described an indirect method of
homonuclear broadband decoupling by acquiring a set of 64 echoes with uniformly
incremented TEs, and then performing 2D FT to produce a 2D J-resolved spectrum.
This was achieved using two basic pulse sequences: The first was a modified Hahn
spin echo experiment, using only a 90° and 180° RF pulse, with echo acquisition
after ti, Figure 3.7(a). The second sequence contained multiple 180° pulses, and so
more closely resembles the 2D J-resolved sequences currently used, Figure 3.7(b).
The standard spin echo sequence was initially modified to include the second 180°
pulse to provide the third orthogonal slice selective pulse, thereby obtaining a
spectrum from a localised volume (123). This sequence is routinely applied as the
standard PRESS spectroscopy sequence employed in conventional ID spectroscopy,
as described in §2.
Following 2D FT, Aue et al produced a stacked plot of the experimental sample,
which contained chemical shift and J-coupling information along the 0)2 (or F2) axis,
and J-coupling information only on the <x>i (or Fl) axis. After tilting, projection of
the 2D spectrum along the C02 axis produced an entirely decoupled spectrum.
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Figure 3.7 (a) The original homonuclear J-resolved experiment, (b) The spin-echo sequence for
2D J-resolved spectroscopy. Time A is the minumn time required to implement the RF pulses
and gradients (22). The evolution time tj is split evenly across the last 180° pulse, and the echo
collected after t| i.e. TE = 2A + tr. GE's PRESS sequence follows the same formula for
allocation of the components of TE between the RF pulses.
Review of the literature has shown that, to date, most of the 2D J-resolved sequences
have been based on PRESS localisation (22-24,27,124). For simplicity, PRESS can
be approximated by a standard spin-echo sequence, if the time between the 90° pulse
and the first 180° pulse is short compared to 1/J (where J is the spin-spin coupling
constant). As described previously, the application of the 90° pulse produces
transverse magnetisation that may be represented by the transitional changes shown
schematically in Figure 3.5. During x in Figure 3.7(a), the magnetisation vectors are
dephased both intentionally by the applied gradient, and unavoidably due to T2*
relaxation, Figure 3.8. Specific to coupled systems, in the time between the 90° and
the following 180° pulse, the J-coupling between the nuclei force the transverse
magnetisation to undergo periodic transformation into 'inphase' and 'antiphase'
magnetisation, (125).
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Inphase magnetisation occurs at even multiples of 1/J, i.e. x = 0, 1/J, 2/J etc, where x
is the time between the 90° pulse and 180° pulse = time between 180° pulse and the
echo. This type of magnetisation is similar to the transverse magnetisation observed




Figure 3.8 Evolution of anti-phase magnetisation of Spin A (MA) in a weakly coupled AX spin
system (a) at equilibrium, and (b) time t after the 90° pulse. During r the spin species are
dephased due to the applied gradient Gx, T2* relaxation and the J-coupling interactions
between the spins.
Antiphase magnetisation is unique to J-coupled systems, and the effects of a non-
ideal 180° pulse (as practically applied) on this type of magnetisation can be
observed at odd multiples of 1/(2J) (90). The evolution of antiphase magnetisation is
inherently more complicated, and to aid understanding, the process can be broken
down into three different responses, Figure 3.9.
The first of these effects is similar to that experienced by the in-phase magnetisation,
in that the vectors are partially refocused to produce a spin-echo after time 2x, Figure
3.9 (a). Due to cosine modulation, refocusing of the spins is perfect but the signal is
inverted by 180°. Secondly, incomplete refocusing of the antiphase magnetisation
allows a proportion of the A2 magnetisation vectors to continue precessing at their
own Larmor frequency, are flipped by the non-ideal refocusing pulse, thus creating
longitudinal magnetisation at time 2x, Figure 3.9 (b). In addition, since a non-ideal
180° is used, the angles close to 90° in the transition band create MQCs. These are
usually dephased by the gradients and their effects not observed. Both these
responses relate to J-couplings within spins that are unaffected by the 180° pulse, and
so they make no contribution to the recorded signal (126).
X
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The third effect is that the non-ideal 180° pulse causes a population inversion of one
the Spin A transitions, in a process known as polarisation transfer, Figure 3.9 (c).
Thus magnetisation originally created on Spin A will be detected on Spin X, and vice
versa. This effect can be observed in the recorded signal since, as with the first
response, only the spin-spin couplings between spins inverted by the 180° pulse and
those unaffected by the refocusing pulse are focused after 2x.
MAAp




Figure 3.9 Evolution of anti-phase magnetisation of Spin A (MA) in a weakly coupled AX spin
system after application of a 180° pulse following Figure 3.8. (a) De-phased anti-phase
magnetisation refocuses to produce spin echo at 2t. (b) Creation of ZQCs and DQCs (which
make no contribution to the recorded signal), (c) Polarization transfer, between Spin A to Spin
X, also contributing to the observed signal at 2t.
At echo times other than those specified, the resultant signals are comprised of a
mixture of both in-phase and anti-phase polarisation. Consequently, signals collected
at different echo times will contain information about the different phases of the
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magnetisation vectors at the time when the refocusing pulse was applied. Since the
change in phase is equivalent to the variation in coupling frequency, then
measurement of the variation of phase with TE will provide information about the
coupling of the system. This is the basis of the 2D J-resolved experiment.
Practically, the 2D J-resolved experiment can be performed by acquiring a series of
PRESS MRS experiments, with the TE uniformly incremented between each one. In
this way, the J-couplings can be evaluated by performing a FT with respect to the
TE. The range of TE values and ATE are important as they determine the bandwidth
and sensitivity of the F1 axis. The resulting bandwidth must be large enough to
include the J-coupling frequency of the metabolites of interest, Equation 3.1. The
number of individual experiments (nTE) performed must also be chosen with care as
it is important that the F1 resolution is fine enough to show the point of maximum




Al Spectral resolution =
nTE x ATE
Equation 3.2
3.3.2.2 Clinical applications of technique
Due to the complexity of the spectra, and strong coupling patterns involved,
applications of this technique in-vivo at field strengths as low as 1.5T has been
difficult, and as such, very few studies investigating this method have been reported.
Of the published work, there has been a trend to running multiple sequences using
the standard PRESS spectroscopy sequence, either automatically as a self-written
protocol, or as a series of individual experiments. In doing so, in-vivo measurements
ofmetabolites including GABA have been reported.
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Ryner et al were one of the first to publish in-vivo results using this technique (22).
Their work comprised a comprehensive study of the individual metabolites
commonly found in-vivo in separate phantom solutions, then as a composite solution,
and the study was completed with the acquisition of in-vivo spectra. The standard
PRESS sequence was modified to allow interleaved acquisition of 64 spectra,
considerably reducing the scanning time required to perform a full 2D experiment
using separate PRESS experiments. Individual phantoms were made containing
common metabolites found in grey matter, at concentrations of 50mM. Of particular
interest to this work, was the result pertaining to GABA. The 2D plot resulting from
the in-vitro experiment of 50mM GABA clearly showed the splitting of GABA into
three distinct groups at 3.01ppm, 2.28ppm and 1.91ppm, each assigned to the three
CH2 groups. The strong coupling patterns between each of the methylene groups
was observed, with the strongest between the groups at 1.91ppm and 2.28ppm due to
their close chemical shift proximity. These 2D assignments of GABA are
comparable to those Behar and Ogino (116) in the acid extracts and extracted brain
tissue of rats, performed at 8.4T.
In a brain phantom containing the same metabolites as previously studied in separate
experiments, Ryner et al added GABA at a concentration of 0.5mM (22). Despite
this being less than half the normal value quoted in (7), GABA resonances were
identified at 3.01ppm and 1.91ppm (F1 = 7Hz), and a strong coupling set at 1.9ppm
(F1 = 20Hz). The results from this phantom were compared to a composite 2D plot,
constructed from the 2D spectra from the individual metabolites. Since the composite
plot was derived from contours acquired separately, it lacked any information due to
coupling between the metabolites, and so was easier to resolve. As such, the main
use of this type of plot is to indicate the position of the different resonances.
However, due to limitations in mimicking the physiological environment of the
metabolites (including high concentration metabolites, the presence of
macromolecules and trace paramagnetic materials, differences in viscosity and
microscopic heterogeneity (25)), any further quantitative comparison with in-vivo
data should be avoided.
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Disappointingly, these results were not replicated in-vivo. Eight volunteers were
scanned multiple times to acquire a total of 18 2D spectra. Using the same standard
imaging set-up of the volume head coil, the authors reported that resonances due to
NAA, glutamate / glutamine and, in some cases, lactate were readily identifiable on
the 2D contour plots, although they were less confident when assigning resonances
due to GABA and to taurine (an amino acid at concentrations similar to GABA (7)).
Lactate was also observed in a very small study (n = 3) using the 2D J-resolved
technique at 1.5T in tumours (124). In this study, Thomas et al proposed that a
major advantage of the technique was the ability to differentiate lactate from any
lipid contamination that would have overlapped the lactate doublet at 1.31ppm in a
standard ID spectrum. On the resulting 2D plots, no resonances were assigned to
other metabolites. However, from the ID spectra, a decrease in all other metabolite
concentrations was reported within the VOI, which may account for the apparent
failure of further 2D assignment.
More recently, further work has been performed to validate this technique in healthy
volunteers. Ke et al also used a modified PRESS sequence to perform 2D J-resolved
MRS and extensive developmental work was carried out on both phantoms and in-
vivo on healthy volunteers (24). In a slight variation to the earlier study by Ryner, a
slightly longer TEmjn of 48ms was used (compared to 25ms) and 14 extra spin-echoes
were collected in a total of 64 experiments. In all instances the quadrature head coil
was used. Phantoms were created with the concentrations of GABA well in excess
of those found in normal physiological conditions (lOOmM), and separate phantoms
were produced to investigate the effect of the overlying metabolites NAA, creatine,
choline, glutamate and glutamine. Reassuringly, GABA was identified in each of the
experiments. Moreover, the resonance at 3.01ppm was deemed the most suitable of
the three GABA resonances for quantification as it was more easily discerned from
the overlying creatine singlet using the 2D technique.
Using the same method, the in-vivo results also facilitated the identification of
GABA at this peak position. The large volunteer group (n = 36) was evenly split
between the sexes and following quantification of GABA, a difference was reported
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between the two sub-groups (1.01±0.36 pmol/cm3 for males; 1.16±0.43 pmol/cnr3
for females). It would be surprising if this difference was significant.
Ke reported that the major disadvantage of this technique was its acquisition time of
40 minutes - considerably longer than standard ID spectroscopy - although not
significantly longer than any of the aforementioned studies. Methods for reducing
this time include the use of a surface coil to increase the sensitivity and thereby allow
a decrease in NEX, and thus scan time. These issues had undergone some
preliminary investigation in the previously discussed study of Ryner et al (22). In
this study, one of the volunteers was re-scanned using a 8" transmit / 5" receive
surface coil arrangement. The reported improvement in SNR facilitated a reduction
in the NEX (and scan time) and a 60% decrease in voxel size. Comparable results
were reported for all resonances apart from lactate where a reduction in signal
intensity was observed. This was attributed to either an increase in signal loss, due to
RF inhomogeneity associated with this coil arrangement, or an actual reduction in
physiological concentration.
Further SNR investigations were performed by Ryner using the body coil transmit /
3" surface coil receive arrangement. Significant differences were reported between
glutamate / glutamine and GABA peaks as seen using this set-up when compared to
earlier in-vitro results, but not so for the NAA peaks. Differences in the T2N of these
metabolites were suggested as a possible cause for this dramatic reduction in
intensity and peak resolution, although this later experiment had a reduced number of
NEX per experiment (20 compared to 16), also reducing the SNR.
GABA measurements have been reported by Levy et al using the same 2D technique
as first presented by Ryner, on a 1.5T GE scanner using the quadrature head coil
(25), (26). However, the NEX was dramatically reduced to 2 which, whilst giving a
more ideal scan time of 6 minutes, greatly reduced the quality of the resulting
spectra. Spectra extracted at both J = 0Hz and J = 7.45Hz were studied to quantify
NAA, choline and creatine in the former spectrum, and GABA in the latter. The
authors reported a significant reduction in the mean GABA/creatine ratio as
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measured between seven patients with focal dystonia and 17 age-matched controls in
both the contralateral sensorimotor cortex (p < 0.01) and lenticular nucleus, (p <
0.01) (25). In a different study of 12 healthy volunteers who all underwent
temporary forearm ischaemic nerve block to induce acute deafferentation, reductions
in the GABA/creatine ratio immediately following deafferentation were also reported
(26).
A similar technique was also used by Hurd et al at GE Medical Systems (now GE
Healthcare), with the F1 created from timing parameters of either 128 evolution time
increments of 2.5ms or 64 increments of 5ms. This was to produce oversampled, J-
resolved spectra, again using a modified PRESS sequence (23). In-vitro spectra were
obtained from the standard GE spectroscopy phantom with an addition of 5.0mM
GABA (approximately x5 normal physiological concentration). In addition, spectra
were collected from an unspecified number of healthy volunteers.
This method differed from that previously discussed, in that the collected spectra
were not water suppressed, so were largely influenced by the water signal. This was
to overcome base-line artefacts otherwise present due to gradient inaccuracies
causing the production of spurious sidebands ofwater. It was found that the coherent
water sidebands were modulated at the sideband frequency throughout the evolution
time, and were present at two lines in the 2D spectrum: F1 = F2 and F1 = F2/2. It
had been found previously that by oversampling in the F1 dimension, it was possible
to resolve the artefacts from the signal of interest.
The authors reported an increase in resolution and specificity using this method, and
were able to model both the water peak and the metabolites from the unsuppressed
2D data. This principle was applied to the in-vitro data, where the modelled GABA
spectra at different J-coupling frequencies were superimposed on the phantom
spectra to aid with identification. Application of the same technique to the in-vivo
data facilitated identification of lactate, not normally easily distinguished above the
noise in a healthy brain spectrum. Disappointingly, identification of the GABA
peaks in-vivo was not attempted.
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In a small study comparing spectral editing, double quantum filter techniques and 2D
J-resolved spectroscopy, in-vivo GABA was not detected using the latter method
(15). As with previous studies, a series of 64 experiments were performed, with the
TE ranging from 35 to 665ms, NEX = 16, resulting in a scan time of 40 minutes. Of
specific interest to this work, in-vitro experiments were performed on phantoms
containing GABA only, and phantoms containing a mixture of alanine, GABA, NAA
and creatine. In the composite phantom, GABA resonances were identified at
2.29ppm and 3.01ppm. Only a single in-vivo spectrum was obtained, from a 131.6ml
voxel positioned to contain both grey and white matter. Although resonances from
several metabolites were identified, no mention of GABA was made, suggesting that
it was not identified by the authors. The 2D plots provided in the paper appeared
noisy, and since no extracted spectra were provided, it is impossible to arrive at a
definitive conclusion as to the success of the experiment with regards to GABA.
In a similar study by Ryner et al comparing 2D J-resolved spectroscopy to several
different sequences, including multiple quantum filter techniques and COSY
variations, no assignment was given to GABA in the resulting 2D J-resolved plot
(123). Again, spectroscopy from a single voxel from only one volunteer was
acquired. The 2D J-resolved sequence itself comprised of 50 individual experiments,
with TE starting at 45ms, ATE = 10ms, TR = 2200ms, and NEX = 20, giving a scan
time of 37 minutes. A grey matter phantom was constructed, including 0.5mM
GABA, but this was only used in the COSY experiments and unfortunately there was
no discussion ofGABA in any of the results.
From reviewing the literature, it is apparent that very little work has been conducted
into identifying GABA using this method at clinical field strengths. Consequently,
there is a need for a full and logical investigation into the feasibility of generating a
spectroscopy tool to quantify this metabolite that can be used routinely in the clinical
setting. The development and reliability of such a technique will form the bulk of
the work presented in this thesis.
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3.3.2.3 Technical issues of 2D J-resolved MRS
The main advantage of employing 2D J-resolved MRS over the other available
methods for detecting GABA (such as spectral editing and quantum filter
techniques), is that 100% of the available GABA signal is maintained (123). In
situations such as this where the metabolite only exists, in-vivo, in very small
concentrations, this is a very important consideration. For example, the application of
a zero quantum filter reduces the available sensitivity by 50% due to the coherence-
transfer pathways selected (123). In a double quantum filter experiment, the
efficiency is further reduced to 25%.
In addition, another of the disadvantages of the alternative techniques is that they are
designed to select a single, specific metabolite. Whilst this work is primarily
concerned with the investigation of GABA, application of 2D J-resolved MRS
acquires J-coupling information from all metabolites in the sample. With the
appropriate post-processing, this then allows analysis of any metabolite without the
need for performing additional experiments.
The main disadvantage of the 2D J-resolved method is the scan time. Although in
more recent papers, scan times of 6 minutes have been reported by reducing the NEX
= 2, the resulting spectra are very poor. In studies where GABA has more
convincingly been identified, the NEX varied between 8 -20 (22), (24), resulting in
acquisition times of between 15-37 minutes. This is considerably longer than the
scan time required for a conventional ID single voxel spectrum, and as such, may
not be tolerated by unwell patients. However, if this experiment is to be performed
at all, then it is important that the data acquired is of sufficient quality to provide
convincing results, thereby justifying the longer scan times.
3.3.3 Two-dimensional Double Quantum Filter
3.3.3.1 Background
2D DQFs are an extension of the ID DQF techniques described previously, Figure
3.10. The advantage of this type of 2D spectroscopy over, for example, COSY is the
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removal of all uncoupled spins. In COSY, singlets produce prominent diagonal
peaks that may obscure the signals from lower concentration metabolites nearby. In
their absence, coupled spins can be more clearly observed. The description of this
technique is included to provide a complete description of 2D techniques at 1.5T as
results using 2D DQ-MRS for GABA measurement have been reported (127,128).
One of the first in-vivo applications of 2D DQ filtering, albeit immediately post¬
mortem and at 2T, was to measure lactate in a human neuroblastoma implanted onto
the back of a mouse (129). The 2D DQF sequence used is shown in Figure 3.10 and
lactate could clearly be distinguished from the lipid resonances in the resulting 2D
DQ plot, whereas in the conventional ID spectrum, the 1.31ppm lactate peak was
obscured by the lipid presence. The presence of lactate was confirmed using
enzymatic assaying. This lactic acid editing sequence was modified to improve the
efficiency of lactate detection, reducing the extent of lipid overlap in the region of
1,4ppm and minimising the amount of residual water resulting in a better defined 2D
spectrum (130). In addition, the acquisition time was reduced from around 30
minutes to just over one minute. A final modification was made to the original ID
sequence to allow CSI of lactate with the addition of phase and frequency encoding
gradients.
TE/2 t, TE/2 t,




Figure 3.10 2D DQF pulse sequence, taken from (129): Pulse sequence repeated with successive
increments of q.
Following the success of lactate editing, in mice in-vivo, a 2D multiple quantum filter
editing sequence was optimised to identify the glutamate / glutamine resonances in
rats at 4.7T (131).
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In 2002, 2D MQ filtering techniques were being introduced at 3T for GABA
measurement (132). This preliminary study only performed in-vitro measurements
on two simple phantoms containing high concentrations of GABA and creatine, but
was able to demonstrate effective GABA detection and an increased efficiency of
water suppression. At the time of writing, it was disappointing to find no further
GABA-related results using this sequence.
3.3.3.2 Clinical applications
In the only work to be published relating to GABA measurement at 1.5T, Wang et al
modified the ID DQF pulse sequence proposed by Keltner et al (17) to include a
series of ti increments immediately after the second refocusing pulse (127,128).
After FT, the F1 dimension therefore contained the DQ frequencies (in ppm) and the
chemical shift information was held in F2. The aim of this method was to resolve the
3.01 ppm GABA resonance from the underlying macromolecules. It has previously
been shown in the ID double quantum filter methods that identification of a GABA
+ macromolecule + homocarnosine signal is possible (17,19,103,104). Similarly,
GABA without contamination was not resolved in the 2D DQF plots. However, from
a purely scientific viewpoint, this is a very interesting extension ofDQF techniques.
3.3.3.3 Technical limitations
The 2D DQF technique applied at 1.5T required 20 mins of scanning time. As with
all 2D methods, it does have the advantage of acquiring information about several
metabolites simultaneously, and so this time penalty can usually be justified.
However, in view of the results from 2D COSY and 2D J-resolved MRS at this field
strength, the associated loss of information from uncoupled metabolites may not.
Since 2D DQF MRS removes the contributions from uncoupled metabolites from the
2D spectrum, the creatine signal will no longer be available to act as an internal
standard. This is a usual point of reference, and often helps with the general reading
of the spectrum, but with training, this problem can easily be overcome. However, in
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centres that insist on quoting in-vivo metabolites in ratios to creatine, this practice
would not be possible.
Finally, another limitation of this sequence is, again, the need of a specialist pulse
sequence. Unlike 2D J-resolved MRS, which can be performed with the
manufacturer provided PRESS sequence, 2D DQF MRS requires extensive pulse
sequence programming, which will be prohibitive for most clinical centres.
3.4 Conclusions
It has been established that additional MRS methods are required to reduce the
complexity of spectra to facilitate the identification of certain metabolites in an
otherwise overcrowded spectrum, and these are summarised in Table 3.1. Spectral
editing techniques have the disadvantage in that they require prior knowledge of the
metabolite of interest in order to design a sequence for selectively retaining the signal
(116). This includes chemical shift information and coupling constants that are not
available from conventional ID spectroscopy, particularly where some of the
resonances are overlapped by other metabolites.
The main advantage of the 2D COSY and 2D J-resolved methods over the spectral
editing techniques is their ability to provide simultaneous assignment of resonances
from several cerebral metabolites. To date, these include NAA, choline derivatives,
creatine, glutamine, glutamate, lactate and GABA (133). Therefore, these 2D
methods are studied in this thesis.
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(1) Can be tailored to edit 3.01 ppm
GABA resonance
(1) Acquires information about only
one metabolite
(2) Requires the acquisition of two
spectra: Susceptible to patient
motion artefacts
(3) SDs of in-vivo GABA
measurement = 23% - 46%
(4) Contamination of GABA
resonance from macromolecules
and homocarnosine
(5) Scan times: 30 minutes - 90
minutes




(1) Can be designed to edit 3.01 ppm
GABA resonance
(2) Scan times: 8.5minutes (+ phase
calibration) -17 minutes
(1) Acquires information about only one
metabolite
(2) Detection efficiency of only 25%
(DQF) - 50% (ZQF)
(3) Contamination of GABA resonance
from macromolecules,
homocarnosine and glutathione
(4) Phase calibration sequences
required in-vivo before application
of DQF sequence
(5) Repeatability of in-vivo GABA+
measurements = 38%
(6) Requires dedicated pulse sequence
2D COSY (1) Acquires information on all
metabolites including 3.01 ppm
GABA resonance
(2) Reproducibly of in-vivo GABA
measurements < 22% (better than
spectral editing methods)
(1) Signal loss associated with
coherence transfer pathways
(2) Requires manual pre-scan
(3) Long scan time: 35 minutes +
manual pre-scan
(4) Requires dedicated sequence
2D J-resolved (1) Acquires information on all
metabolites including 3.01 ppm
GABA resonance
(2) No inherent signal loss
(3) Dedicated pulse sequence not
essential
(1) Long scan time: 40 minutes
(2) Contamination of 3.01 ppm GABA
resonance from macromolecules
2D DQF (1) Allows identification of 3.01 ppm
GABA resonance + other coupled
metabolites
(1) Removes all uncoupled spins from
2D plot: does not acquire
information about all metabolites
(2) Signal loss associated with
coherence transfer pathways
(3) Contamination of GABA resonance
from macromolecules
(4) Requires dedicated pulse sequence
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This chapter describes the preliminary practical work of performing 2D J-resolved
MRS without a dedicated sequence. This was accomplished using a series of
standard PRESS MRS sequences. Initial validation of this approach was achieved by
comparison of the resulting 2D J-resolved spectra against published data. Following
this, the threshold of in-vitro GABA detection was determined, and an estimate of
the general reproducibility of the method was obtained using a standard volume head
coil. In all in-vitro work, the experiments were performed at room temperature and
so include a -O.lppm shift. The results from a single healthy volunteer are
presented. This chapter concludes by discussing different optimisation strategies for
addressing the main disadvantages associated with this method.
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4.2 Sequence description and post-processing
4.2.1 Background
As described in §3, 2D J-resolved MRS can be performed using a modified PRESS
sequence, designed to uniformly increment the TE over a specific number of
experiments. Such an approach relies on either having the expertise to successfully
"modify" a PRESS sequence, or to obtain a suitable, pre-written, 2D J-resolved
sequence. However, one of the over-riding advantages of this technique, compared to
other GABA-detection methods reviewed in the previous chapter, is that the same
result can be achieved without a dedicated J-resolved sequence. 2D J-resolved
spectroscopy can be performed by manually incrementing the TE in an appropriate
number of PRESS sequences.
Original investigation into the viability of using 2D J-resolved MRS to detect GABA
at 1.5T was performed without a dedicated 2D sequence. Therefore, a protocol
comprising 64 individual PRESS experiments was created, with the TE manually
incremented (with values taken from the literature (23,24)) to create the required
second dimension for the 2D J-resolved spectra.
As described in §2.6.2, the PRESS sequence consists of a 90° pulse followed by two
180° pulses. From the description of a general 2D experiment provided in the same
chapter, it follows that in 2D J-resolved spectroscopy, the 90° pulse and first
refocusing pulse constitute the preparation period, and the time either side of the
second 180° pulse, equivalent to TE, comprises the evolution period. Since there is
no polarisation or coherence transfer in this type of experiment, a mixing period is
not required. Therefore, detection of the spin-echo occurs immediately after
evolution, Figure 4.1. A numerical description of the designated timings shown in
this figure can be found in Table 4.1.
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Figure 4.1 GE PRESS timing diagram. Taken from GE Spectroscopy Manual, 1999. The
timing variables are described in Table 4.1.
Table 4.1 Description of timing parameters used in a GE PRESS pulse sequence. Numerical






Time from start to centre of pulse 1 Fixed at 2.548ms
Time from centre of pulse 1 to centre Fixed at 9.392 ms
of pulse 2
Time from centre of pulse 2 to centre
of pulse 3 Varies according to t
Time from centre of pulse 3 to centre








§3.3.2 also states that the main aim of a 2D J-resolved experiment is to resolve the
resonances so that there is only J-coupling information in the F1 dimension and
chemical shift information in F2. This is achieved by applying the second refocusing
pulse at the midpoint of the evolution period, tis to refocus only the chemical shifts,
resulting in their removal from Fl. The homonuclear couplings are unaffected by
this 180° pulse and so appear in the final spectrum, (122). Therefore, in the detection
period, only J modulation and Larmor frequency are effective. This does mean
however, that initially both the Fl and F2 axes contain J-coupling information,
producing multiplets that appear along the y = -x line (i.e. at 45° to either axis). If
left in this way, the couplings will not appear where expected on the Fl axis, and F2
will contain both J-coupling and chemical shift information. Tilting the multiplets
through an angle of 45° will remove the J-coupling contribution from the F2 axis,
and align the coupling information correctly on Fl so projection onto the F2 axis will
produce a decoupled spectrum, as desired. This is shown in the results from a
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GAMMA (General Approach to Magnetic resonance Mathematical Analysis)
simulation of GABA, Figure 4.2. (GAMMA is a C++ toolkit allowing the simulation
of the behaviour of metabolites under various NMR experiments (134).)
Contoured magnitude plot Tilted magnitude pl«
(a)
2 0 F2 (ppm) 1-5
(b)
2 0 F2 (ppm) 15
Figure 4.2 Results from GAMMA spin-system simulation of GABA at 1.5T. The simulations
were based on the standard, asymmetrical GE PRESS sequence, repeated for 64 echo times with
a ATE of 10ms to mimic a 2D J-resolved experiment (135). (a) 2D J-resolved plot prior to tilting
and (b) the same plot after tilting. Note how the resonances now line up in Fl.
In terms of actually displaying the data, the recorded FIDs can be described by a
combination of in-phase and anti-phase components, giving rise to a twisted
lineshape (97). Consequently, it is not possible to display the spectra in pure-
absorption mode and so 2D J-resolved spectra are always shown in absolute mode.
An unavoidable disadvantage of this method of presentation is the decrease in
spectral resolution, due to the broadening of the resonances associated with absolute
mode display.
Another issue that can be at least partly addressed by post-processing is ti noise.
This artefact appears from random fluctuations in the signal intensity arising from
scanner instabilities during the evolution period, hence 'V noise, (113). Such
scanner instabilities are evident as bands of noise, parallel to the Fl axis (prior to
tilting), and occur in the same chemical shift positions as the genuine resonances.
Another characteristic of this noise pattern is the intensity variation of the band: It is
proportional to the amplitude of the corresponding resonance, and so the intense
peaks of singlets are associated with stronger bands of noise. Since the actual
stability of the scanner is the manufacturer's responsibility, where ti noise does exist,
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it is very difficult to completely eliminate. Reproducibility between individual
sequences can be improved by performing regular autoshims to maintain lineshape.
Phantom stability - in terms of temperature and solvent equilibrium - is crucial, and
it is also important to maintain magnetic stability. Thus the movement of magnetic
materials in and around the magnet room is not recommended.
Post-processing methods can be used to reduce ti-noise in the spectra, but may
themselves give rise to artefacts. Exploitation of the symmetrical nature of the 2D J-
resolved plot facilitates comparison of the data points either side of the diagonal, and
then replacement of both with the smaller value. This method assumes that the
difference between the two resonances is due to noise and if applied, must be done so
with care to prevent regions of ti noise becoming enhanced with the multiplets.
However, in the low F1 resolution in-vivo experiments, the resulting spectra are not
entirely symmetrical around J = 0Hz. This is due to incomplete separation of the
multiplet structures in both halves of the 2D spectrum, i.e. ±J Hz, so the intensities of
the resonance pair are not identical. Therefore, "symmetricalisation" at clinical field
strengths is not recommended.
Accurate phase correction can also lessen ti noise, by reducing the effects of phase
changes occurring over the time series of FIDs. The exact procedure depends on the
characteristics of the raw data, and more specifically, whether or not it has associated
reference water information. In addition, the exact order in which the post¬
processing steps are applied will determine the type of phase correction applied (time
domain or frequency domain). This subject is covered in greater depth in §5.
4.2.2 Scanning protocol
All experiments were performed on a 1.5T GE Signa Horizon scanner using a
standard volume head coil. 2D J-resolved spectroscopy was achieved by performing
64 individual, single-voxel PRESS experiments: TEstart = 35ms, TR = 2000ms,
number of excitations per frame of data (NEX) = 4, total number of excitations
required for signal averaging (NSCans) = 32, VOI = 3x3x3 cm and A TE = 10ms
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giving rise to an F1 bandwidth of ± 50Hz, tscan ~ 2.5hours. Initial 2D experiments
were performed simply by loading the required number of PRESS sequences onto
the desktop, setting the appropriate timing parameters and copying the graphic
prescription from the first sequence to the 63 remaining sequences. (The
manufacturer had warned against using the "copy and paste" tool as a method for
repeating the sequences, since the software version at that time was unable to support
this editing function.) After running a few preliminary experiments, the series was
saved as a protocol for use in subsequent 2D J-resolved experiments. In this way,
consistency between each of the 64 experiments and therefore the 2D experiments
was ensured, with only the VOI needing to be copied onto each prescription.
With a set protocol and once the VOI had been prescribed for each experiment, it
was possible to automate the 2D J-resolved experiment by selecting the "autoscan"
mode, thereby allowing each sequence to run sequentially without any operator
input. However, this would have meant that before every sequence, a full prescan
would have been performed. This involves setting the centre frequency, the
transmit- and two receive-gains, and optimisation of the voxel localisation shim and
water suppression. For this 2D experiment, allowing 64 full prescans would add an
extra hour to an already excessive scan time. Since the data were being collected
from the same VOI in a phantom, it was not necessary to re-shim the voxel between
every PRESS experiment, based on the assumption that the subject did not move, and
that there was no significant drift of the scanner settings. Consequently, it was
possible to interrupt the pre-scan as soon as it started (by starting a manual pre-scan
and immediately selecting "Done"), and thus dramatically reduce the amount of time
spent in pre-scan optimisation.
4.2.3 Post-processing Protocol
Following acquisition, each 2D experiment had 64 raw data files, known as "P-files"
on a GE scanner. There are only 196 unique p-file identifiers, starting at P00000.7
and incremented by approximately 512 each time a new file is created. Thus, once p-
file P99840.7 is named, the next P-file created is P00000.7 and so on. If this raw data
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file already exists, then it is over-written by a new version, and the raw data from the
old file is lost. Thus, in a 2D experiment where at least 64 spectroscopy sequences
were being performed, extreme care was taken to ensure that the p-files were
transferred to another location at regular intervals to prevent data loss due to file
over-writing.
To ensure that the p-files were processed in the correct order, that is the order of
acquisition with increasing TE, each of the p-files were renamed according to the TE
used, into the form te###ms.raw, e.g. te35ms.raw, te45ms.raw etc. In-house
software previously developed for processing single-voxel spectroscopy and CSI
data was adapted to automatically process the 64 renamed raw data files. The main
functions of this programme (Jresolved.c, written by Ian Marshall) were to: -
i. Read in the renamed raw data files
ii. Phase correct the FIDs using the water FID as reference
iii. Scale the phase-corrected FIDs according the pre-scan parameters (transmitter
gain (TG) and receiver gain (R1 and R2)) and the spectroscopy voxel volume
iv. Remove the residual water signal
v. Cumulatively save all the processed FIDs in one large text file for further
processing in Matlab (The Mathworks Inc).
Phase correction was based on the well-documented method by Ordidge and
Cresshull (136). This relies on the acquisition of a water reference signal at the same
time as a water-suppressed, metabolite signal. Information about the phase
distortions arising from field inhomogeneities and eddy currents can be obtained
from the phase angle of the reference signal, analysed on a point-by-point basis.
Since the water-suppressed signal experiences phase distortions due to the same field
inhomogeneities and eddy currents, as well as the phase information from the
metabolites, subtraction of the phase angles from the reference signal results in a
phase-corrected metabolite FID. The main disadvantage of this method is the extra
time needed to acquire the reference signal. However, standard PRESS acquisition
on the GE scanner automatically includes a number of frames (set by the total
number of scans / total number of excitations for a single frame of data) of non-water
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suppressed data that can be extracted from the same p-file as the water-suppressed
data and used for phase correction.
Even with the application of a CHESS pulse, the water signal remains dominant in
the resulting spectrum, and so further post-processing is required to remove the
residual water peak. It is well established that an FID can be modelled as a sum of
complex, exponentially damped sinusoids, giving rise to a series of frequency-
domain Lorenzian lines (67), so the FID can be accurately modelled to remove the
water peak. One such method of achieving this is using the Hankel Lanczos singular
value decomposition method (HLSVD) (137,138). Using the known characteristics
of the time domain signal, HLSVD can be used to model the FID using a limited
number of singular values. The time-domain suppressed water signal can be
identified from the central frequencies of the water resonance and from its larger
amplitude sinusoids (compared to those from the metabolites). Once the residual
water is subtracted from the original FID, the predominant information in the
resulting FID will be from the metabolites. The advantage of performing the
modelling and subtraction in the time-domain is that both the main water peak and its
tail are removed from the frequency-domain spectrum, without affecting the
metabolite signals (since these lie outside the water region). Consequently, if the
algorithm performs effectively, there should be no baseline artefacts from the
residual water signal complicating measurement of the metabolites.
In terms of the practical aspects of post-processing the spectroscopy raw data,
especially with a single 2D experiment requiring 64 individual spectra, it was
advantageous that HLSVD was fully automated. In-house software previously
written for spectroscopic analysis was applied (139), using the same initial modelling
parameters and number of iterations.
Once these time domain corrections had been made, the processed FIDs were saved
in a text file, ready for importation into Matlab for frequency domain manipulation.
In Matlab, a second programme (Jres_mag) was applied, performing: -
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i. Apodization of the data using a simple sine bell in the F1 dimension, and a
Lorenzian-Gaussian combination in the F2 dimension. This enabled an
optimum compromise between line width and resolution to be obtained.
ii. ID FT on the FIDs to allow observation of the spectra as typically seen in an
MRS experiment.
iii. Second dimension FT on the results from (ii) to display the complete results
from the 2D J-resolved experiment.
The conventional method of displaying 2D spectra is on a contour plot, with an
appropriate "cut-through" level determined by the concentration of the metabolites
under study. A 2D contour plot is analogous to an Ordnance Survey map, with the
peaks and troughs of the metabolite peaks akin to the peaks and troughs of mountains
and valleys. To represent the 3D information in 2D, it is necessary to choose a
height at which to "cut-through" the plot and thus observe the 2D projection of the
'landscape' at that level, Figure 4.3. Higher up the plot, information is gained about
metabolites with large peaks i.e. those present in high concentrations. As the "cut-
through" level is reduced, more information is obtained about lower concentration
peaks until eventually all information is lost to noise. Once the plot had been
constructed, individual spectra were extracted at rows corresponding primarily to the
GABA J-coupling frequency, although spectra from any other J-coupling frequency
are also possible.
(a) (b)
Figure 4.3 (a) 3D surface plot and (b) 2D J-resolved contour plot from the same 3 x 3 x 3cm3
VOI in a phantom containing lOmM GABA. The metabolite peaks at 3.01ppm, 2.28ppm and
1.89ppm are clearly seen.
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Quantification of the extracted spectra was achieved in Magnetic Resonance User
Interface (MRUI) (http://carbon.uab.es/mrui/). The matlab spectra were converted to
ascii files of the correct form, header layout and size to be properly processed in
MRUI by a function called lineSelect.m, written by the author. Prior knowledge files
were created from 2D J-resolved experiments on high concentration individual
phantoms, with files created for the metabolite resonances both at J = OHz (i.e.
uncoupled spectra) and J = 7.4Hz (GABA J-coupling frequency). Once the
acquisition of the prior knowledge was complete, the quantification process was
semi-automated, requiring no additional data input, thus standardising the procedure.
4.3 In-vitro experiments using 64 PRESS experiments
4.3.1 Individual metabolite phantoms
4.3.1.1 Methods
A number of experiments were performed to establish the validity of 2D J-resolved
MRS from 64 individual PRESS sequences. The first of these involved comparing
the experimental results from the individual metabolites to the published literature, to
confirm their appearance on 2D J-resolved spectra (22). Aqueous solutions of 50mM
creatine, 50mM choline and lOOmM of GABA all underwent 2D J-resolved
spectroscopy using the acquisition parameters given in §4.2.2. In addition, 2D J-
resolved spectra were acquired from aqueous solutions of glutamate and glutamine,
both at concentrations of 25mM.
4.3.1.2 Results
Figure 4.4 shows the 2D J-resolved spectra from individual phantoms containing
50mM of both choline and creatine. The 2D J-resolved plot from lOOmM GABA is
given in Figure 4.5 (a), and Figure 4.5 (b) shows the spectrum extracted from the 2D
plot, corresponding to the J-coupling frequency of GABA: J = 7.4Hz. Finally, the
complex coupling patterns from the phantoms containing glutamate and glutamine
are shown in Figure 4.6 (a) and (b) respectively.
Page 89








2 0 F2 (ppm)
Tilted magnitude pic*
(a) (b)
Figure 4.4 2D J-resolved plot from a 3x3x3 cnr' VOI positioned in a phantom containing (a)
50mM choline and (b) 50mM creatine. Both experiments were performed using a standard





Figure 4.5 (a) 2D J-resolved plot from a 3x3x3 cm3 VOI positioned in a phantom containing
lOOmM GABA, using a standard volume head coil, (b) Extracted row corresponding to GABA
J-coupling frequency (7.4Hz) - the 3.01ppm and 2.28ppm GABA peaks are clearly visible (with
all peaks shifted by -O.lppm in room temperature phantoms).
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Tilted magnitude plot Tilted magnitude plot
(a) (b)
Figure 4.6 2D J-resolved plot from a 3x3x3 cm' VOI positioned in a phantom containing (a)
25mM glutamate and (b) 25mM glutamine. Both experiments were performed using a standard
volume head coil (with all peaks shifted by ~0.1ppm in room temperature phantoms).
4.3.1.3 Discussion
From ID MRS, we know that creatine has a prominent singlet at 3.03ppm. As it is
uncoupled, only a single creatine peak is expected on a 2D J-resolved spectrum, and
this is confirmed by the experimental work, Figure 4.4 (b). However, this spectrum
was not ideal due to the large F1 and F2 artefacts arising from ti noise (as previously
discussed) and truncation artefacts. This may be due to heating of the gradient coils
or indicative of the irregular autoshimming of the voxel, but nevertheless, was of
concern. Once the voxel has been shimmed in a stationary phantom, it should not
need to be reshimmed unless the scanner pre-scan parameters were susceptible to
drift. However, even without deuterium field locks to provide temporal stability,
such as those used in high resolution spectrometers (123), it is unlikely that the Bo
field will drift to an observable extent.
Overall, the general pattern of the metabolites tested was as expected, with their
coupling patterns similar to those published by Ryner et al (22). This favourable
comparison permitted initial validation of this method of acquiring and processing 64
individual PRESS sequences to form a single 2D J-resolved experiment. In light of
this, it was appropriate to evaluate the technique's performance specific to GABA
measurement.
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4.3.2 Threshold of GABA detection
4.3.2.1 Introduction
Before this technique could be applied in-vivo, it was important to establish whether
or not this approach was sensitive enough to detect GABA at normal physiological
concentrations. Therefore, a series of experiments were performed to determine the
threshold at which GABA can be detected in-vitro, and from these results, consider
the suitability of the method in-vivo.
4.3.2.2 Materials and Methods
All experiments were performed following the protocol given in §4.2.2. 2D J-
resolved spectra were acquired from a 3x3x3cm3 voxel in the centre of the phantom,
using a standard volume head coil.
Fourteen individual phantoms were made each containing physiological
concentrations of choline and creatine (3mM and 9mM respectively) and GABA at
concentrations as listed in Table 4.2. The actual concentrations of choline and
creatine were chosen to represent the upper boundaries of normal physiological
concentrations, in all brain regions (140). The metabolite concentrations were
calculated from masses of the dry chemicals (Sigma-Aldrich).
Table 4.2 Phantom metabolite concentration for threshold of GABA detection experiments
Phantom number Metabolite concentration (mM)
Choline Creatine GABA
1 3 9 20.0
2 3 9 5.0
3 3 9 3.0
4 3 9 2.0
5 3 9 1.9
6 3 9 1.8
7 3 9 1.7
8 3 9 1.6
9 3 9 1.5
10 3 9 1.4
11 3 9 1.3
12 3 9 1.2
13 3 9 1.1
14 3 9 1.0
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4.3.2.3 Results
To aid identification and quantification of GABA, an initial phantom containing
20mM GABA and physiological concentrations of choline and creatine was
investigated, Figure 4.7. GABA can be clearly identified in both the 2D J-resolved




Figure 4.7 (a) 2D J-resolved plot from 3x3x3 cm1 VOI positioned in a phantom containing 3mM
choline, 9mM creatine and 20mM GABA. The 3.01ppm and 2.28ppm GABA resonances are
highlighted by the circular markers, (b) Extracted row corresponding to GABA J-coupling
frequency - the 3.01ppm and 2.28ppm GABA peaks are clearly visible (with all peaks shifted by
-0.1ppm in room temperature phantoms).
Figure 4.8 shows the 2D plot from the phantom containing the lowest detectable
concentration of GABA in this experimental set-up, that is 1.2mM. The 3.01ppm
GABA resonance is clearly seen on both the 2D contour plot and the extracted
spectrum in Figure 4.8 (b). Figure 4.8 (c) displays the results after quantification of
the peaks in the extracted spectrum using MRUI. Using the same method, the
3.01ppm GABA peak was quantified in all spectra where it was visible and the
results plotted in Figure 4.9.
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Figure 4.8 (a) 2D J-resolved plot from 3x3x3 cm" VOI centrally positioned in a phantom
containing 3mM choline, 9mM creatine and 1.2mM GABA. The 3.01ppm and 2.28ppm GABA
resonances are highlighted by the circular markers. Extracted GABA (J = 7.4Hz) spectrum
from same phantom: (b) Matlab raw data, (c) After quantification in MRUI: Peaks 1 and 2
correspond to the residual peaks from choline and creatine respectively; Peak 3 is the 3.01ppm
GABA and peak 4 is the 2.28ppm GABA peak (with all peaks shifted by -O.lppm in room
temperature phantoms). The original (bottom), modelled (centre) and residual = original -
modelled (top) spectra are shown.
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Figure 4.9 Results of in-vitro GABA measurement from a 3x3x3 cm3 voxel in 14 phantoms of
decreasing GABA concentration, using 2D J-resolved MRS (64 individual sequences), in a
volume head coil.
4.3.2.4 Discussion
This series of in-vitro experiments has shown that that GABA can be resolved from
the neighbouring resonances of choline and creatine in-vitro, and at concentrations
approaching those found in normal human brains. However, as Figure 4.9 shows, it
is very difficult to discriminate between the actual concentrations of GABA at the
very low concentrations, i.e. less than 1.6mM. Therefore it is important to establish
the reproducibility of these results, before any conclusions can be drawn regarding
the reliability of future in-vivo measurements. This issue of reproducibility is
addressed in the next section.
4.3.3 Reproducibility
4.3.3.1 Introduction
Before applying any new method clinically, it is essential to determine the
reproducibility of the entire process, including acquisition and post-processing. A
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given in §7, preceding a thorough study of the reproducibility of GABA
measurements using a dedicated 2D J-resolved MRS sequence, to which the reader is
directed for a more complete introduction.
Since the ultimate aim was to apply this method in a clinical environment where
scans are repeated in different sessions over many days and weeks (so called
"between-days" reproducibility), a small study (n = 5) was performed to determine
the reproducibility of such measurements, also over many scan sessions.
4.3.3.2 Materials and Methods
2D J-resolved spectra were acquired from a volume head coil, using the same
protocol as given in §4.2.2. A single phantom was made containing physiological
concentrations of the most common cerebral metabolites, as listed in Table 4.3. To
obtain an indication of the general reproducibility of the technique, preliminary
measurements were taken from only acetate (substituted for NAA), choline and
creatine. In light of the previous results with artefacts appearing in both F1 and F2,
extra care was taken with the experimental set-up on each occasion. Temperature
consistency was achieved by allowing the solution to stabilise at magnet room
temperature for at least 24 hours before the experiment, and motion artefacts were
reduced by positioning the phantom within the magnet bore (in the volume head coil)
for a minimum of 15 minutes before commencing scanning.
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To obtain a measure of the between-days reproducibility, five 2D J-resolved spectra
were acquired over a period of nine days. The resulting raw data files were then
transferred to a SUN Ultra workstation and processed as previously described in
§4.2.3. From the J = 0Hz spectra, the acetate, choline and creatine peaks were
quantified in MRUI, using prior knowledge files as previously described.
Coefficients of variation (CVs), defined as the percentage ratio of the standard
deviation to the mean, were calculated for all three metabolites from all five 2D J-
resolved spectra.
4.3.3.3 Results
The results from the five between-days 2D J-resolved experiments are summarised in
Table 4.4. Figure 4.10 shows representative results from the reproducibility study,
showing a 2D J-resolved and an extracted spectrum (at J = 0Hz) respectively.
Table 4.4 Peak areas (arb), as quantified in MRUI, from in-vitro between-days reproducibility
experiments
Metabolite Between-days experiment Mean SD CV(%)
1 2 3 4 5
choline 14.54 11.88 11.05 12.57 14.33 12.87 1.53 11.8
creatine 24.29 19.63 18.39 17.58 19.47 19.87 2.61 13.1
acetate 31.27 24.88 22.78 24.4 27.31 26.13 3.30 12.6
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Figure 4.10 2D J-resolved spectrum from 3x3x3 cm'1 VOI centrally positioned in a phantom
containing physiological concentrations of choline, creatine, acetate (in lieu of NAA), glutamate,
glutamine, myo-inositol, GABA and lactate, Table 4.3. Extracted uncoupled (J = 0Hz) spectrum
from same phantom: (b) Matlab raw data (c) After quantification in MRUI Peaks 1, 2 and 3
correspond to choline, creatine and acetate respectively (with all peaks shifted
by -O.lppm in room temperature phantoms).
Page 98
2D J-resolved MRS using a protocol of 64 individual PRESS sequences
4.3.3.4 Discussion
As will be discussed in §7, large variations in the CVs for in-vivo NAA, choline and
creatine have been detailed, but in-vitro, CVs of < 5% have been reported using
conventional ID methods (141,142). It is somewhat disappointing, therefore, that
the reproducibility of acetate, choline and creatine are all > 10% using this 2D
method. This may reflect scanner instabilities over the 2.5 hour acquisition process.
Without comprehensive study, the reproducibility of GABA measurement using this
technique cannot be established, but it is likely that it will be worse than the
measured CVs of the higher concentration metabolites. If confirmed, then this has




The ultimate aim of this project was to obtain 2D J-resolved spectra from human
volunteers and patients for in-vivo GABA measurement. Although as it stands, this
protocol cannot be clinically applied, it was of interest to acquire at least a single in-
vivo 2D spectrum to relate the results to the in-vitro work.
4.4.2 Methods
A single healthy volunteer was recruited to test this approach in-vivo, and written
informed consent was obtained. Sixty-four PRESS spectra were acquired from a
o
... .. . .
3x3x3cm voxel positioned in the occipital cortex using a series of T2, 3-plane
localising images acquired using a volume head coil, and following the protocol
detailed in §4.2.2. Following post-processing of the raw data files as previously
described in §4.2.3, a 2D J-resolved spectrum and extracted spectrum corresponding
to the J-coupling frequency ofGABA were produced.
Page 99
2D J-resolved MRS using a protocol of 64 individual PRESS sequences
4.4.3 Results
The resulting 2D J-resolved spectrum is shown in Figure 4.11 (a). Figure 4.11 (b)
provides the spectrum extracted from the 2D contour plot corresponding to the J-
coupling frequency of GABA. Comparison to the available 2D J-resolved spectra in
the literature allowed assignment of the 3.01ppm GABA peak. Examination of the
individual ID spectra prior to 2D FT showed that almost all metabolite signal had
disappeared by TE = 475ms, with little evidence of either the choline or creatine
peak after TE = 415ms, Figure 4.12.
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Figure 4.11 (a) 2D J-resolved spectrum and (b) extracted row corresponding to the J-coupling
frequency of GABA from a 3x3x3cm3 VOI in a normal, healthy volunteer. Provisional




Figure 4.12 Conventional ID in-vivo spectra using the 2D J-resolved experiment with TE (a)
45ms, (b) 415ms and (c) 485ms demonstrating the loss in metabolite signal
4.4.4 Discussion
The success of 2D J-resolved spectroscopy, using a composite of individual PRESS
sequences, for in-vivo GABA measurement is not conclusive. A peak assignment to
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GABA has been made at its F1 = 7.4Hz and F2 = 3.01ppm position. The extracted
spectrum shows a distinct peak at ~ 3.0ppm and the corresponding assignment has
been made to GABA. However, the extent of the contribution from contaminating
resonances (such as macromolecules, glutathione and homocarnosine (19)) has not
been established, and it may be that these form the bulk of the observed peak.
Clearly, further work is required.
This experiment has shown though, that it is possible to acquire a 2D J-resolved
spectrum from a normal volunteer using a protocol of 64 PRESS experiments with
the manual increase of TE. That in itself is a result worth achieving, and suggests
that on conventional clinical scanners, with only standard spectroscopy sequences,
in-vivo 2D J-resolved spectroscopy is possible.
4.5 Sequence optimisation
4.5.1 Introduction
The results from the experiments using 64 PRESS sequences to create a 2D J-
resolved experiment have shown that, in principle, the approach works. However,
one of its major disadvantages is the scan time needed to acquire all 64 spectra.
Therefore, an obvious remedy would be to acquire fewer spectra, but this would only
be useful if a similar result could be achieved. Study of the literature has shown that
while most investigators used 64 TEs, variations have been used: Ryner et al used
between 40 and 64 increments, all in 10ms steps (22). Without changing the
stepsize, this variation in step count has direct implications on the achievable
resolution. Despite this, the authors used 50 TE steps in all of their in-vivo work and
were still able to make tentative assignments to taurine and GABA cross-peaks.
Post-processing techniques can also offer a method of reducing the time actually
required in the scanner. Since the metabolite signal has diminished after
approximately TE = 485ms, the remaining spectra could be zero-filled to complete
the matrix, and preserve the F1 resolution. Both these approaches were investigated
using GAMNA simulations and the raw data from results presented thus far.
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Another general method of reducing the total acquisition time is to collect fewer
excitations at each TE. When attempting to measure signals from low concentration
metabolites, this can have a detrimental effect on the end result. This can be
compensated for by exchanging the volume head coil for a more sensitive surface
coil. The application of different coils to the measurement of GABA is investigated
in §6.
4.5.2 Methods
GABA spin-system simulations in GAMMA based on (135) were acquired under
standard conditions (TEstar^ 35ms, number of experiments = 64, ATE = 10ms) and
the results were re-processed in two ways:
(1) Including fewer PRESS experiments in the final analysis to observe the effect of
changing F1 resolution on the resulting spectra.
(2) Substituting the end portion of the original raw data with zeros to mimic the
effect of acquiring a reduced dataset and then zero-filling. In this way, the F1
resolution is preserved at 1.56Hz.
The same post-processing protocol was then applied to a series of in-vitro and in-vivo
data.
4.5.3 Results
Results from applying the optimisation methods to the GAMMA simulations are
shown in Figure 4.13 and Figure 4.14. Representative results from the in-vitro work
are given in Figure 4.15 and Figure 4.16 from a phantom containing 1.2mM GABA
with choline and creatine. The same post-processing applied to the in-vivo dataset
are shown in Figure 4.17 and Figure 4.18.
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Figure 4.13 Result from reducing the number of TEs simulated: (a) 64 TEs (resolution =
1.56Hz); (b) 50 TEs (resolution = 2Hz) and (c) 32TEs (resolution = 3.13Hz)






















Figure 4.14 Results from zero-Filling the simulated data (a) no zero-filling, (b) zero-filling from
TE 525ms onwards and (c) zero-filling from TE 355ms onwards (i.e. at experiment 32).
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Figure 4.15 Result from reducing the number of TEs acquired in a phantom containing 3mM
choline, 9mM creatine and 1.2mM GABA: (a) 64 TEs (resolution = 1.56Hz); (b) 50 TEs




Figure 4.16 Results from zero-filling the data acquired in a phantom containing 3mM choline,
9mM creatine and 1.2mM GABA: (a) no zero-filling, (b) zero-filling from TE 525ms onwards
and (c) zero-filling from TE 355ms onwards (i.e. at experiment 32) (with all peaks shifted by
-O.lppm in room temperature phantoms).
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Figure 4.17 Result from reducing the number of TEs in-vivo: (a) 64 TEs (resolution = 1.56Hz);
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Figure 4.18 Results from zero-Filling the in-vivo data (a) no zero-Filling, (b) zero-filling from TE
485ms onwards and (c) zero-Filling from TE 355ms onwards (i.e. at experiment 32).
4.5.4 Discussion
As expected, by far the worst result in all cases was the acquisition of only 32 spin-
echoes. When zero-filled to the equivalent of 64 spin-echoes, a GABA peak is not
visible in either the in-vitro and in-vivo datasets. Without zero-filling, not only is
there a decrease in the available F1 resolution, but there is considerable spread of the
singlet resonances. In the in-vivo experiment with broader linewidths, this F1 spread
could potentially lead to occlusion of the GABA peak, and so as a post-processing
strategy should be abandoned.
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The results from acquiring 50 FIDs are far more encouraging. Although GABA is
readily identifiable in all examples, the zero-filling option may be preferred as it
allows an F1 resolution of 1.56Hz. This is important, as one of the major advantages
of 2D J-resolved spectroscopy is that information on all the metabolites is acquired,
and so large decreases in the F1 resolution may prevent other metabolites from being
identified. With little differences observed between the complete data set and the
result from zero-filling only the last 18 experiments, this suggests that this approach
may be an acceptable means of decreasing the scanning time. However, further
clarification is required before this approach is adopted for routine in-vivo data
collection.
4.6 Discussion and conclusions
Despite the success of developing a protocol to replicate 2D J-resolved MRS, it was
clear from the start, that such an approach was not going to be viable in the clinical
domain. A "sequence" of over 2.5 hours (excluding patient set-up and localising
scans) was never going to be acceptable to a patient population, and was just barely
so for a healthy volunteer. Nevertheless, it was a very interesting and beneficial
exercise.
The results from the experimental work in this chapter have demonstrated that 2D J-
resolved spectroscopy can be performed without a dedicated sequence. Moreover, in
the single volunteer scanned, a peak assignment to GABA was made. Perhaps with
further optimisation of the protocol, incorporating more sensitive coils and reduced
raw data acquisition, it may be possible to decrease the scanning time further.
However, it is unlikely that these measures alone will reduce the scan time
sufficiently while maintaining adequate resolution and SNR, to allow employment of
this method outside the research environment.
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5 2D J-resolved MRS using a dedicated sequence
5.1 Introduction
The results from §4 demonstrated that it is possible to perform 2D J-resolved
spectroscopy without a dedicated sequence. However, such an approach is not
practically viable as it requires over two and a half hours of scan time. To facilitate a
more viable transition of this method into the clinical environment, a dedicated 2D J-
resolved PRESS sequence was obtained for testing. This is a research sequence,
developed by Dr. N. Sailasuta at GEHC, initially for use at 3T and generously made
available for testing on the university's 1.5T research scanner.
This chapter describes the initial testing and validation work of the dedicated 2D J-
resolved sequence. Detailed descriptions of the acquisition and post-processing
protocols are provided, with particular attention to the differences between the
dedicated sequence and 64 individual sequences. Following a similar pattern as §4,
the results from individual metabolite solutions are presented, the threshold of in-
vitro GABA detection is determined and an estimation of the general reproducibility
of the sequence obtained.
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5.2 Sequence description
5.2.1 Background
As stated in the introduction, the dedicated 2D J-resolved PRESS sequence is a
research sequence, so cannot be used without a research "key": An agreement
between the institution and scanner manufacturer allowing the MRI system to be
used for research. Since all work was performed on the university's dedicated
research scanner, the key was already in place and the research agreement was
updated to include the recent acquisition of the 2D J-resolved sequence.
The dedicated 2D J-resolved sequence is based on the standard PRESS sequence,
modified to allow the time either side of the second refocusing pulse to be uniformly
incremented (90°-180°-ti/2-180°-ti/2-acquire). Fundamentally, the two sequences
are very similar. Both use the same fat and water suppression parameters, and prior
to a scanner software upgrade, the saturation bands were the same too. The same RF
pulses and slice-select gradients are also used. In a standard PRESS sequence, there
are two loops controlling data acquisition: The first is determined by the number of
excitations as specified by the user. The second controls the number of water
reference spectra acquired. This first loop is common to the 2D J-resolved sequence,
but in contrast, the second loop is used to control the number of spectra acquired in
the 2D experiment. I.e. the number of TE steps, known as steps2d. Echo detection
then proceeds along a common route. Since the sequences are so alike, the 2D
version is appropriately named 2D J-resolved PRESS.
5.2.2 Scanning protocol
All experiments were performed on a 1,5T GE Signa Horizon scanner, operating in
research mode. 2D J-resolved spectroscopy was performed using a dedicated
sequence with the following scan parameters: TR = 2000ms, TEstart ~ 35ms, ATE =
10ms, NEX = 16 at each TE. The scanning time for each 2D experiment was
approximately 35 minutes. In all experiments, a 3x3x3cm3 VOI was placed in the
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centre of the phantom using a 3-plane localising image from a standard volume head
coil for localisation, i.e. the same set-up as described in §4.
5.2.3 Post-processing
After transfer of the raw data files to a Sun Ultra workstation, the same general post¬
processing routine as described in §4.2.3 was applied. This consisted of removal of
the water components using HLSVD and scaling of the FID to take into account the
pre-scan parameters. Prior to 2D FT the data were zero-filled and apodized in both
F1 and F2 dimensions using a simple sine-bell filter and Lorenzian-Gaussian
enhancement respectively. After 2D FT, the dataset was tilted to remove the J-
coupling contribution on the resulting 2D plot, and spectra were extracted at J =
7.4Hz for GABA measurement.
Quantification of the metabolite areas in MRUI was extended to include the
conventional, ID spectra prior to FT. The FID raw data was extracted from the
composite text file containing the information from all 64 experiments, and
converted into the appropriate ascii format. Prior knowledge files for the metabolites
at representative long and short TEs (35ms and 135ms respectively) were created in
the same way as previously described in §4.
However, the water reference spectra required for phase correction were no longer
acquired as part of the 2D J-resolved sequence. This meant that the automatic time
domain phase correction as applied to the 64 individual sequences had to be changed
to account for this. As a result, a more in depth study of phase correction methods
was required.
5.2.3.1 Phase correction: Background
As stated earlier, an FID can be modelled as a series of damped sinusoids, but for
various practical reasons, the phase of these signals may not all be zero. Possible
causes of phase shifts include a delay between the start of the RF pulse sequence and
data acquisition, or misadjustment of the phase detector (143). In the latter case, the
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phase distortion will produce a uniform error across the entire spectrum, meaning
that the mixture of absorption and dispersion will be the same for all peaks. This is a
zero-order, frequency-independent phase shift, and can be corrected by a complex
rotation of the signal. Correcting this type of phase shift is of primary concern in this
section.
There is a plethora of work applying time domain phase correction to FIDs using
information from a reference signal e.g. (136,144-148). As discussed in the previous
chapter, the technique of using a reference signal to acquire the necessary
information for zero-order phase correction was introduced by Orididge and
Cresshull (136). Application of the same phase angles from the reference signal to
the water-suppressed signal on a point-by-point basis provides a reliable
approximation of zero-order phase correction. However, in the absence of a
reference signal, such methods cannot be directly applied. One solution is to treat
the metabolite signal as the reference, since without additional processing, the
residual water signal will still dominate the FID. Thus, the metabolite FID will
effectively phase correct itself.
Frequency domain methods of phase correction often rely only on the water-
suppressed, metabolite spectra and not a reference signal. Siegel used a modified
simplex method to optimise the angles needed to phase correct the spectra using pre¬
set criteria based on the area of the absorption (real) signal (149). The actual criteria
on which the phase correction was based originated from the much earlier work by
Ernst (150). In this, Ernst found that a spectrum was correctly phased if the ratio of
the area above the real-mode spectrum to that below was maximum. This approach
was utilised by Chen and Kan to apply both zero and first order corrections to their
spectra (151). In addition, Balacoo used this method as a starting point for his
automatic phase correction method, but went on to optimise the technique for high
resolution spectra (152). Although this method is not without its problems, generally
caused by baseline distortions and noisy spectra (153), it does in theory provide a
logical way of phase correcting spectra without needing the additional information
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from a reference signal. With appropriate selection of the spectral region chosen for
phase correction, it may also be possible to avoid these common pitfalls.
5.2.4 Phase correction testing
It was important to establish a reliable post-processing protocol as quickly as
possible, to allow all the data to be consistently processed. Consequently, two
methods of phase correction were tested on the initial phantom data to allow a
decision to be made early on in the acquisition of data.
5.2.4.1 Time-domain phase correction
The time-domain Ordidge and Cresshull method was adapted to obtain the phase
angle for zero-order phase correction from the water-suppressed signal and then
apply it back onto the FID. This modified version of the original time-domain
method was written by Ian Marshall and included as part of the original post¬
processing C program.
5.2.4.2 Frequency-domain phase correction
Chen and Kan developed an iterative algorithm for the automatic phase correction of
NMR spectra as they were being acquired from the spectrometer (151). This is a
frequency domain method, where the spectra are assumed to be properly phased
when the ratio of the area above the x-axes in the absorption curve to that under the
x-axis is maximum, Figure 5.1. This principle can be applied for both zero and first
order correction.
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ppm
Figure 5.1 Unphased spectrum from a phantom containing choline, creatine and GABA. For
the purposes of the Chen, Kan algorithm, the areas above the absorption curve are shaded in
blue, and the areas below the curve in purple. Phase correction is achieved when the ratio of the
areas above and below the curve is at maximum.
This program was adapted to phase correct the data after acquisition, i.e. as part of
post-processing prior to 2D FT. In addition, zero order phase correction was initially
performed on a specific singlet contained within the spectrum and then the calculated
phase applied to the rest of the spectrum. Figure 5.2 shows the scheme behind zero
order phase correction using this method.
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Calculate five trial spectra
Find min and max for each
Figure 5.2 Flow chart demonstrating how zero order phase correction was performed
Rather than applying the routine to the entire spectrum, as described in the original
paper, the region around creatine was selected. Creatine is a singlet and, as such, is
immune to complicated coupling interactions altering the appearance of its peak with
increasing TE. This means that the correctly phased peak is consistently positive,
making it the most reliable peak upon which to apply the algorithm. In addition,
since this peak is in the closest proximity to the 3.01ppm GABA peak, it is important
to correctly phase this peak to aid GABA identification. Frequency-domain phase
correction was tested using the Matlab functions, PhaseCorrect.m and
RotateSpectrum.m, written by the author.
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5.2.5 Phase correction: results
5.2.5.1 Frequency-domain phase correction: initial results
The Chen and Kan method was based on selecting the best phased spectrum from a
group of five, and then testing this result against a newly selected set of spectra until
the maximum area ratio is found. The advantage of this iterative approach is that the
optimum phase angle for correction can usually be found within a few iterations,
typically less than six.
Another advantage of this method over a non-iterative approach calculating, for
example, the area ratio for all 360° rotation, is that it is possible to obtain angles of
arbitrary accuracy. To achieve 0.1° resolution non-iteratively would required 3600
calculations but using the iterative algorithm, can usually be obtained in less than ten
steps, making it more efficient. However, with only one global solution possible, in
terms of the specifics of the algorithm, the same solution is found, Figure 5.3.
350 400
angle (degs)
Figure 5.3 Results from calculation of the area ratio across all 360° of rotation. In all data
tested, there was only a single global solution, meaning that incorrect results were not going to
be produced from being trapped in local maxima / minima.
As stated in the method, it was originally planned to perform phase correction on the
creatine singlet alone. Preliminary testing on the entire spectrum failed due to the
excessively noisy nature of the water peak, causing over-estimation of the phase
angle. An improvement was seen when phasing the spectral region containing only
the metabolites, but this was only marginal when tested in spectra containing a near
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complete cerebral metabolite set. It was thought that this was due to the complicated
nature of the spectra, with many overlapping peaks, and coupled multiplets that do
not follow a simple pattern of evolution with increasing TE. This poor result led to
considerable bleed in the F1 dimension.
Purely for interest, the algorithm was applied to the acetate (~ NAA) peak only. This
showed an improvement in the results from data sets with multiple metabolites, but it
was difficult to determine the exact start and end positions of the peak. In-vivo, and
particularly at short TEs, this will also be problematic, due to the underlying
macromolecules and metabolites complicating the appearance of the peak. In trying
to optimise the region of the acetate peak, the results showed how sensitive the
algorithm was to the spectral length on which it had to act. Addition or subtraction
of only a few data points changed the phase angle applied to the spectrum for
correction.
As in the original description of the proposed adaptation of the method, the creatine
peak was isolated. Again there was an improvement in the results, Figure 5.4, but
the F1 bleed in the resulting 2D spectrum proved that the phasing was still not
entirely accurate. Consequently, the region of analysis was extended to include the
3.2ppm choline peak. This dramatically improved the phasing of the individual







Figure 5.4 Results from phasing on only the creatine peak, real parts (a) before phase correction
and (b) after phase correction. Although there is some "neatening" of the two peaks after phase
correction, there is still considerable variation in the baseline causing artefacts in the 2D J-
resolved spectra.
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Figure 5.5 Results from phasing on the 3.2ppm choline and 3.0ppm creatine peaks, real parts (a)
before phase correction and (b) after phase correction. Both peaks are better phased when
compared to Figure 5.4 and there is less variation in the baseline, producing much clearer 2D J-
resolved spectra.
5.2.5.2 A comparison of the results between two techniques
Having developed the Chen and Kan zero-order phasing routine to its optimum level
of performance, both the time-domain and frequency-domain methods were tested on
a series of in-vitro data, ranging from single metabolite solutions, phantoms
containing physiological concentrations of choline and creatine with varying GABA
concentrations, to a full physiological phantom. Representative results from these
experiments are shown below. Figure 5.6 shows some of the initial results from
phasing the singlet creatine. The 2D spectra and extracted GABA rows are shown in
Figure 5.7, from a phantom containing physiological concentrations of choline and
creatine and 5mM GABA. Finally, Figure 5.8 shows the spectra acquired from
phasing the results from a physiological phantom.
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Tilled magnitude plot Tilled magnitude pic*
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2 0 F2 (ppm) (a)
2 0 F2 (ppm) (b)
Figure 5.6 Conventional ID spectra (TE 145ms) and 2D J-resolved plot from phantom












Figure 5.7 2D J-resolved plot and extracted GABA row from phantom contacting choline,
creatine and 5mM GABA using (a) time-domain phase correction and (b) frequency-domain
phase correction
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Figure 5.8 2D J-resolved spectra and extracted GABA rows from physiological phantom phase
corrected using (a) time domain and (b) frequency domain methods as described in text.
5.2.5.3 Phase correction: Discussion
It is clear from the presented results that the adapted Ordidge and Cresshull time-
domain method has the most success in phasing the data. Ti noise is considerably
reduced in the resulting 2D J-resolved spectra, confining the singlet resonances
around the J = 0Hz line. Excessive spread of the data in the F1 dimension can cause
contamination of the extracted spectra, leading to unreliable quantification of the
metabolites of interest.
Zero-order phase correction using the frequency-domain methods was less successful
than its time domain counterpart over the entire spectrum. For the spectral region at
which it was applied, the spectrum is correctly phased, but at other frequencies, this
was not the case. The algorithm does, however, ensure that the real part of the signal
is closer to absorption mode than the imaginary part, and as such, may provide a
good first approximation of the phase before applying additional first-order
techniques. However, in light of such encouraging results from the time-domain
method, further exploration of this algorithm was superfluous. Therefore, in all
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subsequent work, the time-domain routine was routinely applied in the post¬
processing of the 2D J-resolved data.
5.3 Individual metabolite phantoms
5.3.1 Introduction
As stated in §4, it was important to establish the validity of the 2D J-resolved
acquisition and post-processing protocols by performing a series of experiments to
compare to the results in the published literature. For this reason, aqueous metabolite
solutions were studied on an individual basis to obtain an indication of the
performance of the technique as a whole.
5.3.2 Methods
2D J-resolved MR spectra were acquired using the specific GE pulse sequence as
described in §5.2. In each case, 64 ti increments were collected with NEX =16
(TEstart = 35ms, ATE = 10ms, TR = 2000ms) resulting in an acquisition time of 35
minutes. The raw data files were then transferred to a Sun Ultra Workstation (Sun
Microsystems, Mountain View, CA) where the data were processed using the
protocol defined in §5.2.3.
Aqueous solutions of the commonly investigated cerebral metabolites (choline,
creatine, myo-inositol, glutamate and glutamine) were prepared at physiological
concentrations in 3.6 litre spherical, glass containers. GABA was investigated at a
concentration of lOmM. The solutions were adjusted to physiological pH of 7.2
using a combination of hydrochloric acid and sodium hydroxide. No attempt was
made to mimic physiological relaxation times in the phantoms. Finally, a 2D J-
resolved dataset was acquired from the commercially available GE spectroscopy
phantom, the contents of which are listed in Table 5.1.
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Table 5.1 GE MRS Head sphere contents, as listed in the GE spectroscopy manual, 2001
Chemical name Concentration (mM)






L-Glutamic acid (monosodium salt) 12.5mM




The 2D J-resolved spectra resulting from the individual metabolite experiments are
provided in Figure 5.9 to Figure 5.11. Figure 5.12 shows the resulting 2D spectrum
from the same experiment carried out on the standard GE spectroscopy phantom.
(a) (b)
Figure 5.9 2D J-resolved plot from a 3x3x3 cm3 VOI positioned in a phantom containing (a)
9mM creatine and (b) 3mM choline. Both experiments were performed using a standard volume
head coil (with all peaks shifted by -O.lppm in room temperature phantoms).
Tilted magnitude plot
2 0 F2 (ppm)
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Figure 5.10 2D J-resolved plot from a 3x3x3 em3 VOI positioned in a phantom containing (a)
12.5mM glutamate and (b) 5.8mM glutamine. Both experiments were performed using a
standard volume head coil (with all peaks shifted by -O.lppm in room temperature phantoms).
« « *° F2 (ppm) < » (3) « 30 20 F2 (pp^,) ' »
Figure 5.11 2D J-resolved plot from a 3x3x3 cm3 VOI positioned in a phantom containing (a)
8.1mM myo-inositol and (b) lOmM GABA. Both experiments were performed using a standard
volume head coil (with all peaks shifted by -O.lppm in room temperature phantoms).
Tilted magnitude plot
e.u o.u c.u F2(ppm) lu
Figure 5.12 2D J-resolved plot from a 3x3x3 cm3 VOI positioned in a standard GE spectroscopy
phantom (contents given in Table 5.1Table 5.1) (with all peaks shifted by -O.lppm in room
temperature phantoms).
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5.3.4 Discussion
Overall, the coupling patterns observed in the 2D spectra agree with those in the
literature (22) and are similar to those produced from the 64 individual experiment
protocol (§4.3.1). There is, however, evidence of a larger residual water peak in
these results compared to those presented in §4. This is probably due to the auto
water suppression (AWS) optimisation in the individual PRESS experiments, which
wasn't applied in the dedicated sequence. It may also indicate poorer shimming of
the voxels in some of the experiments.
5.4 GABA threshold
5.4.1 Introduction
As described in the previous chapter, the threshold of GABA detection needs to be
established using the dedicated 2D J-resolved sequence in a standard brain imaging
set-up. Knowing that high concentrations of GABA can be detected using this
method, the experiments focussed on physiological concentrations of the metabolite.
5.4.2 Materials and methods
All experiments were performed following the acquisition protocol set out in §5.2.2.
2D J-resolved spectra were acquired from a 3x3x3cm voxel in the centre of the
phantoms, using a standard volume head coil.
Eleven individual phantoms were made, each containing physiological
concentrations of choline and creatine (3mM and 9mM respectively). As with the
corresponding experiments described in §4.3.2, the concentrations of these
metabolites were chosen to encompass the normal range of physiological
concentrations in all brain regions (140). GABA was added in different
concentrations to each, from 2.0mM to l.OmM GABA, at O.lmM intervals. The
aqueous solutions were calculated from the dry masses of the chosen chemicals
(Sigma-Aldrich).
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Post-processing and quantification of the extracted spectra followed the method
described in §5.2.3.
5.4.3 Results
A summary of all the quantifiable results is shown in Figure 5.13, with a minimum
identifiable GABA concentration of 1.2mM. The minimum threshold of GABA
detection was determined by visual assessment: The 3.01ppm GABA resonance was
identified by a separate and distinct contour on the 2D plot, at 7.4Hz, with a
corresponding peak on the extracted spectrum. The 2D J-resolved spectrum
corresponding to this concentration of GABA, with extracted GABA row (pre- and
post-quantification) are shown in Figure 5.14.







0.5 1 1.5 2 2.5
Actual GABA concentration (mM)
Figure 5.13 Results of in-vitro GABA measurement from a 3x3x3cm3 voxel in 11 phantoms of
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(b)
Figure 5.14 2D J-resolved spectrum from a 3x3x3cm VOI centrally positioned in a phantom
containing 3mM choline, 9mM creatine and 1.2mM GABA. The 3.01ppm and 2.29ppm GABA
resonances are identified by the circular markers. Extracted GABA spectrum (J = 7.4Hz) from
the same phantom: (b) Matlab raw data and (c) After quantification in MRUI (with all peaks
shifted by -O.lppm in room temperature phantoms). Peaks 1 and 2 correspond to the residual
peaks from choline and creatine; Peak 3 is the 3.01pm peak and peak 4 is the 2.28ppm GABA
peak.
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5.4.4 Discussion
It is interesting to note that the same threshold ofGABA detection has been shown in
both the series of experiments using a composite and a dedicated 2D J-resolved
sequence. Thus, in the standard clinical brain-imaging set-up, that is using a volume
head coil at 1.5T, concentrations ofGABA can be detected as low as 1,2mM. This is
within physiological concentration as cited in (7) but may not be sensitive enough to
detect the reductions in GABA associated with depressive disorders (8).
Although these are encouraging results, the reliability of such measurements need to
be established before applying the work in-vivo. Preliminary results from a
reproducibility study addressing this issue are presented in the next section.
5.5 Reproducibility
5.5.1 Introduction
As part of a much larger study looking at the reproducibility ofGABA measurement
using the dedicated 2D J-resolved sequence, a general indication of the
reproducibility of the technique was obtained by quantifying the peak areas of
choline and creatine. The results from this work are included here to establish the
background on which the GABA-specific reproducibility work is set (§7).
5.5.2 Materials and methods
2D J-resolved spectra were acquired following the protocol outlined in §5.2.2. Five
phantoms containing physiological concentrations of choline and creatine (3mM and
9mM respectively) were made in the same 3mm thick, 3.6 litre, glass, spherical shell.
Three measures of reproducibility were taken:
(1) Within-run reproducibility: Variation due to scanner instability alone (same scan
session).
(2) Within-session reproducibility: Variation due to scanner instability and voxel re¬
positioning (in the same scan session).
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(3) Between-days reproducibility: Both scanner and set-up variation over several
days.
In each of the three sets of reproducibility measurements, five 2D J-resolved spectra
were acquired. Each experimental set was repeated for all five phantoms, giving rise
to a total of 75 experiments performed in the volume head coil.
The resulting raw data files were transferred to a Sun Ultra workstation and
processed as described in §5.2.3. Uncoupled spectra were extracted at J = 0Hz for
quantification of choline and creatine. CVs were calculated for both metabolites in
each of the within-run, within-session and between-days reproducibility experiments.
5.5.3 Results
A representative uncoupled spectrum following quantification in MRUI is shown in
Figure 5.15. To ensure that the correct row was selected for quantification, rows
either side of the central row were extracted and quantified for comparison. In all
cases, the original selection of the central row was correct. Table 5.2 lists the CVs
calculated in all of the reproducibility experiments, with the CVs ranging from
0.86% to 9.57%.
Figure 5.15 showing example uncoupled spectrum from phantom containing physiological
concentrations of 3mM choline and 9mM creatine (peaks 1 and 2 respectively).
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Table 5.2 Summary measures of the five phantoms containing the 3mM choline and 9mM






1 3.17 6.37 8.02
2 9.06 9.09 9.36
3 5.51 4.75 4.34
4 2.47 3.01 8.19
5 0.86 6.67 8.28
creatine
1 2.78 7.49 5.50
2 8.74 9.57 9.22
3 4.38 4.78 3.58
4 3.22 2.98 9.21
5 1.35 6.04 7.76
5.5.4 Discussion
In relation to phantom work, a between-days CV of less than 5% is expected for the
three main metabolite peaks, including choline and creatine (142). This result was
not reflected in the quantified data, with over half the CVs > 5% and the largest
rising to 9.57%. This may suggest an overall decrease in the reproducibility of 2D
MRS or indicate problems with scanner stability over the acquisition time. However,
with such a wide variation in reproducibility values published for conventional ID
MRS (154), these results do not exceed any the outer limits of the quoted
reproducibility ranges.
5.6 Discussion and conclusions
The most obvious advantage of the dedicated 2D J-resolved sequence over the
composite sequence described in the last chapter, is the decrease in acquisition time.
This is due to the continuous acquisition of data during the scan time, with the
automatic loop through of TEs, and the requirement of only one pre-scan. Although
35 minutes is still long when compared to other imaging and spectroscopy
sequences, it is a very efficient method of collecting both chemical shift and J-
coupling information over the entire ppm range. From a clinical viewpoint, it is clear
that this sequence would dominate any scanning session, with perhaps only time for
Page 127
2D J-resolved MRS using a dedicated sequence
a localising and T2-weighted image, but it is certainly more viable than an in-magnet
time of over three hours!
Of course, the time gain would be of no advantage if the sequence didn't perform as
expected. These initial results have shown that both the acquisition and post¬
processing protocols are able to produce 2D spectra allowing differentiation of the
metabolites by their J-couplings. In addition, the reproducibility of the results for
choline and creatine are within acceptable limits.
Having established the validity of the method in theory and in-vitro, further
investigation needs to be performed to assess its applicability to in-vivo GABA
detection. The optimisation strategies employed to meet this aim are the focus of the
next chapter.
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6 Optimisation of 2D J-resolved MRS for GABA
measurement
6.1 Introduction
Results from the previous chapter have established that a dedicated 2D J-resolved
sequence is able to measure GABA in phantoms at concentrations approaching those
in-vivo, in an acceptable scanning time. However, there are many factors that need
to be addressed before translating this work in-vivo.
GABA is a very low concentration metabolite, and so improvements in the SNR
during acquisition would aid its detection. In principle, this can be achieved using
surface coils and prescribing large spectroscopy VOI. The advantages of using such
approaches are discussed in §6.2 and §6.3. The TE / ATE / TR timings were
optimised to record the largest available GABA signal whilst at the same time,
reducing the contribution from the underlying macromolecule resonances, shown in
§6.4. In all cases, a compromise had to be found between the theoretical and
physiological / anatomical limitations, to arrive at the optimum protocol for in-vivo
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work. Once established, the protocol was tested on a phantom containing
physiological concentrations of ah the common cerebral metabolites, §6.5.
6.2 Coil arrangement
6.2.1 Introduction
In standard MR brain imaging, a volume (birdcage) head coil is used as it gives full
coverage of the brain for both imaging and spectroscopy purposes. However, for
single-voxel spectroscopy experiments, it is often useful to use a surface coil,
exploiting the increase in SNR associated with the excitation of a smaller localised
volume. This is particularly useful when aiming to record signals from low
concentration metabolites. Therefore, a series of in-vitro experiments were
performed to measure the variations in 2D J-resolved MRS introduced with different
coil arrangements.
6.2.2 In-vitro experiments
All experiments were carried out on the centre's 1.5T GE Signa Horizon scanner,
operating in research mode and using a dedicated 2D J-resolved sequence as
previously described (§5) (TEstart - 35ms, TR = 2000ms, ATE = 10ms, number of
TEs (steps2d = 64)). Two sets of experiments were conducted: First, a general
measurement of changes in SNR of GABA signals from the same phantom using
different coil arrangements. Secondly, a series of in-vitro experiments using
decreasing concentrations of GABA to see how these changes translated into
differences in the threshold ofGABA detection.
6.2.2.1 GABA SNR in each coil arrangement
2D J-resolved spectra were acquired from a single phantom containing lOmM
GABA in a standard volume head coil, 3" and 5" surface coil. The experiments were
performed consecutively, using the same acquisition parameters. To replicate in-vivo
set-up with a voxel placed in the occipital cortex, a VOI was positioned in the lower
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half of the phantom (equivalent to the high signal region in the surface coils) for all
three coil arrangements. In each case, the same 3x3x3cm3 voxel was prescribed.
As expected, all three 2D J-resolved spectra were similar in appearance, Figure 6.1.
However, the increase in sensitivity of the surface coils was translated into an
increase in the GABA peak areas after quantification, Figure 6.2 and Table 6.1, with
a corresponding increase in the SNR.
(a) (b) (c)
Figure 6.1 2D J-resolved spectra from 3x3x3 cm3 VOI in lOmM GABA phantom using (a)
standard volume head coil, (b) 5" surface coil and (c) 3" surface coil (with all peaks shifted by
-O.lppm in room temperature phantoms).
3100
(a) (b) (c)
Figure 6.2 Extracted spectra from 2D J-resolved spectra from lOmM GABA phantom using (a)
standard volume head coil, (b) 5" surface coil and (c) 3" surface coil (with all peaks shifted by
~0.1ppm in room temperature phantoms).
Table 6.1 Quantification of GABA peaks, in-vitro, using three different coil arrangements




3.01 ppm 2.28ppm 1.89ppm
Volume head coil 1.61 2.13 0.13 0.03 67.1
5" surface coil 4.32 4.82 0.89 0.06 90.0
3" surface coil 5.60 5.98 0.90 0.06 116.7
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The results confirm that the highest SNR is obtained using the 3" surface coil, as
would be expected. However, the overall excited volume is smaller in this coil
compared to the both the 5" surface coil and the head coil. As a result, the VOI used
- that is 3x3x3cm3 - encompassed almost the entire high signal volume. Although
not an issue in-vitro, in-vivo it is desirable to have a large high-signal region in which
to place a large VOI, to allow changes in exact VOI locations to account for
variations in anatomy. Therefore, it might prove that the 5" surface coil provides the
best compromise between increased SNR and excited volume.
6.2.2.2 Threshold of GABA detection in each coil arrangement
The threshold for in-vitro GABA detection using a standard volume head coil has
previously been determined at 1.2mM, §5.4. Given the increase in sensitivity
associated with the surface coils compared to the volume head coil, it was of interest
to investigate the limit of GABA detection using 2D J-resolved MRS and a surface
coil arrangement.
Results from the literature suggest that in-vivo GABA concentrations as low as
0.8mM have been recorded (6,11). Since it is already known that concentrations of
1.2mM can be observed in the volume head coil, three additional experiments were
carried out in the 5" surface coil using GABA concentrations as low as 0.8mM,
Table 6.2. For comparison, 2D J-resolved spectra were also acquired from phantoms
four and five using a 3" surface coil.
Table 6.2 Phantom metabolite concentration for threshold ofGABA detection experiments
using a 5" surface coil.
Phantom number Metabolite concentration (mM)
Choline Creatine GABA
1 3 9 2
2 3 9 1.5
3 3 9 1.2
4 3 9 1.0
5 3 9 0.8
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A summary of the results is given in Figure 6.3. The minimum concentration of in-
vivo GABA reported in the literature (0.8mM) was detected using the surface coils,
and the 2D J-resolved spectra and extracted rows corresponding to this concentration
are shown in Figure 6.4 (for the 3" surface coil) and Figure 6.5 (for the 5" surface
coil). A two-fold increase in the SNR was calculated for the lowest two
concentrations of GABA when using the 3" surface coil compared to the 5" coil,
Table 6.3.
Threshold of GABA detection
0.5 1 1.5
Actual GABA concentration (mM)
2.5
Figure 6.3 Results of in-vitro GABA measurement from a 3x3x3 cm3 voxel in five phantoms of
decreasing GABA concentration, using a dedicated 2D J-resolved MRS sequence in two
different sized surface coils.
(a)
(b)
Figure 6.4 (a) 2D J-resolved spectra from 3x3x3 cm3 VOI in a phantom containing 3mM choline,
9mM creatine and 0.8mM GABA phantom using a 3" surface coil. The circular marker
identifies the 3.01ppm GABA resonance, (b) Extracted GABA row from same phantom (with
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Tilted magnitude plot
Figure 6.5 (a) 2D J-resolved spectra from 3x3x3 cm3 VOI in a phantom containing 3mM choline,
9mM creatine and 0.8mM GABA using a 5" surface coil. The circular marker identifies the
3.01ppm GABA resonance, (b) Extracted GABA row from same phantom (with all peaks
shifted by -O.lppm in room temperature phantoms)
Table 6.3 Peak areas (arb), as quantified in MRUI, of GABA, in-vitro, using two surface coils
Actual GABA
cone (mM)


















1 0.39 0.04 9.0 0.78 0.04 19.5 216.7
0.8 0.26 0.03 7.8 0.58 0.04 15.8 202.8
It is reassuring that GABA concentrations as low as 0.8mM can be detected using
both sizes of surface coil. Since only a single experiment was performed at each
concentration in each coil arrangement, no measure of the reproducibility was
obtained. However, this is addressed in the formal reproducibility study described in
§7. In terms of the in-vivo work, these initial results are encouraging. They suggest
that the entire normal physiological range of GABA concentrations can be studied
using 2D J-resolved MRS, as reported by recent spectral editing studies
(6,11,98,100).
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6.2.3 In-vivo experiments
6.2.3.1 Introduction
The results from the in-vitro work suggest that in terms of SNR, the better coil to use
would be the 3" surface coil. To estimate the improvement in sensitivity seen in-
vivo, single voxel spectra were acquired from the same brain region, using the same
acquisition parameters in both a volume head coil and 3" surface coil in four normal
volunteers.
6.2.3.2 Scanning protocol
Written informed consent was obtained from all four volunteers. In each case, the
volunteer was set-up in a volume head coil and a series of T2 FSE images obtained to
verify their neuro-radiological status. Using these as the localising images, a
3x3x3cm3 VOI was placed in the occipital cortex and a single voxel spectrum
acquired (TE = 55ms, TR = 2640ms, NEX = 16). The scan series was then repeated
using a 3" surface coil.
6.2.3.3 Post-processing
Following acquisition, the raw data files were transferred to a Sun Ultra Workstation
and were processed as described in §5. In summary, this consisted of automatic
time-domain phase correction and removal of the water peak (using HLSVD). The
files were then converted into ascii format for quantification in MRUI. Due to the
poor baseline in the spectra from the surface coil, it was not always possible to
accurately separate the choline and creatine peaks. Therefore only the NAA peak
was quantified in all spectra. MRUI prior knowledge files were created for each coil
arrangement to ensure that the same peak parameters were applied in case.
6.2.3.4 Results
The results from all four volunteers following quantification of the NAA peak are
provided in Table 6.4. In all cases, at least a 133% increase in SNR is observed
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when using the surface coil instead of the volume head coil. Figure 6.6 shows a set
of representative spectra from one of the volunteers in both coil arrangements.
Table 6.4 Peak areas (arb), as quantified in MRUI, of the NAA peak from four healthy
volunteers.
Volunteer
volume head coil 3" surface coil
% increase










1 1.67 0.07 3.56 0.11 135.7
2 1.62 0.13 4.85 0.24 162.2
3 1.83 0.07 3.95 0.11 137.4













Figure 6.6 Conventional ID spectra (TE = 58ms, TR = 2640ms, NEX = 16) from a 3x3x3cm3
VOI located in the occipital lobe of a healthy volunteer using (a) volume head coil and (b) 3"
surface coil.
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6.2.4 Discussion and conclusion
It is expected that an increase in SNR of the 3.01ppm GABA peak will be measured
in-vivo, albeit not to the same extent as that seen in-vitro. However, the size and
location of the voxel must also be taken into consideration. Figure 6.7 shows the
images acquired from the same volunteer using both the 3" and the 5" surface coils.
Since the sensitive volume of the coil is determined by the coil radius (155), it is
immediately obvious that the 5" allows excitation of a larger voxel, which is also
important for improving the SNR. In addition, the larger excited volume allows
more freedom with regard to actual voxel location, with more opportunity for the
operator to fit the voxel around the unique anatomy of the patient, e.g. avoiding large
blood vessels or ventricles.
Figure 6.7 T2 axial FSE localising images for spectroscopy using (a) a 3" surface coil and (b) a
5" general-purpose surface coil.
Overall, these results have confirmed that surface coils are more sensitive than a
volume head coil for performing 2D J-resolved MRS, a characteristic that is
particularly useful when attempting to quantify low-concentration metabolites such
as GABA. Although the 3" surface coil shows further improvement in SNR over the
5" coil, for in-vivo applications, the 5" coil is more suitable as it allows the individual
placement of larger voxels as dictated by the neuro-anatomy. Therefore, a 5" surface
coil should be considered as standard when acquiring 2D J-resolved spectra in-vivo.
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6.3 VOI size
6.3.1 Introduction
Performing MRS experiments in a homogenous, aqueous phantom allows a countless
number of voxel sizes, limited only by the size of the outer walls of the phantom. In-
vivo, this is clearly not the case. Not only are the voxel sizes limited by the size and
shape of the brain mass, the specific dimensions of the voxel are also bound by the
anatomy of the brain, and in particular, in the avoidance of ventricles, large sulci and
blood vessels. In addition, it is important to position the voxel away from the scalp
to avoid contamination of the spectra from scalp lipids. These problems are
accentuated when acquiring spectra from patients with abnormal brain tissue, e.g.
lesions arising from acute brain infarcts, as the investigator may wish to include
mostly tissue from these regions or avoid them altogether. Clearly voxel set-up in-
vivo is much more complicated than in a glass bowl full of chemicals!
Since MRS allows the acquisition of signals from low concentration metabolites, it is
desirable to excite a large volume of tissue, to increase the SNR of the measurement.
Given the constraints of voxel size and placement that exist in-vivo, especially in the
abnormal brain, it is important to establish the minimum voxel size feasible for
GABA measurement.
6.3.2 Methods
To investigate the effect of VOI size on the GABA signal quantified, a phantom
containing 1.2mM GABA was made. 2D J-resolved spectra were acquired using a
dedicated sequence (TEstart= 35ms, TR = 2000ms, ATE = 10ms, steps2d = 64) and a
5" surface coil, following the protocol given in Table 6.5. After acquisition, the
extracted GABA row was quantified in MRUI as previously described in §5.
Table 6.5 Protocol for the investigation of measured GABA signal with VOI size
Experiment 1 2 3 4 5 6 7 8 9 10 11
VOI (cm3) 27.7 24.7 22.3 19.7 17.6 15.6 13.8 12.2 10.6 9.3 8.0
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6.3.3 Results
Figure 6.8 shows the results following quantification of the 3.01ppm GABA peak,
with increasing voxel size. As described in §4.2.3, part of the initial post-processing
involves normalisation of the signal to take into account the calibration values set in
the individual MRS experiments, and this includes VOI size. Therefore, a flat
horizontal line would be expected if consistent GABA measurement had been
achieved.
Variation of GABA signal with VOI
♦
*
* r , ,
5.0 10.0 15.0 20.0 25.0 30.0
VOI (cubic cm)
Figure 6.8 Results of in-vitro GABA measurement from increasing voxel sizes in a single
phantom containing 1.2mM GABA. 2D J-resolved spectra were obtained using a dedicated 2D
J-resolved MRS sequence in a 5" surface coil (see text for details).
6.3.4 Discussion and conclusions
These results clearly show that in-vitro, GABA measurement begins to breakdown in
voxels below 15cm . Repetition of these experiments in a high concentration GABA
phantom Figure 6.9, showed that this was due to the poor SNR at 1.2mM GABA,
leading to failure to quantify any discernible GABA peak in MRUI or an inaccurate
measurement. Either way, when translating this work in-vivo, at all times voxels
larger than 15cm3 should be prescribed, and unless designated by a set protocol, the
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Figure 6.9 Results of in-vitro GABA measurement from increasing sizes in voxel in a single
phantom containing lOmM GABA. 2D J-resolved spectra were obtained using the same
protocol as for the phantom used described previously
6.4 Acquisition parameters
6.4.1 introduction
At the time ofwriting, five variations of performing 2D J-resolved spectroscopy had
been published, and these were discussed in §3. Although all were based on the
same pulse sequence, there were three main differences in the timing parameters
used. To determine the effect this had on the resulting spectra, a series of GAMMA
simulations (135) and in-vitro experiments were performed using each set of timings.
The in-vitro experiments were performed on a lOmM GABA phantom, in the same
scanning session with prescription of the same voxel. Thus, in the absence of any
significant scanner fluctuations, any changes in the results following quantification
of the GABA peaks were due to the changes in applied timings.
6.4.2 Materials and methods
As described in §4, results from GAMMA simulations of GABA at 1.5T have been
previously reported. It was possible, therefore, to adapt the modelling parameters of
the 2D J-resolved sequence to replicate the timing parameters used in literature, to
predict what effects these would have on real data. Since the GAMMA modelling
ignored the effects of relaxation, only three of the five variations were simulated as
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used in (23,25-27). The remaining two differed only in the TEstart used (22,24), and
any differences would not been shown without taking into account GABA relaxation
characteristics.
Three different acquisition models were tested, the details of which are given in
Table 6.6. The experiments were then repeated in-vitro using a 3.61, glass spherical
phantom containing lOmM GABA. The phantom was positioned on a specially
designed headrest that was placed directly on a 5" surface coil. Using a localiser
image, a 3x3x3cm voxel was positioned in the region of high signal intensity in the
lower half of the phantom. The set-up was the same in all experiments. A modified
set of these experiments, designed to more clearly show the differences resulting
from changes in TE, were conducted on a phantom containing 1.2mM GABA, Table
6.7.
To aid quantification of the resulting spectra, a prior knowledge file was created in
MRUI. Each of the three GABA peaks were quantified (3.01ppm, 2.28ppm and
1.89ppm), although since only the 3.01ppm peak will be visible in-vivo, particular
attention was paid to the effects of the timing variables at this resonance.
Table 6.6 Timing parameters used in all of the published methods of 2D J-resolved MRS
Timing
method
TEmin (ms) TR (ms) ATE (ms) steps2d Reference GAMMA
simulated?
1 35 2000 10 64 (25,26) Yes
2 35 2000 5 64 (23) Yes
3 35 2000 2.5 128 (23,27) Yes
4 25 2200 10 64 (22) No
5 48 2640 10 64 (24) No
Table 6.7 Second set of timing experiments performed on a phantom containing 1.2mM GABA
only
Timing method TEstart (ms) TR (ms) ATE (ms) steps2d NEX
1 35 2000 10 64 16
2 35 2000 5 64 16
3 35 2000 2.5 128 16
4 35 2000 5 128 16
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This work was then extended to investigate the practical implications of changing the
NEX, Table 6.8, and TR (to min TR for longest TE), Table 6.9.
Table 6.8 Protocol for the investigation of NEX on GABA measurement using 2D J-resolved
MRS
TEmin (ms) TR (ms) ATE (ms) steps2d NEX t_scan (mirrsec)
35 2000 10 64 8 17:20
35 2000 5 64 8 17:20
35 2000 2.5 128 8 34:24
35 2000 10 64 16 34.:40
35 2000 5 64 16 34:40
35 2000 2.5 128 16 68:48
Table 6.9 Protocol for investigation of TRmin on GABA measurement using 2D J resolved MRS
TEmin (ms) TR (ms) ATE (ms) steps2d NEX t_scan (miirsec)
35 1800 10 64 8 15:36
35 1800 5 64 8 15:36
35 2000 10 64 8 17:20
35 2000 5 64 8 17:20
35 2200 10 64 8 19:04
35 2200 5 64 8 19:04
35 2500 10 64 8 21:40
35 2500 5 64 8 21:40
6.4.3 Results
The 2D J-resolved spectra and corresponding extracted GABA rows resulting from
the GAMMA simulations of the published timings are shown in Figure 6.10. Table
6.10 lists the results post-quantification of the simulated GABA peaks. Figure 6.11
gives a representative 2D J-resolved plot, and associated GABA row, from the series
of in-vitro experiments using the same published timings as the simulations. The
extracted spectra from all five 2D J-resolved plots are overlaid in Figure 6.12 and the
results from quantification in Table 6.11.
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Figure 6.10 Results from GABA simulations of literature timings for 2D J-resolved experiments.
The numbers in the left-hand column correspond to the timing numbers in Table 6.6. All 2D
spectra have been scaled to the 2.28ppm GABA peak. To obtain results more akin to those
obtained from practice, F1 and F2 apodization (Lorentzian and Gaussian respectively) = 2.6Hz
was used in each dimension.
Table 6.10 Peak areas (arb), as quantified in MRUI, of the simulated 3.01ppm and 2.28ppm
GABA peaks, from the extracted J = 7.45FIz row, in the timing variations listed in Table 6.6
Timings TEstart (ms) ATE (ms) steps2d GABA
3.01ppm 2.28ppm
1 35 10 64 5.65 4.19
2 35 5 64 6.23 4.59
3 35 2.5 128 6.61 4.88
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Tilted magnitude plot
Figure 6.11 Representative results from phantom containing lOmM GABA only; Timing
parameters 1: TEmin = 35ms, TR = 2000ms; ATE = 10ms; steps2d = 64; NEX = 16. (a) 2D J-
resolved plot and (b) the extracted ID spectrum at the GABA J-coupling frequency (J = 7.45Hz)
(with all peaks shifted by -O.lppm in room temperature phantoms).
Figure 6.12 Extracted spectra at 7.4Hz for all timing experiments: Timing 1; timing 2;
timing 4; timing 5. Phantom = lOmM GABA only (with all peaks shifted by ~0.1ppm in room
temperature phantoms).
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Table 6.11 Results from quantification of the 3.01ppm GABA peak, from the extracted J =
7.45Hz row, for the timing variations listed in Table 6.6.






The extracted spectra corresponding to J = 7.45Hz from the 1.2mM GABA phantom
are overlaid in Figure 6.13, and Table 6.12 summarises the results following










Figure 6.13 Extracted spectra at 7.4Hz for timing experiments on phantom containing 1.2mM
GABA only: timingl, timing2, timing3, (with all peaks shifted by -O.lppm in room
temperature phantoms)
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Table 6.12 Results from quantification of the 3.01ppm GABA peak, from the extracted J =
7.45Hz row, in the timing variations listed in Table 6.7





The results following variation of the NEX and TR are shown in Table 6.13 and
Table 6.14 respectively.
Table 6.13 Peak areas (arb), as quantified in MRUI, of the 3.01ppm GABA peak, extracted from
the J = 7.45Hz row, after reduction of the NEX. All other experimental parameters remained
constant.
TEstart (ms) ATE (ms) steps2d TR (ms) SNR 3.01 ppm GABA peak
NEX = 16 NEX = 8
35 10 64 2000 19.5 10.3
35 2 64 2000 20.3 12.5
35 2.5 128 2000 28.2 11.9
Table 6.14 Peak areas (arb), as quantified in MRUI, of the 3.01 ppm GABA peak, extracted from
J = 7.45Hz row, with increasing TR. All other experimental parameters remained constant.
TR (ms) 3.01 ppm GABA peak (arb)





6.4.4 Discussion and conclusions
At first sight of the results from the simulations, it would appear as though the
method using 128 steps of 2.5ms (timings 3) yields the higher GABA peak in the
extracted spectrum, Figure 6.12. However, this is deceiving as there is a
corresponding increase in the noise, resulting in only a ~ 17% increase in the SNR,
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Table 6.10. Similar results were obtained in the in-vitro work Figure 6.12, although
the SNR increase between timing set one and three are less (-10%), Table 6.11.
Although any SNR increase is desirable for translation of this work in-vivo, it is also
important to consider the loss of F1 resolution using these acquisition parameters,
which may prevent the measurement of metabolites at different J-coupling
frequencies. In view of this limitation, the small decrease in SNR associated with
acquiring 64 steps at 10ms intervals as seen in the phantom experiments, is an
acceptable compromise to maintain the F1 resolution necessary to adequately
differentiate between J-coupling frequencies, and therefore resolve multiple
metabolites using this technique.
In spectroscopy experiments, the value of the number of excitations, "NEX",
determines the phase cycling used, to exploit the advantages of signal averaging
every time an RF pulse is applied. A NEX = 8 means that phase cycling (in a cycle
of 2) is performed on all three RF pulses. In practice, this means that for each pulse,
the phase is altered so that the frame consists of 8 excitations. By using NEX =16,
the phase cycling scheme applied when NEX = 8 is repeated for a second time.
As expected, the results from NEX = 8 all show large reductions in the 3.01ppm
GABA peak compared to NEX = 16, Table 6.13. This would contraindicate
changing the NEX for the 2D J-resolved experiment. 2D COSY in-vivo results from
Thomas et al also suggest that GABA measurement is more reliable when using
NEX = 16 compared to NEX = 8 (21), although in more recent work, GABA peak
assignments have been made using an NEX = 8 (20). Since some uncertainty exists
as to the effectiveness of GABA measurements at 1.5T with a reduced NEX (albeit
using COSY), it would seem prudent to perform all 2D J-resolved experiments with
an NEX = 16, at least until there is sufficient evidence to suggest otherwise.
As with decreasing the NEX, a reduction in the scanning time associated with a
decrease in TR would only be truly beneficial in the absence of any detrimental
effects on the resulting spectra. Again, this is not the case, Table 6.14. Over the
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range of TRs investigated, a change in GABA signal of ~ 6% is seen for both
acquisition sets. This suggests that particularly for the last three experiments, full
recovery of the longitudinal relaxation had been achieved, giving maximum SNR.
Therefore, in the absence of any significant gain in signal by using the longest TR, a
TR of 2000ms is an appropriate compromise between the GABA SNR and scan time.
In conclusion, the results presented thus far would suggest use of the acquisition
parameters given in Table 6.15 for optimum GABA measurement using 2D J-
resolved MRS at 1.5T.
Table 6.15 Protocol for optimum in-vitro GABA measurement
Coil 5" GP surface coil







6.4.5 Elimination of macromolecule contributions
6.4.5.1 Introduction
During the comparison of MRS techniques for GABA measurement in §3, the
problem of contamination of the 3.01ppm GABA peak was highlighted. This is due
to contributions from macromolecules, and the peptides homocarnosine and
glutathione (GSH) (19).
"Macromolecule" is a general term covering the high molecular weight proteins and
nucleic acids that exist across the entire MR spectrum, including a distinct resonance
at 3.00ppm (40). Since macromolecules have shorter T2 relaxation times than the
lower molecular weight cerebral metabolites, they can be eliminated from MR
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spectra by using long TEs. At short TEs, the presence of macromolecules will
complicate quantification and identification of the over-lying metabolites (43).
Measurements of the coupling constants of GSH specify that the 2.93ppm and
2.98ppm resonances have J-coupling frequencies distant to that from GABA (at
4.71Hz and 14.06Hz) so can easily be separated from GABA using 2D J-resolved
MRS (40). However, similar measurements of the prominent macromolecule
resonances indicate that the 3.00ppm resonance has a J-coupling frequency of 7.8Hz,
very close to that of GABA at 7.4Hz (40). High-resolution 2D J-resolved spectra
also show distinct macromolecule resonances exactly where GABA would appear in-
vivo (40). This suggests that the inclusion of short TEs in the 2D J-resolved
acquisition protocol prevents the designation of the observed resonance at F1 =
7.5Hz, F2 = 3.01ppm solely to GABA. Therefore the minimum TE for the 2D J-
resolved experiment should be a compromise between the absence of
macromolecules and loss of metabolite signal. This approach was first applied in 2D
J-resolved MRS by Lymer et al in 2003 (156).
6.4.5.2 Scanning protocol for 1D in-vivo MRS of macromolecules
Five healthy volunteers were recruited for this study and from each, written informed
consent was obtained. MRI was performed on a 1.5T GE Signa Horizon Scanner,
using a standard volume head coil to acquire a series of axial T2 image to confirm the
neuro-radiological status of the volunteers.
MRS was performed using a 3" surface coil for localisation. In each volunteer a
3x3x3cm VOI was placed in the occipital cortex, using a 3-plane localiser for
positioning.
To obtain a spectrum containing only resonances from macromolecules, an inversion
recovery (IR) sequence was employed. This uses a 180° pulse to invert the
longitudinal magnetisation after which their recovery is determined by the T1 of the
individual tissues. Macromolecules have a shorter T1 than the cerebral metabolites,
so its recovery is faster. Careful choice of the time delay between the inversion pulse
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and preceeding 90° pulse allows excitation of the macromolecule signal once it has
almost recovered and nulling of the signal from the metabolites (40,41,44,87). This
time delay between the two pulses is known as the inversion time (TI).
To determine an optimum TI for full inversion of the metabolite signal whilst
maintaining the macromolecule contribution, preliminary experiments were
conducted on both the standard GE spectroscopy phantom (metabolite only) (see
Table 5.1 for listing of phantom contents) and a volunteer. From this work, a TI of
675ms was chosen.
Each subject underwent a series of ID MRS experiments, with the TE ranging from
35ms - 85ms (TR = 2640ms, NEX = 16). IR spectra were also acquired
contiguously at every TE to obtain metabolite-nulled spectra.
6.4.5.3 Post-processing
The raw data files were transferred to a Sun Ultra Workstation for processing using a
combination of in-house and commercially available software. In-house software
was used to automatically phase correct and remove the residual water peak using
HLSVD, §5. The metabolite-nulled spectra were quantified in both MRUI and
SAGE (GE Medical Systems).
6.4.5.4 Results
A summary of all the results from all five volunteers is given in Figure 6.16. Figure
6.14 provides representative IR spectra from one of the volunteers and the
corresponding metabolite plus macromolecule spectra are shown in Figure 6.15.
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Figure 6.15 Conventional short-echo spectra corresponding to the IR spectra in Figure 6.14.
Page 151
Optimisation of 2D J-resolved MRS for GABA measurement
























20 40 60 80 100
TE (ms)
Figure 6.16 Summary of quantification of the 3.0ppm macromolecule peak, in all five
volunteers. Results are given as a percentage of the maximum macromolecule signal at TE
38ms.
The in-vivo results show a large reduction in the macromolecule signal at around
55ms. It was important therefore, to establish whether or not a delay of 20ms on the
onset of the 2D J-resolved experiment would have a sufficiently negative impact to
prevent GABA detection. To test this, a series of in-vitro experiments was
performed encompassing the entire TE range of interest: That is from 35ms to





Figure 6.17 Results from in-vitro 2D J-resolved experiment with lOmM GABA (64TEs, TEmin =
35ms and ATE = 10ms): (a) 2D J-resolved spectrum and (b) extracted GABA row (with all
peaks shifted by -0.1ppm in room temperature phantoms).
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Figure 6.18 Results from in-vitro 2D J-resolved experiment with lOmM GABA (64TEs, TEmin =
55ms and A TE = 10ms): (a) 2D J-resolved spectrum and (b) extracted GABA row (with all
peaks shifted by ~0.1ppm in room temperature phantoms).
Table 6.16 Summary of results following quantification of the 3.01ppm GABA peak area in
MRUI using different acquisition protocols.
peak(arb) TEstart
35ms 55ms
3.01 ppm GABA 5.59 5.56
6.4.5.5 Discussion and conclusions
The general trend was as expected with a decrease in macromolecule resonance with
increasing TE, Figure 6.16. A distinct reduction in the macromolecule presence was
observed at TE = 55ms, with results from all volunteers falling to below 45% of the
maximum (recorded at TE = 35ms). After this TE, the same general trend was
observed, although quantification was more difficult as the macromolecule resonance
approached the level of noise. The results demonstrate that by starting acquisition
after TE = 55ms, the contribution ofmacromolecules to the GABA resonance will be
reduced.
A 20ms delay in the start of acquisition of data for the in-vitro 2D J-resolved
experiment (TEstart = 55ms not 35ms) makes only a very small difference to the
3.01ppm GABA peak area in the extracted spectrum (<1%). However, with only
1:04 minutes difference in the actual acquisition time between collecting 64 TEs
(35ms - 665ms) and 66 TEs (55ms - 685ms), it would be interesting to acquire in-
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vivo data over both ranges to compare any differences in the 2D results.
Consequently, the optimised protocol for in-vivo GABA measurement is given in
Table 6.17.
Table 6.17 Protocol for in-vivo GABA measurement
Coil 5" surface coil







6.5 Optimised protocol test
6.5.1 Introduction
In the preceding sections in this chapter, a number of experiments have been
performed to determine the optimum protocol for GABA measurement, in-vivo,
using 2D J-resolved MRS at 1.5T. Before applying this procedure to a volunteer, it
was prudent to test the protocol on a phantom containing physiological
concentrations of all the common cerebral metabolites, corrected to physiological
pH. Although relaxation effects were unaccounted for, the results from this
experiment allowed the complete acquisition and post-processing method to be
validated in-vitro, offering the best possible results before in-vivo translation.
6.5.2 Methods
2D J-resolved MRS was performed on a 1.5T GE Signa Horizon scanner, operating
in research mode and using a 5" surface coil. The acquisition parameters were as
listed in Table 6.17.
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An aqueous solution containing the cerebral metabolites listed in Table 6.18 were
placed into a 3.61, glass spherical phantom. The pH of the solution was adjusted to
pH 7 using a mixture of sodium hydroxide and hydrochloric acid. After allowing
the temperature of the solution to stabilise at the magnet room temperature, the
phantom was set-up on a specially designed headrest that was placed directly on a 5"
surface coil. This was positioned in the magnet and left to settle for approximately
20 minutes to reduce artefacts arising from solution movement. Using the localiser
image, a 3x3x3cm voxel was prescribed in the lower half of the phantom, in the
region of high signal intensity, from which a 2D J-resolved spectrum was acquired.










Acquisition of spin-echoes across the range TE = 35ms - 685ms, allowed two 2D J-
resolved spectra to be processed. The first, from TE = 35ms (steps2d = 64) and the
second, as if avoiding macromolecule contribution with a TEstart = 55ms (steps2d =
64).
Note on phantom preparation.
Previous to this experiment, all in-vitro experiments thus far had consisted of simple
hand-made phantom solutions or the commercially available GE spectroscopy
phantom. With the spectral peaks appearing at the expected chemical shifts (given
an approximate 0.1 ppm shift due to room temperature phantoms not body
temperature brains) in all spectra, it had not been deemed necessary to routinely
perform additional adjustments to the solutions (e.g. temperature, pH). However, the
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situation was hugely complicated with the introduction of glutamate to the stock
metabolite solutions.
Initial experiments revealed that on addition of glutamate to a mixed metabolite
solution, the 3.01ppm GABA peak "disappeared", even with GABA at
concentrations several orders ofmagnitude higher than physiological levels that had
previously been detected. Simulations of the two chemicals demonstrated that there
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Figure 6.19 Results from spin-system simulations of (a) GABA and (b) glutamate. The
extracted spectra show a distinct separation between the 3.01ppm GABA resonance and
glutamate at J = 7.5Hz.
The solution to this problem was found from helpful discussions with Professor Peter
Sadler and Dr. Vivienne Munk, School of Chemistry, The University of Edinburgh,
and the results from NMR performed on a Bruker 800 MHz spectrometer (-18.8T),
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performed by Dr. Munk. The author is indebted to them both for their valuable
contributions to this work.
The high-resolution spectra from aqueous solutions of GABA, glutamate and then
GABA and glutamate combined are shown in Figure 6.20. The spectra have been
expanded across the 1.9ppm to 3.9ppm range to focus in on the chemical shifts of
interest when using a clinical MRI scanner.
B
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Figure 6.20 High-resolution spectra (800Mz) of (A) 1.5mM GABA, (B) 12.5mM glutamate and
(C) a mixture of both metabolites. Dioxane was added as an internal standard (3.76ppm). All
experiments performed by Dr. V. Munk, School of Chemistry.
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Figure 6.21 High-resolution spectra (800mHz) of (A) 1.5mM GABA, (B) 12.5mM glutamate and
(C) a mixture of both metabolites after pH correction. Dioxane was added as an internal
standard (3.76ppm). All experiments performed by Dr. V. Munk, School of Chemistry.
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Without regulation of the pH, the chemical shifts of some of the peaks (including the
3.01ppm GABA peak) changed when the two metabolites were mixed. Specific to
the GABA peak of interest, the distinct triplet significantly broadened when in
mixture with glutamate. The results after pH adjustment to pH 7.4 are shown in
Figure 6.21. With no differences in the chemical shifts in the spectrum from the
chemical mixture, these results clearly show the importance ofpH correction.
(b) (d)
Figure 6.22 (a) 2D J-resolved plot and (b) extracted GABA row from analysis of data with
TEstart = 35ms. (c) 2D J-resolved plot and (d) extracted GABA row from analysis of data with
TEstart = 55ms. All results from a 3x3x3cm3 VOI in a physiological phantom containing the
metabolites listed in Table 6.18 (with all peaks shifted by -O.lppm in room temperature
phantoms).
6.5.3 Results
The 2D J-resolved spectra and corresponding extracted GABA rows from both TE
ranges are shown in Figure 6.22. Table 6.19 summarises the results post-
quantification.
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Table 6.19 Quantification of 3.01ppm GABA peak area (in MRUI) in both datasets
TEstart ATE steps2d TR NEX 3.01 ppm GABA peak
(ms) (ms) (ms) (arb)
35 10 64 2000 16 0.80
55 10 64 2000 16 0.73
An alternative to collecting 64 spin-echoes was proposed in §4.5, whereby only 40
spin-echoes were acquired and then the dataset zero-filled to 64 to achieve the same
F1 resolution. This approach was applied to the physiological phantom and the
results are presented in Figure 6.23 and Table 6.20.
Tilted magnitude plot
Figure 6.23 (a) 2D J-resolved plot and (b) extracted GABA row from same physiological
phantom. Only the first 40 spin-echoes were included in the analysis, with the remainder of the
dataset zero-filled to maintain the F1 resolution achieved with 64 spin-echoes (with all peaks
shifted by -O.lppm in room temperature phantoms).
Table 6.20 Quantification of 3.01ppm GABA peak area (in MRUI) when post-processing only
the first 40 spin-echoes
TEstart ATE steps2d TR NEX 3.01 ppm GABA peak
(ms) (ms) (ms) (arb)
35 10 40 2000 16 0.56
6.5.4 Discussion and conclusions
The results from the physiological phantom demonstrate that GABA measurements
can be made from 2D J-resolved spectra acquired at 1.5T. Using an optimised
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protocol based on a dedicated 2D J-resolved sequence, the total number of spin-
echoes required for post-processing can be obtained in 35:28 minutes.
As expected, there is a small decrease in the peak area of the 3.01ppm GABA peak
acquired with a TEstart= 55ms (< 10%). With only an extra one minute to acquire the
additional two spin-echoes required for dual analysis, it would be extremely useful to
collect the full range of spin-echoes to allow comparison between 2D J-resolved
spectra both with and without macromolecule contributions.
A reduction in the number of spin-echoes and zero-filling the remaining dataset was
proposed as a technique for reducing the acquisition time while maintaining the F1
resolution required to measure GABA, §4. Application of this approach on the
physiological phantom shows considerable F1 bleed from the three main metabolite
peaks of choline, creatine and acetate (~ NAA in-vivo). With such spread of the
resonances, there is a real danger than the 3.01ppm GABA resonance would be
obscured. Although not the case in this example, the measured GABA peak did
show a 30% reduction compared to the equivalent peak from a full 64 spin-echo
acquisition, and the broader linewidths obtained in-vivo are likely to further
complicate the issue. Consequently, acquisition of the full 64 spin-echoes (or 66
spin-echoes for with / without macromolecule data processing) is recommended.
Overall, the results from this final experiment are very encouraging for in-vivo
translation. However, before doing so, it is important to establish the reproducibility
of the technique, a matter that is formally addressed in §7.
Page 160
2D J-resolved reproducibility of in-vitro GABA measurement
7 2D J-resolved reproducibility of in-vitro GABA
measurement
7.1 Introduction
It has been established in §3 that results from 2D spectroscopy techniques are being
increasingly reported (13,17,19,22-24). However, there has been very little
published work regarding the reproducibility of these methods. As with all new
procedures, it is important to evaluate the associated reliability and reproducibility of
the technique before it can be applied routinely as a research or clinical tool.
Therefore, any observed changes can be attributed to true physiological changes
rather than systematic variation. This is particularly important for 2D MRS
techniques as these aim to quantify peaks from low concentration metabolites, using
protocols that have inherent differences in their methodology and sensitivity.
Most previous single-voxel proton MRS reproducibility studies have been concerned
with ID techniques, both in-vitro and in-vivo using short and long TEs. Since ID
MRS is a well understood technique, using established acquisition and post-
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processing methods, the coefficients of variation (CVs) obtained from such studies
may reflect the optimum achievable reproducibility in 2D MRS, so it is useful to
examine these studies in more detail.
Many of the factors affecting reproducibility in ID experiments are common to 2D
investigations, therefore it is important that these components are investigated as
fully as possible in a well-constructed protocol. Brooks et al (157) listed five
possible causes of variation among quantified spectroscopy results. These are:
1. Instrument variability
2. Biological variability
3. Voxel variability - i.e. errors associated with volume of interest (VOI)
placement on repeated scans
4. Operator variability with regard to scanning protocols
5. Differences in data analysis procedures
Since biological variation is the factor of interest, it is desirable to minimise all other
variables so that the measured result reflects only physiological changes.
Within the same research / clinical centre, any differences in the data analysis
procedure can be eliminated by adopting a standard post-processing protocol, ideally
fully-automated to reduce any operator bias or variability. The same principle can be
applied to the scanning protocol to reduce differences in acquisition parameters.
Hence, with standardisation of data acquisition and post-processing, it is the voxel
positioning and instrument variability that have the most influence on the
reproducibility, particularly in serial studies, and it is these factors that need to be
investigated.
Marshall et al specifically addressed these issues by measuring both "within-run"
and "between-days" reproducibility (141). The former relates to successive
measurements of the subject without any movement or re-positioning of the voxel,
therefore any variation in the results should reflect only the scanner instability.
"Between-days" reproducibility refers to measurements made on different days, thus
necessitating both subject and voxel re-positioning. Therefore, the calculated CVs
Page 162
2D J-resolved reproducibility of in-vitro GABA measurement
reflect both set-up and instrument variability. Results from in-vitro work using the
scanner manufacturer's standard spectroscopy phantom containing only acetate and
lactate showed that, as expected, the between-days reproducibility was in most cases,
worse than the within-run. Moreover, the largest measured between-day CV was
only 3.3% (standard PRESS, TE/TR = 135 / 1600 ms, VOI = 8ml, Nacquisitions = 16).
Disappointingly, these results were not reflected in-vivo. In a small group of 12
healthy volunteers, spectra were obtained from an 8ml VOI placed in the left or right
parietal matter (PRESS, TE/TR = 135 / 1600 ms, VOI = 8ml, NacquiSitions = 256). The
CVs of the absolute metabolite peak areas for NAA, choline and creatine rose to
18%, with the lowest CV having a value of 9%. Repeated measurement of the same
volunteers on a second day showed no significant differences between the data for
both days. In a second group of four volunteers, six spectra were acquired from each
subject on four different days from an 8ml VOI placed in the right parietal white
matter. Again, the between-day reproducibility was larger than the within-run, and
with a change in acquisition parameters to reduce the scan time (PRESS, TE/TR =
135 / 1600 ms, VOI = 8ml, NaCqUisitions = 64), the CVs fell as low as 4.4%, although
extremely large CVs were quoted for creatine (up to 25.8%). This was attributed to
post-processing problems of fitting the creatine peak using the modelling software.
In the most recent of the ID reproducibility studies, Schirmer et al investigated
several different aspects of reproducibility at 1.5T, in three series of phantom and
volunteer studies (142). All experiments used the quadrature head coil and the
PRESS spectroscopy sequence (VOI = 8ml, NaCquisitions = 128). The first part was an
in-vitro study using the standard GE spectroscopy phantom (TE/TR = 30/1500ms).
Over a period of 13 months, 84 spectra were acquired using two different scanner
software versions (due to an upgrade approximately half-way through the
experimental period). Since spectra from the same phantom were collected, the
changes in the measured metabolite concentrations from phantoms using the same
software version could only be attributed to scanner instabilities and set-up
variations. As expected, there were significant differences between the metabolite
concentrations between software versions. However, CVs of 3.8%, 4.0%, 3.3% and
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6.1% were obtained for choline, creatine, NAA and myo-Inositol (ml) respectively
following analysis from both software versions.
In the first series of in-vivo results reported, five spectra (TE/TR = 35/2000ms) from
the same volunteer in six separate scanning sessions over 10 days (at the same time
of day) were acquired, thus providing a total of 30 spectra. All VOIs were positioned
in the right parietal white matter using anatomical landmarks from the scout images
for positioning. In this respect, variations due to patient set-up and scanner instability
would be expected, but over such a short time period and with efforts to maintain a
consistent nutritional state, physiological changes in the measured metabolites are
not. For the same four metabolites, CVs (following analysis of all 30 spectra from
the same individual) of 4.9% (choline), 6.4% (creatine), 3.8% (NAA) and 7.7% (ml)
were obtained. These results are comparable to those obtained from the phantom
study. Since both involved the repeated scanning of the same subject (be it phantom
or human head), they reflect changes in scanner performance and repositioning, not
physiological changes, and so the similarity in results should be expected. However,
exact interpretation of these results is difficult since they are from spectra both within
the same scanning session and in different sessions, with some results being
influenced by set-up variations and others not. Still, as an overall estimation of the
in-vivo CV obtained, these results are encouraging.
Similar results were obtained by Brooks et al in a study of neurologically normal
volunteers (n = 10) also conducted at 1.5T, using the volume head coil but using the
STEAM spectroscopy sequence (157). Each subject was scanned at three time points,
the second scan an hour after the first, and the third approximately a month later. Six
spectra from the same VOI were acquired in each scanning session. Again, mean
coefficient of variations (CV) were reported of 5.30%, 4.33% and 3.30% for choline,
creatine and NAA, and 8.10% for ml. Following analysis of the mean variance from
the between-sessions results, it was suggested that differences in concentration of
choline, creatine, NAA and ml above 20.1%, 16.7%, 12.8% and 20.8% respectively
could be attributed to physiological changes
Page 164
2D J-resolved reproducibility of in-vitro GABA measurement
In the last part of Schirmer's study, spectra from 35 healthy volunteers were acquired
(142). In all cases, a single spectrum (TE/TR = 35/2000ms) was acquired from the
parietal white matter. In 12 subjects, a second spectrum was obtained immediately
following the first, in the same brain region, but following re-positioning of the
subject. Eight volunteers were re-scanned 8-14 days after the first session, again
acquiring spectra from the same brain region. In the single voxel from all 34
volunteers, the CVs for choline, creatine, NAA and ml were 15.0%, 10.3%, 7.6%
and 14.6% respectively. These show a large increase in CV when compared to the
results from the same subject, but are more realistic in terms of the clinical
environment: Different subjects (age and sex) scanned at different times of day, with
different operators responsible for patient positioning and adhering to the scanning
protocol. It is therefore possible that these CVs may reflect actual changes in
metabolite concentration, in addition to previously mentioned causes of variation.
However, since no brain matter segmentation was applied, these differences may also
indicate changes in the white / grey matter brain composition and CSF content of the
VOI between the subjects. In addition, it is possible that differences in the relaxation
rates of the metabolites between volunteers may have some influence on the results.
In the sub-set of eight volunteers that were reseamied approximately a fortnight after
the first scan, the CVs were < 7% for choline, creatine and NAA and < 9% for ml,
results approaching those for the first and second parts of the study.
However, these three studies by no means reflect the extent of the reproducibility
results reported. In a letter to the editor, Wardlaw et al included a table of results
from 11 ID reproducibility studies performed between 1991 and 1998 (154). For
NAA alone, CVs from absolute values ranged from 13% to 29%, with one study
quoting a general error of 39%. In terms of 2D, no less variation should be expected.
Pertaining to reproducibility in 2D J-resolved MRS, only Ke et al performed any
quantitative analysis of their results, and for the mean detected GABA
concentrations, a 36.5% standard deviation (SD) was quoted (24). This is
considerably poorer than that reported using other techniques, Table 7.1. This
disappointing result was attributed to the decrease in sensitivity due to use of the
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volume head coil compared to a surface coil, and a smaller VOI. In addition, it was
suggested that the longer scan time required for this J-resolved method encouraged
patient motion, thus further reducing the SD.
Table 7.1 Comparison of published reproducibility results for 2D MRS techniques
Method number of
subjects
SD and range of measured GABA Reference
Spectral editing at 1.5T 10 mean: 0.12 ± 0.05(SD)
range: 0.04 - 0.20
(13)
Spectral editing at 1.5T 8 SD 20%
reliability coefficient of repeated
experiments = 0.7
(14)
DQF at 1.5T 15 SD = 0.2mM (repeatability = 38%) (19)
DQF at 1.5T 10 mean: 0.20 ± 0.05 (SD) (17)
The specific topic of reproducibility in 2D MRS was addressed by Binesh et al, using
a 2D L-COSY sequence in 40 in-vitro experiments and on 10 volunteers, each
scanned four times (20). The spectra were acquired on a 1.5T GE scanner using body
coil transmit / 3" surface coil receive set-up, thus providing an increased SNR
compared to results from the head coil. The phantom used was the standard GE
spectroscopy phantom, which does not contain GABA, and as such, no results were
quoted specifically for GABA in in-vitro experiments.
In the within-run in-vitro experiments performed, CVs of less than 2% were
observed for the diagonal metabolite peaks and less than 6% for the cross-peaks.
Since the volume selection and data processing methods were unchanged, these
differences were accounted for by temporal instability of the scanner, affecting the
quality of shim and water suppression. Comparison of measurements taken over the
eight-month period gave CVs of between 7% - 15%. Differences in the phantom set¬
up, or changes in the transmit gain, as well as small daily fluctuations in the magnetic
field inhomogeneity or RF power could account for this poorer CV. Marshall et al
recently presented data showing a clear increasing trend in spectroscopy QA results,
accounted for by temporal changes in the RF transmitter causing a drift in the
transmit gain (158). So, without regular checks (and re-calibration where necessary),
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such factors may remain unaccounted for leading to an over-estimation of any
physiological changes.
In terms of the 2D COSY in-vivo work, there was a large range of CVs for each
metabolite (20). For example, the CV for the diagonal peaks of choline, creatine and
NAA were less than 9% in both the intra- and inter-subject experiments. This figure
rose to about 17% for the cross-peaks from glutamine / glutamate, ml, asparate and
threonine / lactate. The results for GABA showed an increased variation again; both
intra-and inter-subject experiments gave a mean CV of about 22%. This higher CV
was attributed to possible overlap of the GABA cross peak from ridges of the nearby
creatine and NAA.
As an additional part to this work, the intra-class correlation was calculated using the
in-vivo peak integrals and metabolite ratios (with creatine taken as reference). All
the major metabolites (NAA (diagonal and cross-peak), creatine, Glx) demonstrated
significant correlations of the measured ratios with respect to the diagonal peak of
creatine, yet this was not true of the lower concentration metabolites. Thus, the
lower SNR of these peaks prevents the difference of these peaks between subjects to
be significant when compared to the peaks from the same subject at different times.
It was suggested that improvement in coil design might improve the CV of the cross-
peaks by increasing the SNR.
It is against this background, that a series of local reproducibility experiments was
conducted, to identify the reliability of 2D J-resolved MRS, particularly for the
detection and quantification ofGABA, on the centre's 1.5T scanner.
7.2 Method
7.2.1 Scanning protocol
As have been previously discussed in §3, identification of the 3.01ppm GABA
resonance was chosen as initial experiments had shown that it was possible to resolve
this resonance from the overlapping resonance using the 2D J-resolved technique.
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To test the reproducibility of this approach, five spherical phantoms containing
physiological concentrations of choline and creatine (3mM and 9mM respectively)
and concentrations of GABA of lOmM, 5mM, 2mM, 1.5mM and 1.2mM were
evaluated. The GABA concentration of 1,2mM had been previously shown to be the
lowest detectable concentration using the volume head coil, §5. Since GABA at a
lower concentration of 0.8mM had been detected using a 5" surface coil, §6,
reproducibility measurements were also taken at this concentration in the surface
coil. For comparison, these experiments were also repeated in a 3" surface coil.
Three measures of reproducibility were taken: (1) Variation due to scanner
instability alone (within-run reproducibility); (2) variation due to scanner instability
and voxel re-positioning (within-session reproducibility); (3) both scanner and set-up
variation over several days (between-days reproducibility). In each of the three sets
of experiments, five 2D J-resolved spectra were acquired, Table 7.2. Results from §6
have shown that the optimum scanning protocol for GABA measurement uses a 5"
surface coil. However, since this is a formal reproducibility study, each experimental
set from lOmM GABA to 1.2mM GABA was carried out in both 5" surface coil and
a volume head coil since this is used for standard neuro-imaging / spectroscopy.
With the additional very low GABA concentration experiments in two sizes of
surface coil, a total of 180 separate experiments were performed.
For experiments using the volume head coil, the phantom was positioned in the
centre of the coil, which in turn was positioned in the isocentre of the magnet, and a
3x3x3cm3 voxel was centred in the phantom using a 3-plane localising image. In
experiments using the surface coils, the phantom was placed on a specially designed
headrest, and once positioned in the centre of the magnet, a 3x3x3cm3 voxel was
placed in the central part of the lower half of the phantom. Consequently, in all
cases, the ideal set-up for each coil arrangement was chosen.
All experiments were performed on a clinical 1.5T GE Signa Horizon system using a
dedicated 2D J-resolved spectroscopy sequence [N. Sailasuta, GE Healthcare] as
described in §5. 2D J-resolved spectra were obtained with the optimised protocol
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given in Table 6.17, i.e.: TEstart= 35ms, ATE = 10ms, steps2d = 66, TR = 2000ms,
NEX = 16. The total scanning time for each experiment was approximately 35
minutes.
Table 7.2 Number of experiments made for the calculation of within-run, within-session and
between-days reproducibility, in both a volume head coil (VHC) and 5" general-purpose surface





VHC 5"GP VHC 5"GP - VHC 5"GP
1.2 5 5 5 5 5 5
1.5 5 5 5 5 5 5
2.0 5 5 5 5 5 5
5.0 5 5 5 5 5 5
10.0 5 5 5 5 5 5
Total 25 25 25 25 25 25
7.2.2 Post-processing
As described in previous chapters, the resulting P-files from each scan were
transferred to a SUN Ultra workstation where the FIDs underwent automatic time-
domain phase correction, removal of water components using HLSVD and
apodization in both the F1 and F2 dimensions. Following 2D Fourier Transform of
the data, 2D magnitude contour plots were produced, allowing the identification of
the metabolites. Spectra were then extracted at J = 0Hz (providing an uncoupled
spectrum) and J = 7.4FIz, the J-coupling frequency of GABA. Conversion of these
spectra to MRUI format facilitated quantification in MRUI to obtain integral peak
values for each of the metabolites. In addition, ratios to creatine were obtained for
the GABA measurements.
Using the data acquired from experiments of individual metabolites, prior knowledge
files were created in MRUI to allow the automatic quantification of the extracted
spectra. In the J = 0Hz spectra, the choline and creatine peaks were quantified, and
the results were presented in §5. In the J = 7.4Hz extracted spectrum, the two GABA
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peaks (at 2.28ppm and 3.01ppm) and the residual choline and creatine peaks were
identified for quantification, although only the 3.01ppm GABA peak was analysed as
part of the reproducibility study.
CVs were calculated for GABA, using both the absolute values and metabolite ratios
to creatine, Equation 7.1. Variance was calculated according to the F-test in
Microsoft Excel (Microsoft corporation).
„ , n . . ... . . GABA (7.4Hz)GABA (metabolite ratio) =
creatine (0Hz)
Equation 7.1 Applied ratio for GABA metabolite ratios
7.3 Results
Following each experiment, 2D contour plots were produced and the row
corresponding to the J-coupling frequency of GABA was extracted and quantified.
At this frequency, peaks from GABA at both 3.01ppm and 2.28ppm were identified,
as well as peaks resulting from residual choline and creatine. Representative
examples ofmodelled spectra from experiments containing 5mM GABA and 1.2mM
GABA are shown in Figure 7.1 and Figure 7.2 in the volume head coil.
Corresponding spectra from the same phantoms using the surface coil are shown in
Figure 7.3 (5mM GABA) and Figure 7.4 (1.2mM GABA). Figure 7.5 presents the
results at 0.8mM GABA from both surface coils.
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Figure 7.1 Results from the 2D experiment using a phantom containing physiological
concentrations of choline and creatine, and 5mM GABA using a volume head coil, (a) 2D J-
resolved spectrum with the GABA resonances marked by circular markers. The extracted
spectrum at the level of the GABA J-coupling frequency is shown in (b). This spectrum was then
quantified in MRUI using the associated prior knowledge file, results of which are shown in (c).
Both GABA peaks (peaks 3 and 4) and the residual choline and creatine peaks (peaks 1 and 2
respectively) were quantified, and the results displayed in the table on the left-hand side of the
figure (with all peaks shifted by ~0.1ppm in room temperature phantoms).
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Figure 7.2 Results from the 2D experiment using a phantom containing physiological
concentrations of choline and creatine and 1.2mM GABA. Again, the GABA resonances are
identified within the oval markers, appearing at the 7.4Hz coupling frequency (a). The
extracted spectrum (b) was quantified in the same way, using the prior knowledge files to
identify and quantify the residual choline and creatine peaks, and the GABA peaks at 3.01ppm
and 2.2ppm (c) (with all peaks shifted by ~0.1ppm in room temperature phantoms).
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(a) (b)
Figure 7.3 Results from the 5mM phantom scanned using the 5"GP coil. Note the increase in
amplitude of all metabolites due to the increased sensitively of the surface coil compared to the
volume coil - in both the 2D plot (a) and extracted spectrum (b), GABA is more easily identified
(with all peaks shifted by -O.lppm in room temperature phantoms).
Tilted magnitude plot
-20
3 0 2 0 1 0 F2 (ppm)
Figure 7.4 Results also from the 1.2mM GABA phantom, with physiological concentrations of
choline and creatine using the 5" GP coil. On the 2D plot, (a), the GABA resonances are
identified within circles. With the increased sensitivity of the surface coil, even at this low
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Tilted magnitude plot Tiled magnitude plot
(c) (d)
Figure 7.5 2D J-resolved spectra from a phantom containing 9mM creatine, 3mM choline and
0.8mM GABA using (a) 5" surface coil and (b) 3" surface coil. The corresponding extracted
rows at the GABA J-coupling frequency are shown in (c) and (d) for the 5" and 3" surface coils
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The within-run experiments for each phantom were performed consecutively in the
same scanning session, requiring no re-positioning of the phantom and no reselection
of the VOI between each scan. The results from these experiments are shown in
Figure 7.6 and listed in Table 7.3. There was no significant difference between the




















♦ 5" surface coil
■ volume head coil
10
Figure 7.6 Results from the within-run reproducibility experiments in both coil arrangements.
In each series, the phantoms contained GABA in concentrations varying between lOmM to
1.2mM as described in the text. The error bars in this, and all proceeding graphs, relate to the
Standard Deviation of the mean.
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The within-session measurements evaluate the reproducibility of data acquisition
including both scanner and set-up variability. Figure 7.7 shows the within-session
results across the range of GABA concentrations in each of the five phantoms. These
results are summarised in Table 7.3. Analysis of variance, using the f-test,
demonstrated a significant difference between the results from the two coil types at



















• 5" surface coil
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Figure 7.7 Results from the within-session reproducibility experiments in both the 5"GP and
volume head coil. The results from the 5"GP are more reproducible than the volume head coil,
overall, with the lowest CYs at the higher GABA concentrations.
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The between-days in-vitro experiments most accurately reflect clinical experience,
were the subjects require re-positioning on different days. The mean and SDs from
the results across the full-range of GABA concentrations investigated are presented
in Figure 7.8 and Table 7.3. Significant differences between the data collected from
the two coils were observed at GABA concentrations of lOmM (p = 0.05) and


























Figure 7.8 Mean and SDs of the results from the between-day reproducibility experiments in
both the 5"GP and volume head coil. As will all previous results, the general trend of measured
concentration with actual concentration is observed, however, the results from the 5" GP coil
are generally more reproducible. More importantly for this work and potential for clinical
application, this is particularly true at the lower GABA concentrations.
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As described in the methods, it is not uncommon to find the results from 2D GABA
measurements quoted as ratios to creatine and so to allow comparison with these, the
GABA values were scaled to creatine, Table 7.4. The results from the low
concentration GABA experiments in the surface coils are presented in Table 7.5.
Table 7.3 The Coefficients of Variation (CV %) of the absolute values of GABA (peak areas as
calculated in MRUI) for all the within-run, within-session and between-days experiments in a
volume head coil (VHC) and 5" general purpose surface coil (5"GP).
[GABA]
(actual mM)
CV absolute GABA (%)
Within-run Within-session Between-days
VHC 5"GP VHC 5"GP VHC 5"GP
1.2 39.92 21.58 26.15 19.87 67.57 8.33
1.5 13.33 24.93 24.00 10.16 59.03 17.32
2 22.68 14.12 13.42 12.68 28.74 16.30
5 8.06 4.84 12.94 8.22 7.33 7.98
10 8.68 3.33 11.55 6.80 13.57 4.40
Table 7.4 CVs of the GABA ratios with respect to creatine for all the within-run, within-session




CV GABA / Cr (%)
Within-run Within-session Between-days
VHC 5"GP VHC 5"GP VHC 5"GP
1.2 21.57 21.82 28.18 17.40 67.57 15.47
1.5 12.38 16.89 25.61 11.79 54.99 15.43
2 23.39 16.41 14.43 7.70 28.40 12.32
5 7.86 3.11 13.53 7.30 4.52 14.48
10 8.31 5.42 8.87 2.21 11.79 4.67
Table 7.5 CVs (%) of the GABA ratios with respect to creatine for all the reproducibility
measurements from a phantom containing 9mM creatine, 3mM choline and 0.8mM GABA
Coil CV GABA / Cr (%)
within run within-session between-days
5" surface coil 16.93 17.01 22.53
3" surface coil 19.28 20.56 30.21
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7.4 Discussion and conclusions
Reassuringly, a clear trend of increasing measured GABA concentration with an
increase in the known actual concentration is observed, Figure 7.8, with most results
demonstrating a reduced CV (i.e. improved reproducibility) using the surface coil
compared to the volume head coil. This is expected due to the increase in sensitivity
associated with the surface coil. Rose et al noted a trend towards higher CV values
for low concentration metabolites when using a quadrature head coil for their single
voxel spectroscopy measurements (159), and Ke et al suggested that use of a volume
head coil contributed towards the poor CV obtained in their work (24). In neither
study were comparative experiments performed in both a volume and surface coil.
In the published in-vivo GABA-related MRS performed at 1.5T, there is considerable
variation among the quoted reproducibility of the measurements. Using a 2D J-
resolved sequence, Ke et al reported a ± 36.5% standard deviation (SD) in the mean
GABA concentrations using a volume head coil to localise a 2x3x2cm voxel (24).
For in-vivo GABA measurements using a double quantum filter at 1.5T, a
repeatability of 38% (± 2 SDs) in a 35cc voxel has been recorded (19). Using a
spectral editing technique also at 1.5T, in-vivo GABA SDs of 46% and 23% for 8cc
and 4cc voxels respectively, localised using a 5" surface coil, have been cited (13).
More promising results were reported by Binesh et al investigating the
reproducibility of 2D COSY where CVs for in-vivo GABA were less than 22% (raw
volumes) (20). These results were obtained using a 3" surface coil to localise a 3 x 3
x 3cm voxel in the anterior cingulate gyrus. In comparison to the published data,
the initial reproducibility measurements from this work contrast very well: In the
between-days experiment with a GABA concentration of 1.2mM, a CV of 8.33%
(15.47% using metabolite ratios) was obtained using the 5" GP surface coil, Table
7.3.
However, further investigation of lowest concentration GABA solutions showed a
dramatic reduction in the reproducibility, Table 7.5, with the value of the between-
days CV in the 5" surface coil rising to 23%. This suggests that the results obtained
at 1.2mM provide an over-optimistic view of the achievable reproducibility (a
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hypothesis that is supported by the larger CVs calculated from the within-run and
within-session measurements). Therefore, it may be that the results obtained at
0.8mM GABA reflect a more realistic idea of the obtainable reproducibility.
In translating this present work to an in-vivo protocol, increases in the CVs are
expected due to patient motion and voxel placement in different brain regions. In
addition, inhomogeneities within the brain matter, and in particular the sinuses and
ventricles, will reduce the shim efficiency leading to broader linewidths than the 2Hz
FWHM linewidths recorded in this work, which may also complicate GABA
measurement. Application of the in-vitro 2D COSY work in-vivo saw increases in
the CVs of the high concentration metabolites from < 10% to < 17% (20). Although
2D J-resolved MRS does not suffer the same theoretical signal loss as 2D COSY
(21), it is likely that similar decreases in reproducibility may be recorded when
measuring GABA in-vivo. However, with changes of the order of 50% in GABA
observed in depression and epilepsy using MRS at higher field strengths (8,160), 2D
J-resolved MRS may remain sufficiently reproducible to allow the routine study of
these neuropsychiatric disorders at clinical field strengths.
The results from this work have shown that 2D J-resolved MRS can be used to
measure in-vitro GABA concentrations falling within the normal physiological range
of 1.3mM - 1.9mM (7) and as low as 0.8mM. CVs from between-days absolute
reproducibly measurements of GABA were less than 23% at all GABA
concentrations using the 5" surface coil, supporting the earlier decision to perform all
in-vivo work using this coil. In addition, the CVs from the 5" coil suggest that 2D J-
resolved MRS may yet be sufficiently reproducible to detect changes in metabolite
concentrations in-vivo.
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8 In-vivo 2D J-resolved MRS
8.1 Introduction
The aim of all the work thus far has been to facilitate the measurement ofGABA in-
vivo, using 2D J-resolved MRS. Therefore, having established the optimum protocol
for data acquisition and post-processing, and shown that the reproducibility of the
technique is sufficient to allow real, physiological changes to be measured, it was
appropriate to apply the method in-vivo.
This chapter describes the results from the in-vivo experiments, specifically the
application of 2D J-resolved MRS for GABA measurement, §8.2. Evaluation of the
general reproducibility of the method is discussed in §8.3, and §8.4 discusses further
problems associated with applying the method to in-vivo data. To complete the in-
vivo work, results from acquiring 2D J-resolved spectra at 3T and applying the same
post-processing principles are presented in §8.5.
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8.2 In-vivo GABA measurement using 2D J-resolved MRS
8.2.1 Scanning and post-processing protocol
Normal, healthy volunteers were recruited for 2D J-resolved MRS and written
informed consent was obtained. Each volunteer was set-up on a 5" surface coil, using
a specially designed headrest for comfort and immobilisation. After acquiring a
series of T2 FSE axial images on which the spectroscopy VOI was positioned, a
conventional single-voxel PRESS experiment was performed (TE = 35ms, TR =
2000ms, VOI = 3x3x3cm in the occipital cortex) to ensure the acquisition of good
quality spectra during the 2D sequence. The spectral linewidth was noted, and the
VOI was re-positioned and / or re-sized to ensure a linewidth of less than 5Hz. In all
2D J-resolved experiments, the optimum scanning parameters were used as chosen in
§6.4. These are listed in Table 8.1.
Table 8.1 Scanning parameters for in-vivo acquisition of 2D J-resolved spectra
Coil 5" surface coil







The raw p-files were transferred to a Sun Ultra Workstation for post-processing as
described in §5.2.3. After 2D FT, the 7.45Hz rows were extracted from the 2D
contour plot and converted to ascii format for quantification of any visible GABA
peak.
8.2.2 Results
To date, a total of eight 2D J-resolved spectra have been acquired from four
volunteers. A representative 2D J-resolved spectrum is shown in Figure 8.1 from a
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healthy volunteer, using a TEstart = 35ms to replicate the minimum TE most
commonly used in the literature. The peak at 3.01ppm, in the extracted spectrum,
has been identified. Comparison with results in the literature would suggest a peak
assignment ofGABA and macromolecules (i.e. GABA+).
Tilted magnitude plot
7.4Hz
Figure 8.1 (a) 2D J-resolved spectrum and (b) extracted GABA row from a normal healthy
volunteer scanned at 1.5T using the acquisition parameters listed in Table 8.1. The arrow
indicates the GABA+ resonance since TEstart= 35ms.
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8.2.3 Discussion
After all the preparatory in-vitro work, it was interesting to finally see the spectra
resulting from the 2D J-resolved experiments in-vivo. It was disappointing that in no
experiment, a clear and distinct GABA peak was resolved (comparable to those
acquired in-vitro), although the results were no worse than the 2D J-resolved spectra
presented in the literature (24,27). In both these examples cited, a peak assignment
to GABA at 3.01ppm was made, without acknowledging any macromolecule
contribution, despite both studies using a TEstart = 35ms. Thus, direct comparison
between the published results and those presented here would suggest that in-vivo
GABA measurement is possible. However, the final stage before applying this
technique to a patient population is to determine if the in-vivo reproducibility is
sensitive enough to allow physiological changes to be detected. This issue is
addressed in the next section.
8.3 In-vivo reproducibility
8.3.1 Introduction
Before applying this method to a patient population, it was important to establish the
reproducibility of the 3.01ppm GABA plus macromolecule peak in a normal healthy
volunteer. Since in an abnormal population, the assumption of unchanging
macromolecule baseline cannot be made (42,44,87), it was also vital to evaluate the
results from 2D J-resolved experiments arising from a TEstart = 55ms.
Since 2D J-resolved MRS can be used to measure metabolites other than GABA, it
was also important to gain some measure of the reproducibility of the technique -
both acquisition and associated post-processing protocol - in-vivo. Therefore, the
peaks from the commonly studied metabolites NAA, choline and creatine were
quantified following 2D J-resolved MRS. At high concentrations, and free from
significant overlap from other metabolites, these will provide a measure of the best
achievable reproducibility using this technique in-vivo.
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8.3.2 Scanning protocol
A measure of the "within-run" reproducibility was obtained by scanning the same
volunteer three times in succession. Although a "between-days" measure may be
more clinically relevant, the within-run protocol ensures that real physiological
changes do not contribute to any variation. Thus, a best-case indication of in-vivo
reproducibility was calculated. Only three experiments were performed to make the
protocol more volunteer-friendly!
A single healthy volunteer was recruited for the experiment and informed consent
was obtained. The volunteer was set-up on a 5" GP coil using the purpose built
headrest. A 3-plane localiser was acquired, on which a 3x3x3cm3 VOI was
positioned in the occipital cortex for both ID MRS and 2D J-resolved MRS. A ID
PRESS spectrum was acquired before 2D MRS to ensure appropriate VOI placement
and the collection of good quality spectra. In addition, the voxel size and placement
was chosen to ensure a 4Hz linewidth after shimming. Once satisfied that the VOI
had met all these conditions, this same volume was excited in all spectroscopy
experiments. Three 2D J-resolved MRS experiments were performed consecutively
in the same VOI, using the acquisition parameters listed in Table 8.1. A total
scanning time (including 3-plane localiser and ID MRS) of 2.5 hours was required.
8.3.3 Post-processing
Initial post-processing was performed as was described in §5.2.3. For quantification
in MRUI, a new set of prior knowledge files was created to allow quantification of
the J = 0Hz NAA, choline and creatine peaks. Two 2D J-resolved spectra from each
experiment were produced: One with a TEstart = 35ms and the second with TEstart =
55ms. The GABA peak at 3.01ppm was quantified from both spectra in all three
experiments in MRUI, using prior knowledge from previous in-vitro results and
guidance from existing published work.
CVs were calculated for the three main metabolites in the extracted J = 0Hz spectra
and the GABA peak at 3.01ppm in the extracted J = 7.45Hz row.
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8.3.4 Results
The results obtained following quantification are shown in Table 8.2. An example
set of results are presented in Figure 8.2 with a TEstart= 35ms and the corresponding
spectrum from a TEstart= 55ms in Figure 8.3.
Table 8.2 Within-run reproducibility results from three consecutive in-vivo 2D J-resolved
experiments on one subject (NB All metabolite peak areas are given in arbitrary units).
FEstart
(ms)
J (Hz) Metabolite Experiment mean SD CV (%)
1 2 3
35 0 choline 2.97 2.83 3.31 3.04 0.25 8.13
35 0 creatine 2.55 2.92 2.92 2.80 0.21 7.64
35 0 NAA 6.85 6.92 7.35 7.04 0.27 3.85
35 7.4 GABA 0.10 0.12 0.07 0.10 0.03 26.03
55 7.4 GABA 0.09 0.08 0.05 0.07 0.02 28.39
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7.4Hz
ppm (b)
Figure 8.2 Set of in-vivo results from the within-run reproducibility experiments with TEstart =
35ms (a) 2D plot; (b) extracted J = 7.4 Hz row (c) extracted J = 0 Hz row. GABA+ is indicated
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Figure 8.3 The same set of in-vivo results from the within-run reproducibility experiments as
Figure 8.2 with TEstart= 55ms (a) 2D plot; (b) extracted J = 7.4 Fiz row. GABA is indicated by
the circle and arrow in (a) and (b).
8.3.5 Discussion and conclusion
Reassuringly, the reproducibility of the three main metabolites (that is choline,
creatine and NAA) in the J = 0Hz extracted spectra were all within ± 10%. This
suggests that in general, 2D J-resolved MRS is a repeatable technique when applied
in-vivo.
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The results from the 2D spectra with a TEstart = 35ms provided a CV for
measurements of the 3.01ppm "GABA" peak of 26%. This is comparable to the in-
vitro results presented in §7. However, as has been previously noted, this peak also
contains contribution from macromolecules, so cannot be assigned only to GABA.
By delaying the onset of the 2D experiment until a TEstart = 55ms, then the
macromolecule contribution is reduced. However, the resulting peak at 3.01ppm is
almost indistinguishable from the surrounding noise, as indicated in both the 2D
spectrum and extracted row, Figure 8.3. As expected, the peak areas are reduced
when compared to their counterparts with a TEstart = 35ms, Table 8.2, and there is a
decrease in the reproducibility indicated by a CV of almost 28%. This suggests that
the GABA plus macromolecule measurement may be the more reproducible to make,
corresponding to a TEstart= 35ms, although in patients, changes in the macromolecule
baseline cannot be ignored.
8.4 Problems with in-vivo acquisition of 2D J-resolved MRS
8.4.1 Introduction
The comparatively poor appearance of GABA in the in-vivo 2D J-resolved spectra
was poorly predicted by the in-vitro results. This may be due to a number of reasons,
including differences in linewidth and metabolite relaxation times between in-vitro
and in-vivo samples. This section discusses each of these issues in turn and offers
possible solutions for improvement, where applicable.
8.4.2 Signal to noise ratio
SNR is always the limiting factor when performing MRS using a clinical MRI
scanner. Fundamentally, MRS is an insensitive technique, with the recorded signal
arising from metabolite protons that only exist in concentrations of between ImM
and 20mM. Techniques to improve the metabolite signal include increasing the
number of signal averages (§6.4) increasing the magnetic field (§8.5) or lowering the
temperature (67). Clearly, in human subjects, the latter option is not possible.
Additional factors that reduce the sensitivity of in-vivo spectra compared to in-vitro
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signals include T2* relaxation, reducing the length of the detected FID, and signals
arising from the many complex metabolite spin-systems other than those modelled
in-vitro. These are inherent characteristics of the biological system under study, over
which the operator has no control, and give rise to the dramatic differences in the
SNR of phantom and human spectra. Despite this, it was of interest to explore the
extent to which these factors affect 2D J-resolved spectra.
8.4.2.1 Relaxation effects
Throughout the thesis, it has been acknowledged that no attempt has been made to
replicate in-vivo relaxation times. Basic spin physics theory has shown us that the
rate of decay of an FID is given by I/T2* and so has components from magnetic field
inhomogeneities and spin-spin relaxation. With the phantom chemicals in free
solution, the energy exchange required for T2 relaxation is less efficient than for
similar molecules confined within the anatomy of the brain, so the in-vitro T2 times
are longer. Since B0 inhomogeneities will exist in all experiments, it was important
to establish how the differences in relaxation times effect the end results of GABA
quantification in 2D J-resolved MRS. For this purpose, the T2 of creatine was
calculated for both in-vitro and in-vivo experiments.
Using existing data from previously run 2D J-resolved experiments, a standard
approach for T2 measurement was taken (94). That is, the creatine peak area was
measured over a range of TEs, whilst keeping the TR constant (as in a standard 2D J-
resolved experiment), and the results fitted to Equation 8.1. Since 66 spin-echoes
were collected for each single 2D J-resolved experiment, the creatine peak area was
quantified for all resulting ID spectra, and an exponential function fitted in Excel
(Microsoft Corporation). This method was applied to two sets of three consecutive
2D experiments, one from a within-run phantom experiment and the other from the
within-run volunteer experiment. The 3.0ppm creatine peak was chosen since it is a
singlet and so does not participate in homonuclear coupling, which complicates the
appearance of the spectra with changing TE.
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Equation 8.1 T2 measurement where S = measured signal at each TE and S0 = measured signal
at the shortest TE (94).
It is possible to model T2 relaxation using a multiexponential decay curve, to allow
for the different relaxation components within the VOI, and include a correction
factor to take account of noise (161). However, such forms of Equation 8.1 were not
included to allow direct comparison between these results, and those previously
obtained on the same scanner (162).
The results following quantification of the creatine peak in all ID spectra from the
three 2D J-resolved experiments are shown in Figure 8.4 and Figure 8.5 from the in-
vitro and in-vivo experiments respectively. The T2 times calculated from the mean
results of each data set are presented in Table 8.3, with equivalent published values
for comparison.
Figure 8.4 Quantification of creatine peak areas (from MRUI) for all ID spectra comprising 2D
J-resolved experiment. Acquired from 3x3x3cm3 VOI in a phantom containing physiological
concentrations of choline, creatine and GABA (3mM, 9mM and 1.2mM respectively). Data from
three consecutive 2D J-resolved experiments all using a 5" surface coil.
Page 191
In-vivo 2D J-resolved MRS
Variation of in-vivo 3.0ppm creatine peak with TE
TE (ms)
Figure 8.5 Quantification of creatine peak areas (in MRUI) for all ID spectra comprising 2D J-
resolved experiment. Acquired from 3x3x3cm3 VOI in the occipital cortex of a healthy
volunteer. Data from three 2D J-resolved experiments all using a 5" surface coil. The solid
black line indicates the mean noise quantified.
Table 8.3 Comparison of results of measured creatine T2 from this work, and published results
from Soher et al and Bruce, S.D. In both cases, the published data was acquired on a 1.5T GE
scanner, with that from Bruce on the same scanner as used for the work in this thesis
Source creatine T2 (sees)
in-vitro in-vivo
Mean experimental result 0.97 0.27
Soher et al (94) 0.61 0.21
Bruce, S D (162) 0.87-1.00 N/A
There is very good agreement between the results from this practical work and the
published data. The Ti values calculated on the centre's MRI scanner are longer than
those by Soher et al since Soher's phantom was doped with nickel chloride which
will reduce the relaxation times. The T2 times from both the in-vivo experiments are
also in excellent agreement, thereby validating the in-house measurement results.
As expected, the T2 of creatine in-vitro is much longer than in-vivo, the result of
which is the acquisition of metabolite information, with a good SNR, in all 64 (or 66)
spin-echoes of the 2D J-resolved experiment. This is demonstrated in Figure 8.4
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with just under half of the creatine signal remaining even in phantom experiments
with TEs of 665ms. From Figure 8.5 it is clear that the much shorter in-vivo creatine
T2 leads to quicker dephasing of the FIDs so at about TE = 485ms, all useful signal
has been reduced to the level of noise. With similar patterns expected in the other
metabolites, including GABA, it is small wonder that in-vivo measurements are so
much harder to make.
8.4.2.2 Linewidth
The natural linewidth of a spectrum is determined by the T2 relaxation of the
metabolites and the inhomogeneities of the main magnetic field, Bo, Equation 8.2.
Thus, the spectral lines from immobile macromolecules have much broader
linewidths than those from the more highly mobile metabolites, even in the absence
of magnetic field inhomogeneities. The combined effects of T2 relaxation and Bo
inhomogeneities result in increasing linewidths of all the spectral components,




Equation 8.2 Definition of natural linewidth of spectral lines in terms of the full width at half
maximum (FWHM), where T2* is the effective relaxation resulting from inhomogeneities of B0
and the transverse relaxation of the metabolites, (70).
Active shimming of the magnet is essential in spectroscopy to improve the
homogeneity of B0, and to allow the very small changes in frequency associated with
the metabolite resonances to be observed. By ensuring a uniformly homogeneous
field across the spectroscopy volume, spectra of the narrowest linewidth and highest
SNR are obtained.
Successful shimming relies on a small, well-defined VOI, in a homogenous
environment. With the in-vitro spectra obtained in such a setting, it is clear why
linewidths of 2Hz were achieved. However, with the anatomical variations that exist
in a human head, and an MRI system with only 1st order shim coils, such a narrow
linewidth is unachievable.
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The linewidths of all in-vivo experiments were 4Hz, which in general spectroscopy
terms, is very good. This was often achieved only after moving / resizing the VOI
and / or repeated shimming of the volume. To appreciate how this 2Hz linewidth
difference between the in-vivo and in-vitro work contributed to the lack of GABA
measurement in-vivo, a series of in-vitro experiments with a phantom containing
1.2mM GABA was performed, with linewidths increasing from 2Hz to 5Hz, Table
8.4.
The poorer linewidths were achieved by moving the same voxel closer to the edge of
the phantom. First in one dimension (i.e. positioned on the central slice but closer to
the bottom of the phantom) and then in two (i.e. moving the VOI superiorly through
the slices so it bordered the phantom edge on two sides). Care was taken to ensure
that the entire VOI was contained within the phantom so that no signal loss could be
attributed to a smaller actual VOI.
Four 2D J-resolved spectra were acquired and processed as described in §5, and the
results from these experiments are summarised in Table 8.4.
Table 8.4 Summary of results from investigation on linewidth on measured 1.2mM GABA signal
in-vitro
linewidth TES(art ATE TR NEX GABA peak area (arb)
(Hz) (ms) (ms) (ms) 3.01ppm 2.28ppm 1.89ppm
2 35 10 2000 16 0.71 0.83 0.10
3 35 10 2000 16 0.30 0.29 0.10
4 35 10 2000 16 0.19 0.24 0.05
5 35 10 2000 16 0.19 0.13 0.08
The results from quantification of all three GABA peaks show a general trend of
decreasing area with increasing linewidth. Focusing in on the peak of interest, there
is a dramatic reduction in the 3.01ppm GABA peak from 2Hz to 3Hz, with further
reductions as the linewidth increases further.
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Study of standard ID spectra from the outer limits of the linewidths investigated
show huge differences in the quality of spectra, as one would expect, Figure 8.6:
With a linewidth of 2Hz and GABA at a concentration of 1,2mM GABA, only a
small peak at 2.28ppm is observed. It is also clear from this spectrum, that there has
been good removal of the residual water peak, leaving an undistorted baseline. This
is not true in the spectrum obtained with a 5Hz linewidth, with evidence of a large
residual water peak and an uneven baseline. This is probably due to a combination
of poor shimming on the badly positioned VOI. Consequently, the 2.28ppm GABA
peak is less obvious above the noise, and so it is no surprise that the 2D J-resolved
spectra are degraded.
(a) (b)
Figure 8.6 Conventional ID spectra from same phantom containing 1.2mM GABA only with a
linewidth of (a) 2Hz and (b) 5Hz.
The 2D spectra and corresponding extracted GABA rows with varying linewidth are
shown in Figure 8.7. The results from the in-vitro experiments with a 4Hz linewidth
are shown to try to replicate the effects seen in-vivo. The spread of the residual water
peak is immediately obvious in the spectra with the larger linewidth, with its
presence contaminating the entire spectrum at J = 0Hz.
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Figure 8.7 Resulting 2D J-resolved spectra and extracted GABA rows (J = 7.45Hz) from the
same phantom containing 1.2mM GABA with a linewidth of 2Hz ((a) and (c) respectively) and
4Hz ((b) and (d) respectively).
In the extracted spectra, two distinct GABA peaks, corresponding to 3.01ppm and
2.28ppm are clearly seen in Figure 8.7 (c), acquired with a linewidth of 2Hz. In the
equivalent spectrum at 4Hz linewidth, the 3.01ppm GABA peak is approximately a
quarter of the same peak at 2Hz, Table 8.4. Thus improper voxel positioning and
spectral line broadening has an extremely detrimental effect on the resulting 2D
spectra and on the ability to accurately quantify the metabolites in the extracted J =
7.45Hz row. With such increases in linewidth recorded in-vivo, it is likely that the
increase in linewidth also impaired identification ofGABA.
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8.5 2D J-resolved MRS at 3T
8.5.1 Introduction
The results from §8.2 do not suggest that GABA can be confidently measured in-
vivo. With some of the most obvious limiting factors being the lack of SNR and
chemical shift (F2) resolution, an obvious solution was to perform the experiment at
a higher field strength.
Through the collaboration with Dr. N. Sailasuta, the author of the dedicated 2D J-
resolved sequence, in-vivo data at 3T using this same sequence was acquired. The
experiments were all performed by Dr. Sailasuta at GE Healthcare in California, and
the raw p-files were sent here for processing using the methods outlined in §5.2.3.
8.5.2 Scanning protocol
All experiments were performed on a GE 3T scanner using a standard volume head
coil. Three volunteers with possible elevated levels of GABA were recruited from a
mood study to undergo 2D J-resolved MRS. The scan parameters used in each case
are listed in Table 8.5.
Table 8.5 Acquisition parameters for 2D J-resolved in-vivo experiments performed at 3T
Scan parameters Volunteer
A B C
TES(art 35 35 35
ATE 2.5ms 2.5ms 2.5ms
steps2d 64 128 64
NEX 4 4 16
TR 2000ms 1500ms 1500ms
coil volume head volume head volume head
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8.5.3 Results
The 2D spectra and corresponding extracted GABA rows are provided in Figure 8.8
to Figure 8.10. Disappointingly, in no case could the spectral assignment be made to
the 3.01ppm GABA peak.
Tilted magnitude plot
(a) (b)
Figure 8.8 (a) 2D J-resolved spectrum from volunteer A and (b) corresponding extracted GABA
row. Experiment performed at 3T - see Table 8.5 for details.
Tilted magnitude plot
(a) (b)
Figure 8.9 (a) 2D J-resolved spectrum from volunteer B and (b) corresponding extracted GABA
row. Experiment performed at 3T - see Table 8.5 for details.
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(b)
(a)
Figure 8.10 (a) 2D J-resolved spectrum from volunteer C and (b) corresponding extracted
GABA row. Experiment performed at 3T - see Table 8.5 for details.
8.5.4 Discussion and conclusions
The in-vivo results obtained at 3T are all very disappointing as in no example was the
3.01ppm GABA peak identified. This may be due to a variety of reasons specific to
the protocol used, in addition to the general problems of the technique, §8.4.
In all cases, the volume head coil was used which, as shown in §6.2, has a poorer
sensitivity than a surface coil. However, it is disappointing that even at 3T, with the
increased SNR, GABA is undetectable.
The F1 resolution may also contribute to the lack of GABA results. Using the
optimum protocol described in §6.4, an F1 resolution of 0.78Hz / frame of data is
achieved after zero filling. The spectra from volunteers A and C had an F1
resolution of 3.13Hz after zero filling and with the increased number of TEs acquired
for volunteer B, the F1 resolution was 1.56Hz. Consequently, the extracted spectra
from volunteers A and C were at a J-coupling frequency of ~6Hz, which may be
distant enough from the ideal 7.45Hz to prevent GABA detection. Although the F1
resolution was better for volunteer B, a GABA peak still remained undetected, but
the quality of the spectra may have also contributed towards this. The spectra from
volunteers A and B were collected under a previous software version, with the oldest
acquired almost two years ago, and they are clearly much noisier than the later
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spectra for volunteer C and even the spectra acquired at 1.5T. An important
difference between this and the data acquired at 1.5T is the NEX: At 1.5T, a NEX =
16 was used, but at 3T only a NEX = 4 was applied. As explained in § 6.4, a NEX of
eight means that all three RF pulses are phase cycled to eliminate any undesirable
signals, in a total of eight combinations. Therefore, when NEX = 16 is applied, the
phase cycle is repeated for a second time. A NEX = 2 indicates that only the first RF
pulse is phase cycled so that the data frame consists of an average of two excitations.
Thus, the NEX used in the 3T experiments (NEX = 4), implies that this phase
cycling scheme has been repeated so that the final signal is averaged from four
excitations. Clearly, this will have a detrimental effect of the final spectra.
The F1 bleed observed in the spectra may also indicate scanner instability, although
since the system is used for GE's own research, it is hoped not! Another possibility
could be patient movement during acquisition. The spectra were all acquired from
patients, who may not be as used to being scanned as the volunteers recruited locally
for study on the 1.5T system. Any patient movement during the scan may have
given rise to phase variations in the spectra, which may have contributed to the poor
spectral quality.
Without direct access to a 3T scanner on which to perform 2D J-resolved
experiments, the author was unable to exactly replicate the experimental work
performed at 1.5T. The 3T data presented was acquired as part of a patient study,
also looking at in-vivo GABA levels, and the author is grateful for the opportunity to
work with higher-field spectra. It is disappointing that the datasets were not of a
better quality to help with the detection ofGABA.
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9 2D L-COSY for GABA measurement
9.1 Introduction
Although the 2D J-resolved spectra presented in the previous chapter suggested that
in-vivo GABA measurement was possible, the results - and particularly those
minimising macromolecule contributions - were not entirely convincing. Therefore,
an alternative method of GABA measurement at 1.5T was investigated. Compared
to spectral editing techniques, 2D methods have the advantage of acquiring
information from all metabolites, and so it was desirable to attempt GABA
measurement using another 2D technique. This would ensure that even if
assignments to GABA resonances were not made, there was still an abundance of
data pertaining to the other metabolites, allowing different measurements and
comparisons to be made.
Collaborative work with Dr. M. Albert Thomas, University of California, facilitated
access to a 2D Localised-COSY sequence (2D L-COSY) that had previously been
applied on GE scanners at both 1.5T and 3T with encouraging results (20,21,133).
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The author is grateful to Dr. Thomas for sharing his sequence, and in doing so, for
allowing the practical work presented in this chapter.
As the only chapter on 2D L-COSY, the following sections describe the initial single
metabolite experiments to validate the acquisition and post-processing protocols. In
keeping with previous investigations of GABA measurement, preliminary results
from experiments determining the threshold of GABA detection and the




For a general description of COSY, including its basic pulse sequence, the reader is
directed to §3. Localised COSY (L-COSY) was performed using the sequence
shown in Figure 9.1, comprising of a series of 90° - 180° - 90° RF pulses. From the
general description of a 2D sequence as provided in §2, the first excitation and
refocusing pulse form the preparation period, with the mixing period comprising the
second 90° pulse. The evolution and detection periods are designated fi and t2
respectively. Water suppression was achieved with the application of CHESS
immediately before 2D L-COSY.
90° 180° 90°
A
» > r r > r A ^ tz ^ ACQUIREw W WW w W
Figure 9.1 L-COSY pulse sequence as described in (21). The evolution time, tj, is uniformly
incremented to provide the required spectral width in the second dimension (Fl). The detection
period is denoted by t2. A represent the minimum rise time of the gradients.
As with the dedicated 2D J-resolved sequence, the version of 2D L-COSY acquired
for this work was also a research sequence. However, unlike the 2D J-resolved
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sequence that only required manipulation of the user CVs after voxel prescription, far
more user interaction was needed to run COSY. This included manual shimming to
optimise the spectroscopy signal and water suppression. To aid this process, a
conventional, single-voxel PRESS experiment was performed prior to COSY from
which the optimisation parameters (e.g. transmitter gain) could be obtained from the
automatic prescan. The manual prescan is described in more detail in the next
section.
The FIDs arising from COSY acquisition contain both in-phase and anti-phase
components, and so are displayed in magnitude mode, in a similar way to the 2D J-
resolved data. A post-processing protocol was chosen to replicate that used by
Thomas et al, (21,133). In contrast to the post-processing applied to raw data from
2D J-resolved FIDs, no phase correction or removal of the residual water peak
occurred. The application of a shifted, skewed, squared sine-bell apodization
function meant that affects from the higher intensity section of the water signal were
considerably reduced. Thus further post-processing of the water peak was
unnecessary.
9.2.2 Scanning protocol
All experiments were performed on a 1.5T GE Signa Horizon scanner operating in
research mode and using a 5" surface coil. Prior to 2D L-COSY acquisition, a ID
PRESS experiment was performed in the defined VOI to evaluate the quality of the
spectra and to provide baseline settings for the manual prescan preceding 2D L-
COSY. The transmitter gain (TG) set during the automatic PRESS prescan was
noted.
After loading the COSY sequence, prescription of the spectroscopy voxel and setting
of the initial timing parameters was completed on the scan desktop, as with
conventional ID spectroscopy. To allow the manual prescan to be completed in the
shortest possible time, both the total number of scans and NEXs were minimised
during the initial sequence set-up.
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Manual pre-scan involved setting the TG and receiver gains, after which the voxel
was shimmed by adjusting the gradients using the slider bars on the manual prescan
screen. With a magnitude display of the FID on the screen, optimisation progressed
until the maximum water signal was obtained.
Once satisfied with the appearance of the water signal, the next step was to optimise
the water suppression. Both the user CVs "sup" and "suppress" were set to one to
activate the water suppression gradients and RF pulse respectively. Optimal
suppression was achieved by changing the flip angles associated with the second and
third water-suppression RF pulses. In practice, this was an iterative process achieved
by viewing the FID in magnitude mode, and changing the values of the flip angles
consecutively until maximum metabolite signal had been obtained.
The final part of the process was to modify the user CVs to reflect the values
obtained in pre-scan optimisation (notably those of the water suppression flip
angles), and to change the acquisition parameters to those more suitable for 2D L-
COSY. For all initial in-vitro experiments, the parameters used for COSY as set
after the pre-scan, are listed in Table 9.1, giving rise to a scan time of 25:52 minutes
(excluding the pre-scan).
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Table 9.1 Acquisition parameters used in 2D L-COSY
Variable Meaning Value
TEm|n Minimum echo time (ms) 30.008
TR Repetition time (ms) 2000
specpts number of complex points acquired per excitation 1024
specwidth total frequency width (Hz) 2500
echomode acquisition of a partial echo, where nearly a full echo
is recorded in a shorter TE than that required for a full
echo
1
dda number of "dummy scans" acquired and discarded at
the start of the sequence to achieve steady state
during acquisition
4
opnex determines phase cycling method (see §6.4 for
details)
8
total_scans total number of excitations for signal averaging 768
deltate2 f increment (ps) 1600
ref_count number of frames for water referencing 0
flip_rf02 flip angle of second water suppression pulse as determined
during manual
prescan




The outcome of a 2D COSY experiment was a contour plot showing the correlations
of J-coupled spins. As described in §3, both dimensions of the contour plot are in
ppm, from which the chemical offset of both the diagonal peaks and, more
significantly in terms of coupled molecules, the cross-peaks can be identified.
Compared to 2D J-resolved MRS, the post-processing required to achieve this was
minimal. A strategy was developed to replicate the post-processing carried out by
M.A. Thomas's group to allow direct comparison between their work and the results
produced here. To do this, the phase-correct and removal of the residual water peak
functions were omitted from the Jresolved.c programme, used for initial post¬
processing of the 2D J-resolved raw data files, and so LCOSY.c performed the
following:
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i. Read in the raw p-file
ii. Scale the FIDs according to the pre-scan parameters (TG, receiver gains and
spectroscopy voxel volume)
iii. Save the processed FIDs in a text file for further processing in Matlab (The
Mathworks Inc).
In Matlab, LCOSY.m, executed the following main functions:
i. Zero-fill the raw data in both dimensions
ii. Simple sine-bell squared apodization in the F1 dimension
iii. Shifted, skewed squared sine-bell apodization in the F2 dimension to emphasise
the cross-peaks in comparison to the diagonals (formulae obtained by I.
Marshall from personal correspondence with M. A. Thomas)
iv. 2D Fourier Transform
Quantification of spectra extracted for specific cross-peak and diagonal peak areas
was achieved in MRUI. In a similar method to the extracted J-resolved spectra, the
rows of data were converted to the appropriate ascii format using
GABA2DLCOSY.m for the F2 = 3.0ppm and F1 = 2.0ppm GABA peak. This cross-
peak had been previously identified in published in-vivo data (133). The diagonal
peaks from choline (F2 = 3.2ppm, F1 = 3.2ppm) and creatine (F2 = 3.0ppm, F1 =
3.0ppm) were quantified using cholcre2DLCOSY.m. Prior knowledge files were
created from 2D L-COSY experiments on high concentration metabolite phantoms,
thereby allowing the quantification process to be standardised.
9.3 Individual metabolite phantoms
9.3.1 Introduction
Preliminary validation of 2D L-COSY data acquisition (including the manual
prescan) and post-processing protocol was performed using a series of individual
phantom solutions. The resulting 2D spectra were then compared to examples
provided in the literature.
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9.3.2 Methods
2D L-COSY spectra were acquired using the protocol described in §9.2.2 and the
raw data files were transferred to a Sun Ultra Workstation (Sun Microsystems,
Mountain View, CA) for processing, §9.2.3.
Aqueous solutions of the commonly reported cerebral metabolites, at physiological
concentrations, were made in 3.6 litre, glass spherical phantoms. GABA solutions
were prepared at both physiological concentration (1.5mM) and at lOmM. All
solutions were pH corrected to physiological pH (7.2) using a combination of sodium
hydroxide and hydrochloric acid. No attempt was made to replicate physiological
relaxation times.
9.3.3 Results
The 2D L-COSY spectra from the individual metabolite experiments of choline,
creatine, glutamate, glutamine, myo-inositol and lactate are presented in Figure 9.2 to
Figure 9.4. The corresponding results from both GABA concentrations are presented
in Figure 9.5.
F1(ppm) Contoured magnitude plot




Figure 9.2 2D L-COSY spectra from a 3x3x3cm VOI positioned in a phantom containing (a)
3mM choline (diagonal at F2 = F1 = 3.2ppm arising from the methyl protons), (b) 9mM creatine
(diagonals at F2 = F1 = 3.0ppm and F1 = F2 = 3.9pmm; weak cross-peak at F2 = 3.9ppm, F1 =
3.0ppm). NB All cross-peaks quoted for below the diagonal (with all peaks shifted by -O.lppm in
the room temperature phantoms).
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Figure 9.3 2D L-COSY spectra from a 3x3x3cm' VOI positioned in a phantom containing (a)
12.5mM glutamate (diagonals at F2 = F1 = 2.4ppm and F2 = F1 = 3.7ppm; cross-peaks at F2 =
3.6ppm, F1 = 2.0ppm). (b) 5.8mM glutamine (diagonals at F2 = F1 = 2.5ppm and F2 = F1 =
3.8ppm; cross-peaks at F2 = 3.8ppm F1 = 2.1ppm). NB All cross-peaks quoted for below the





4.0 3.5 3.0 2.5 2.0 1.5
F2(ppm) F2(ppm)
(a) (b)
Figure 9.4 (a) 8.1mM myo-inositol (diagonals at F2 = F1 = 3.5ppm and F2 = F1 = 4.0ppm; cross-
peaks at F2 = 3.5ppm, F1 = 3.2ppm). (f) lactate (diagonal at F2 = F1 = 1.31ppm; cross-peak at
F2 = 4.1ppm, F1 = 1.3ppm). NB All cross-peaks quoted for below the diagonal (with all peaks
shifted by -O.lppm in the room temperature phantoms).
F1(ppm) Contoured magnitude plot
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Figure 9.5 2D L-COSY spectra from a 3x3x3cm3 VOI positioned in a phantom containing
GABA at (a) lOmM and (b) 1.5mM. In both spectra, the diagonals at F2 = F1 = 2.28ppm and F2
= F1 = 3.01ppm are visible. In the higher concentration phantom, the diagonals at F2 = F1 =
1.9ppm and the cross-peaks at F2 = 3.01ppm, F1 = 1.9ppm are more clearly seen. NB All cross-
peaks quoted for below the diagonal (with all peaks shifted by ~0.1ppm in the room temperature
phantoms).
9.3.4 Discussion and conclusions
The correlation patterns in the 2D L-COSY spectra are as predicted by the literature
(20,21,124), thereby validating the technique as a whole. However, it should be
noted at this point, that the quoted scan time of 25:52 minutes was rarely close to
being achieved. Manual prescanning took, at best, five minutes, and at worst an
extra 20 minutes - in all cases immediately following a standard single-voxel PRESS
experiment. The prescan is a crucial step in the process, and will be of even greater
importance in-vivo with the increased linewidths. However, an additional 20 minutes
may not be tolerated by the subject, which brings into question the appropriateness of
applying such a user-dependant method. This too, raises the issue of the reliability of
the results, and specifically any reduction in reproducibility associated with the
manual prescan. The results from a preliminary reproducibility study are discussed
in §9.5.
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9.4 GABA threshold
9.4.1 Introduction
As described in the 2D J-resolved MRS work in §4 and §5, it is important to
determine the threshold of GABA measurement, to ensure that it falls within normal
physiological levels. Therefore, a series of experiments were performed to establish
the minimum GABA concentration detectable, in-vitro, using 2D L-COSY.
9.4.2 Materials and methods
Initially, all experiments were conducted following the scanning protocol described
in §9.2.2 and using a 5" surface coil. 2D L-COSY spectra were acquired from a
3x3x3cm voxel centrally placed in the high signal region in the lower half of the
phantom.
Seven phantoms containing physiological concentrations of choline and creatine
(3mM and 9mM respectively) were made. GABA was added to three of these
phantoms at higher than physiological concentrations (lOmM, 5mM, 2mM), to
ensure that it could be adequately detected in aqueous solution with choline and
creatine. Three further phantoms were made to investigate GABA detection in
normal physiological ranges (1.5mM, 1.2mM, LOmM, and 0.8mM). The aqueous
solutions were made from dry masses of the chemicals (Sigma-Aldrich).
At the lower GABA concentrations, variations in acquisition parameters, including
the use of a 3" surface coil, were investigated to aid detection of the metabolite. As
discussed in §6, the SNR of the spectra can be improved by increasing the NEX and
total number of scans. Since the number of FIDs acquired at different TEs is
dependant on both these parameters in 2D L-COSY, Equation 9.1, both values need
to be increased to ensure that a sufficient number of TEs are collected to perform
COSY, at the same time as increasing the SNR. Therefore to increase the SNR and
have 64 TEs for 2D Fourier Transform, NEX = 16 and total number of scans = 1024
were investigated in a scan time of 34:24 minutes.
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number of TEs =
total number of scans
NEX
Equation 9.1 Variation of number of TEs acquired for 2D L-COSY with the total number of
scans and NEX.
Post-processing and quantification of the spectra followed the procedure described in
§9.2.3.
9.4.3 Results
A summary of the results over all identifiable GABA concentrations is shown in
Figure 9.6. Using the standard set-up (i.e. 5" surface coil and acquisition parameters
as listed in Table 9.1), GABA was only detectable to 1.5mM. By increasing total
number of scans and NEX, 1.2mM GABA was identified using the 5" surface coil.
However, even with changing to the smaller surface coil and using the improved
SNR acquisition parameters, cross-peaks from GABA at F2 = 3.01ppm, F1 = 1.9ppm
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Figure 9.6 Results of in-vitro GABA measurement from a 3x3x3cm3 voxel in six phantoms of
decreasing GABA concentration, using a dedicated 2D L-COSY MRS sequence.
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The 2D L-COSY spectrum from the phantom containing 1,2mM GABA, using the
increased NEX/total number of scans, is shown in Figure 9.7 with the corresponding




Figure 9.7 (a) 2D L-COSY spectrum from a 3x3x3cm3 voxel in a phantom containing 3mM
choline, 9mM creatine and 1.2mM GABA, using a 5" coil. The cross-peak at F2 = 3.0ppm, F1 =
1.9ppm is highlighted, (b) Extracted row from 2D contour plot showing the corresponding
GABA cross-peak pre-quantification and (c) post-quantification in MRUI.
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9.4.4 Discussion
These results suggest that 2D L-COSY is not as sensitive as 2D J-resolved MRS for
GABA measurement. Clear peak assignments were made to GABA, in-vitro, at
concentrations as low as 0.8mM using 2D J-resolved spectroscopy, but
corresponding convincing results could not be produced using COSY. This would
suggest that 2D L-COSY may only detect GABA, in-vivo, when present in the upper
limits of the normal range of physiological concentrations (7).
However, before any conclusions can be made about the suitability of 2D L-COSY
for in-vivo GABA measurement at 1.5T, the reliability of such results needs to be
established. Results from preliminary work specifically addressing this issue are
presented in the next section.
9.5 Reproducibility
9.5.1 Introduction
Although the specific application of this sequence is GABA measurement, it was
also important to obtain a general measure of the reproducibility of the technique -
including acquisition and post-processing. This was achieved by quantifying the
diagonal peaks from choline and creatine.
In this pilot study, GABA reproducibility measurements were made in phantoms
containing 5mM and at the threshold of GABA detection: 1.2mM. In each case,
within-run, within-session and between-days reproducibility measurements were
calculated. In addition, the results from the experiments at these GABA
concentrations allowed direct comparison to the 2D J-resolved reproducibility study
presented in §7.
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9.5.2 Materials and methods
2D L-COSY spectra were obtained from a 5"and 3" surface coil, using a similar
protocol as that given in Table 9.1. However, the NEX and total number of scans
were increased to improve the SNR, as described in §9.4.2.
Two phantoms of physiological concentrations of choline and creatine (3mM and
9mM respectively), were made in two 3.6 litre glass, spherical containers. In one
phantom, GABA was added at a concentration of 5mM and in the second, at 1,2mM.
As described in §7, three measures of reproducibility were taken: Within-run, within-
session and between-days. In each of the three sets of measurements, five 2D L-
COSY spectra were acquired, with each set performed in both phantoms. The
resulting raw data files were transferred to a Sun Ultra Workstation and processed as
described in §9.2.3. Coefficients of variation (CV) were calculated for all three
measures of reproducibility in both phantoms.
9.5.3 Results
A summary of all the GABA measurements is given in Table 9.2, with the
corresponding results from choline and creatine in Table 9.3. A representative
example from the 5mM GABA phantom with results pre- and post-quantification is
shown in Figure 9.8.
Table 9.2 Coefficients of Variation (CV, %) of the absolute values of GABA for all the within-












5" coil 3" coil 5" coil 3" coil 5" coil 3" coil
1 2mM 21.7 - 39.0 - 42.1 -
5mM 22.7 39.6 21.8 39.3 24.4 43.8
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Table 9.3 CVs of the absolute values of choline and creatine for all the within-run, within-










5" coil 3" coil 5" coil 3" coil 5" coil 3" coil
choline 22.7 17.7 20.8 25.2 26.9 25.7
creatine 25.1 18.7 26.3 22.9 26.0 22.8
4.0 3.5 3.0 2.5 2.0 1.5 1.0 0.5
F2(ppm)
Figure 9.8 Results from the 2D experiment using a phantom containing physiological
concentrations of choline and creatine, and 5mM GABA using a 5" surface coil, (a) 2D L-
COSY spectrum with the F2 = 3.01ppm, F1 = 1.9ppm GABA cross-peak marked. The extracted
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9.5.4 Discussion
It has already been noted in §7 that there is considerable variation in the published
reproducibility measurements of in-vivo GABA at 1.5T. Even so, in comparison to
some of the published data and the 2D J-resolved results presented in §7, the
reproducibility measurements obtained using COSY are very disappointing.
Using the same 2D L-COSY sequence, Binesh et al gives a between-days CV for the
choline diagonal of 2.2%, in-vitro (20). This is compared to 25.7% obtained locally,
with both sets of measurements performed with a 3" surface coil. Since Binesh and
colleagues used a standard GE spectroscopy phantom that doesn't contain GABA,
evaluation of the GABA in-vitro results between both centres is not possible.
However, in-vivo, Binesh cited a GABA between-days CV of 22%, again using a 3"
surface coil. This is a considerable improvement on the only between-days measure
obtained here, using the 5" surface coil, Table 9.2.
These comparatively poor results raise serious questions about scanner performance,
operator dependency and perhaps, although less likely, the post-processing. The
within-run experiments provide an indication of scanner performance, since neither
the phantom nor the VOI is moved between acquisitions. Using the 5" surface coil,
CVs of 22.7% and 25.1% were obtained for choline and creatine respectively, with
only slightly better results when using the smaller surface coil, Table 9.3. With the
equivalent results using 2D J-resolved MRS all less than 10%, §5, scanner instability
cannot account for all the variation observed. Therefore, it is likely that differences
in the optimisation of the signal during the manual prescan contribute significantly to
the reproducibility.
With such inconsistency in five consecutive experiments, even among the high
concentration metabolites, the reliability of in-vivo data acquisition has to be given
careful consideration. In this practical work, all of the 2D L-COSY experiments
were performed after a standard PRESS sequence, which incorporates automatic
optimisation of the signal. In-vitro, it may be possible to use these pre-scan
parameters for 2D L-COSY acquisition, since neither the phantom nor voxel will
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have moved between one sequence and the next. In-vivo, this is not always the case,
particularly when scanning patients. Consequently, it would be incorrect to assume
zero patient / voxel movement, and so the pre-scan parameters from the PRESS
sequence would not be transferable to COSY. Thus, a full prescan immediately
before COSY acquisition is essential, and without automation, may not be consistent
between scans.
Variation in prescan performance is evident in all measurements, in all three sets of
reproducibility calculations. Results from the high concentration GABA phantom in
the 5" surface coil are comparable to those from physiological concentrations of
choline and creatine, with a between days CV of 24.4%. However, GABA
measurement in the 3" surface coil is far worse: At 5mM, the between-days CV =
43.8%. Also in the 3" surface coil, at a concentration of 1.2mM, GABA was
consistently undetectable. These appalling results are probably due to poor voxel
shimming / signal optimisation. Even so, they do not bode well for in-vivo
translation using a 3" surface coil.
In the 5" coil, GABA detection at F2 = 3.01ppm, F1 = 1,9ppm was not constant. Out
of the 15 experiments performed at GABA concentrations of 1.2mM, the GABA
cross-peak was identified in only eight of the resulting 2D spectra. This failure rate
is far greater than that associated with 2D J-resolved MRS, which for the same
GABA concentration and coil arrangement, failed to produce a clear GABA peak in
only two spectra. This raises issues about the reliability of 2D L-COSY in terms of
GABA detection performance, and about the decision processes involved in the
interpretation of the 2D contour plots. For example, the F2 = 3.01ppm, F1 = 1.9ppm
GABA cross-peak was not identified from the experiment giving rise to the 2D L-
COSY spectra shown in Figure 9.9 (a): Spread of both the choline and creatine peaks
obscured any evidence of GABA at this position. Study of the extracted row
corresponding to F1 = 1.9ppm (Figure 9.9 (b)) showed two peaks around 3.01ppm,
which from comparison with the contour plot, appeared to be from the higher
concentration choline and creatine resonances. However, it is entirely possible that
GABA may also have contributed to the peak area, but without a distinct and
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separate contour on the 2D L-COSY plot, such assignment is very difficult. As a
result, it would appear that in its current form, this approach does not have a high
specificity for GABA detection.
(a) (b)
Figure 9.9 Results from the 2D experiment using a phantom containing physiological
concentrations of choline and creatine, and 1.2mM GABA using a 5" surface coil, (a) 2D L-
COSY spectrum and (b) extracted row corresponding to Ft = 1.9ppm. No clear GABA cross-
peak at F2 = 3.01ppm, F1 = 1.9ppm is visible.
In any subjective test, requiring an observer to interpret a set of results, the outcome
of the test will change according to the applied decision threshold. This forms the
basis of receiver operating character analysis, which describes the compromises in
decision making that affect the true positive fractions (TPF) and false positive
fractions (FPF) (163). (A TPF is defined as the ratio of number of true positive
decisions to the number of actual positive cases; Conversely, the FPF is the ratio of
the number of false positive decisions to number of actual negative cases.) In GABA
detection using 2D L-COSY, a "lax" decision could be the simple criterion of the
appearance of a contour at the appropriate cross-peak frequencies that gives rise to a
peak in the extracted spectrum. Applying these principles to Figure 9.9 would enable
a "GABA" peak to be quantified and reported on. Consequently, in this instance and
in general, such relaxed criteria would increase the TPFs and FPFs. A stricter
threshold requiring the "GABA" contour to be distinct from any noise or from
contours arising from neighbouring metabolites, would result in the failure ofGABA
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Therefore, it is vital that an appropriate decision threshold is reached and adhered to,
to allow consistent interpretation of the results.
Despite the poor reproducibility and inconsistent reporting of GABA cross-peak in-
vitro, 2D L-COSY data was acquired in-vivo.
9.6 In-vivo results
9.6.1 Introduction
The aim of this work was to achieve in-vivo GABA measurement using 2D L-COSY.
Despite the issues arising from the in-vitro reproducibility measurements, a protocol
for quantification of GABA from 2D L-COSY spectra had been developed, and it
was prudent to test this in humans. Therefore, the final section of this chapter
presents the results from the in-vivo 2D L-COSY experiments on healthy volunteers.
9.6.2 Methods
Normal, healthy volunteers were recruited and written informed consent was
obtained. Each volunteer was set-up on a 5" surface coil, in a specially designed
headrest allowing immobilisation of the head.
After a series of T2 FSE axial images, a 3x3x3cm VOI was positioned in the
occipital cortex, and a conventional single voxel PRESS experiment performed (TE
= 35ms, TR = 2000ms). Upon acquisition of a well-resolved spectrum, free from
skull-lipid contamination, 2D L-COSY was performed in the same VOI using both
the scan parameters listed in Table 9.1 and those described in §9.4 to increase the
SNR. The resulting raw data was processed as described in §9.2.3.
9.6.3 Results
At the time of writing, only three healthy volunteers had been scanned using the
dedicated 2D L-COSY sequence. By applying the same criteria as for the in-vitro
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data (i.e. a separate contour in the appropriate F1 / F2 intersection, distinct from any
surrounding noise), in only one of the three resulting spectra could an assignment to
the F2 = 3.01ppm and F1 = 1.9ppm GABA cross-peak be made, Figure 9.10 (a). The
extracted spectrum corresponding to this GABA assignment is provided in Figure
9.10(b).
Figure 9.10 (a) 2D L-COSY spectrum from a 3x3x3cm1 VOI placed in the occipital cortex of a
normal, healthy volunteer, (b) Extracted spectrum corresponding to Fl~1.9ppm from the same
volunteer.
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9.6.4 Discussion and conclusions
Following the disappointing in-vitro results, a success rate of only one in three
volunteers is not surprising. In addition to the SNR problems of in-vivo acquisition
discussed in the previous chapter, this may be due to a number of other reasons:
Imperfect optimisation of the signal or voxel shimming during the manual prescan,
insensitivity of the technique to the lowest concentrations of GABA and patient
movement.
However, with successful GABA identification in one subject, it is hopeful that this
result can be repeated. The reliability of the sequence may be improved by
incorporating an automatic prescan, and this would undoubtedly reduce the overall
scan time. This would also decrease the opportunity for patient movement, thereby
enhancing the quality of the spectra. Investigation of the acquisition parameters,
particularly the NEX and total_scans, may offer further improvements to the SNR





GABA measurement at 1.5T is very difficult due to its low concentration, complex
spectrum and the overlapping of higher concentration metabolites, particularly NAA
(1.9ppm), glutamate (2.35ppm) and creatine (3.0ppm). Nevertheless, the ability to
measure GABA with 'H MRS has become an area of increasing interest over the past
decade.
Results from GABA measurement at 1.5T using a variety of techniques have been
published, including difference editing, double quantum filters and 2D methods.
Two-dimensional spectroscopy has the major advantage over spectral-editing
methods of acquiring information about all the metabolites contained within the
sample, thus providing a more complete description of the metabolic status of the
individual.
The aim of this chapter is to draw together the conclusions from three years of work
on 2D J-resolved and 2D L-COSY MRS. Although in-vivo GABA measurement was
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not clinically applied as originally intended, the viability of these techniques as
routine clinical tools will be assessed and suggestions made for improvements in
further work.
10.2 GABA measurement using 2D J-resolved MRS
comprising 64 individual PRESS sequences
Access to highly specific sequences or the skills to write and compile dedicated
programmes, can be the limiting factor in applying non-standard acquisition
protocols outside the research environment. The capacity to review published results
from a technique of interest and then apply it on a standard MRI scanner is
immensely desirable, particularly if it does not require the purchase of a dedicated
sequence. For this reason, 2D J-resolved spectroscopy was performed using a
conventional PRESS sequence.
As described in chapter two, one-dimensional spectroscopy using PRESS
localisation is routinely applied on clinical MRI scanners, particularly when
performing MRS of the brain. It is a straightforward sequence, allowing
uncomplicated prescription of a spectroscopy voxel and selection of the acquisition
parameters, and incorporates an automatic prescan to optimise the spectroscopy
signal and suppress the water. With familiarisation of PRESS and an understanding
of the general principles behind 2D J-resolved spectroscopy, the practical
implementation of 2D J-resolved MRS is achievable, as shown in chapter four.
Requiring a scan time of over 2.5 hours, it was clear from the outset that 2D J-
resolved spectroscopy using 64 individual PRESS sequences was never going to be
clinically viable. However, from a purely scientific viewpoint, it was an interesting
exercise. The resulting 2D spectra from phantoms containing aqueous solutions of
single metabolites compared well to published spectra, thus confirming that accurate
2D J-resolved spectra could be produced without a dedicated sequence.
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With a threshold of in-vitro GABA detection of 1.2mM, well within normal
physiological ranges, these were encouraging results for in-vivo translation.
However, the in-vitro reproducibility results from the high concentration metabolite
peaks of choline, creatine and acetate (in lieu ofNAA) were somewhat disappointing
with coefficients of variation (CV) (defined as the percentage ratio of the standard
deviation to the mean) of between 11% and 13%. As reproducibility is an important
factor in the application of any new technique in-vivo, it was formally addressed in
its own chapter at a later stage in the thesis.
For completeness, this work was taken to its logical conclusion of performing 2D J-
resolved MRS, using a protocol of repeated PRESS sequences, in-vivo. After
setting-up the volunteer in a standard volume head coil, the total scanning time
including imaging and spectroscopy was almost 3.5 hours, emphatically
demonstrating that the protocol could never be applied to patients. Nevertheless, it
was a very worthwhile exercise, permitting a peak assignment to GABA (including a
macromolecule contribution) from the resulting 2D contour plot. This brought the
work to a very pleasing end, showing that 2D J-resolved MRS using 64 individual
PRESS sequences allowed GABA measurement both in-vitro and in-vivo.
Aside from the academic interest of showing that 2D J-resolved MRS could be
performed using a standard, manufacturer provided MRS sequence, the work was
extremely useful in developing the post-processing protocol for the analysis and
quantification of the all the 2D J-resolved data. Ian Marshall wrote the C program
that performed the initial post-processing step, executing functions common to the
processing of most spectroscopy data. This included phase correction, removal of
the residual water peak and scaling of the FID according to VOI size and the pre-
scan parameters. Variations of this program had been used extensively in both
single-voxel and CSI analysis prior to its application in 2D J-resolved MRS, and so
its operation had been well established.
The functions specific to 2D J-resolved spectroscopy, such as 2D Fourier Transform
and apodization of the data were all performed in Matlab, based on a function also
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written by Ian Marshall. Variations of this function, plus the programs required to
convert the data to MRUI format for quantification were written by the author. This
allowed the metabolite peaks in extracted rows from the 2D contour plots to be
quantified using prior-knowledge files, thus standardising the whole procedure.
These principles, once developed and tested for the 2D J-resolved experiments using
64 individual PRESS sequences, were used for the post-processing of data from both
the dedicated 2D J-resolved and L-COSY sequences.
10.3GABA measurement using a dedicated 2D J-resolved
sequence
Collaboration with Dr. N. Sailasuta, a software engineer from GE Healthcare,
permitted evaluation of a dedicated 2D J-resolved sequence. This was based on the
same PRESS sequence used in the protocol described above, modified to allow the
time either side of the second refocusing pulse to be uniformly incremented. Thus
the raw data required for processing both dimensions of the 2D J-resolved
experiment was acquired in a single pulse-sequence. Without the time to load and
prescan each new sequence, the 2D J-resolved experiment that had previously taken
2.5 hours was now accomplished in 35 minutes! This clearly had more scope for
clinical application.
Although the standard PRESS and dedicated 2D J-resolved sequence are
fundamentally the same, a difference in the reference-data acquisition between the
two necessitated a modification of the established post-processing protocol, as
described in chapter five. PRESS routinely acquires water-reference spectra that
were used to phase correct the data using a time domain method introduced by
Ordidge and Cresshull (136). In a time-reducing effort, these water-reference, so-
called "dummy scans", were no longer acquired as part of the dedicated sequence.
Thus, the phase information for correction could no longer be obtained from a water-
only signal. This prompted study of the various phase-correction methods in use for
NMR data and the development of a frequency-domain, phase correction algorithm,
written by the author. However, when tested against the adaptation of the original
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phase correction function used in the post-processing of the standard PRESS
sequence, the time-domain method consistently out-performed the frequency-domain
method and so was implemented as standard.
Initial validation of the dedicated sequence was achieved by repeating a series of
single-metabolite phantom experiments. These resulted in a set of 2D J-resolved
spectra that compared favourably to those acquired using the protocol of repeated
PRESS experiments and results in the published literature. Satisfied with the
performance of the sequence, and that the threshold of GABA detection again fell
within normal physiological levels, further practical work was performed to optimise
the sequence for in-vivo application.
When performing any MRS experiment in-vivo, the aim is to acquire the maximum
SNR of the metabolite(s) of interest in the shortest possible time. To do this, there
are many possible variables that can be optimised, including coil arrangement, VOI
size and position, acquisition parameters and modifications to the post-processing
protocol. Each of these variables was investigated in turn and the results presented in
chapter 6 are summarised below.
Although conventional brain imaging is performed using a volume head coil, the
greater sensitivity associated with the surface coils led to an improved SNR of the
quantified GABA peaks in-vitro. The increased sensitivity was also translated into a
lower threshold of in-vitro GABA detection, from 1,2mM in the volume head coil to
0.8mM in both the surface coils. Results from ID conventional MRS experiments
in-vivo using both a volume head coil and 3" surface coil showed similar
improvements in the SNR ofNAA, further supporting the argument for surface coil
use. Although the best improvement was seen with the 3" surface coil, the larger
excitable volume associated with the 5" surface coil meant that overall, the larger
surface coil was the best overall choice for in-vivo spectroscopy.
Another limiting factor in the overall SNR of the spectra is the size of voxel. In
terms of anatomical definition and selecting specific volumes for excitation, a small
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VOI is often desirable. However, in order to improve the SNR of the spectra,
especially when attempting to measure signals from low concentration metabolites, a
large VOI is required. A series of in-vitro experiments using GABA at a
physiological concentration determined a minimum VOI size of 15cm , after which
GABA quantification broke down due to poor SNR.
As far as the 2D J-resolved sequence is concerned, there are very few parameters that
can be manipulated to improve the sequence performance. Obviously, the actual RF
pulse sequence and timing definitions are fixed. However, the TE range of the
experiment can be optimised, as can the TR and the phase cycling and number of
scans to help with signal averaging. Comparison of the available literature showed
that three main timing arrangements had been used to perform 2D J-resolved MRS
(23,25-27). GAMMA simulations and in-vitro experimental work using these
different timings showed differences in SNR and F1 resolution, with both factors
affecting GABA quantification. Consequently, 64 TE steps uniformly incremented
at 10ms was chosen as a compromise between SNR and an F1 resolution sufficient to
analyse the data at the GABA J-coupling frequency.
With the number of excitations (NEX) controlling the phase cycling scheme adopted,
a NEX of 16 was chosen to improve the signal averaging by phase cycling through
all three RF pulses, twice. Although the increase in NEX from 8 to 16 doubled the
acquisition time, it was considered a sacrifice worth making for the associated
improvement in spectral sensitivity. With in-vivo GABA detection so close to the
threshold of detection using a 1.5T scanner, signal averaging is an important factor in
determining the success of the experiment (21). A similar balance between SNR and
scan time was achieved in choosing a TR = 2000ms.
In-vivo, macromolecule resonances exist at similar chemical shifts and J-coupling
frequencies as the targeted GABA resonance at 3.01ppm. Conventional single-voxel
experiments in-vivo demonstrated that by starting acquisition at TE = 55ms, an
optimum balance between a reduction in macromolecule contribution and metabolite
signal loss in 2D J-resolved MRS was achieved. However, since only an extra
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minute was required to acquire spin-echoes from another 2 TEs (bringing the total
number of TE steps to 66), the final protocol started the 2D acquisition at 35ms.
This facilitated the production of two, 2D spectra: The first (TE 35ms - 665ms) with
and the second (TE 55ms - 685ms) without macromolecule contributions.
Consequently, the spectral changes arising from differences in in-vivo acquisition
timings could be compared.
Before applying the optimised protocol in-vivo, it was tested on a phantom
containing physiological concentrations of all the common cerebral metabolites. At
the J-coupling frequency of GABA and at its chemical shift position, GABA was
clearly identified. Processing the two TE ranges resulted in a decrease in the
3.01ppm GABA peak of approximately 10%. Changes in post-processing were also
explored to demonstrate the affect of acquiring a reduced number of TE steps and
zero-filling compared to the ideal number of 64. On the physiological phantom, this
had a detrimental affect with considerable F1 bleed from acetate, choline and
creatine, which negatively impacted on quantification of the 3.01ppm GABA
resonance. The potential loss of in-vivo GABA signal was deemed too big a risk to
justify the reduced acquisition time, so the protocol remained at 64 (+2 = 66) TE
steps.
The final stage before in-vivo application was a formal reproducibility study of
GABA measurement using 2D J-resolved MRS, chapter seven. This was a large
study comprising 180 individual experiments, and was a crucial part of evaluating
the performance of the technique. Phantoms were made containing physiological
concentrations of choline and creatine - the metabolites with the greatest possibility
of obscuring the 3.01ppm GABA resonance - and GABA at six different
concentrations, covering the entire normal physiological range (164). Three
measures of reproducibility were made: Within-run, within-session and between-
days. From these, indications of scanner stability and errors due to re-positioning in
the same scan session and over several days were obtained. The experiments were
carried out in a combination of volume head coil, 5" and 3" surface coils. As the first
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reproducibility study specific to 2D J-resolved MRS for GABA measurement, it has
significant implications for the interpretation of in-vivo data.
Overall, the results were very encouraging. The CVs were all less than 10% for
choline and creatine for all three measures of reproducibility. Specific to GABA
measurement, a general improvement in reproducibility was seen when using the 5"
surface coil instead of the volume head coil. At the lowest GABA concentration
tested of 0.8mM, a CV of 22.5% was obtained following the optimised protocol.
This is comparable to the only other 2D reproducibility study (20), where a CV of
22% was obtained for in-vivo 2D L-COSY GABA measurement. Although increases
in the CVs are expected with in-vivo translation, these results were an encouraging
point from which to start.
After all the in-vitro validation and optimisation of the 2D J-resolved sequence and
its associated post-processing, the in-vivo results were disappointing, although they
were comparable to those in the published literature (24,27), chapter eight,
ffowever, in the first reported 2D J-resolved experiments specifically designed to
reduce the macromolecule contribution to the 3.01ppm GABA peak, the resulting
GABA peaks were far from convincing. This suggested that the "GABA" peak, as
identified in the literature using a starting TE of 35ms, comprised largely of
macromolecules, and so prevents accurate GABA measurement. The lack of a
distinct GABA-only peak in-vivo prevented the application of 2D J-resolved MRS to
the patient population for which it was originally intended.
Results from 2D J-resolved experiments performed on a 3T scanner by Dr. Sailasuta
at GE Healthcare and processed by the author failed to yield any "GABA" peak,
even with a starting TE of 35ms. The failure of 2D J-resolved MRS to produce
spectra even similar to those at 1.5T was attributed to the very poor quality of the
spectra. However, with equally unremarkable results from an attempt to perform
GABA CSI using 2D J-resolved MRS on a 4T system, as presented at the most
recent scientific meeting of ISMRM (165), it would suggest an inherent SNR
problem with using 2D J-resolved MRS for GABA measurement at medium fields.
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10.4GABA measurement using a dedicated 2D L-COSY
sequence
As an alternative to 2D J-resolved MRS, 2D L-COSY was evaluated as a method for
in-vivo GABA measurement at 1.5T, chapter nine. This was achieved using a
dedicated sequence as provided by Dr. M.A. Thomas, from which in-vivo GABA
results had been previously published at both 1.5T and 3T (21,133).
Correlation patterns in the 2D L-COSY spectra resulting from experiments on
individual metabolite phantoms were similar to those predicted by the literature, thus
validating the technique as a whole. However, it became clear in a very early stage
of the experimental work that the theoretical scan time of 25 minutes could never be
practically achieved due to the required manual pre-scanning. As a crucial step in
the process of acquiring 2D L-COSY spectra, optimisation of the prescan parameters
could take an additional 30 minutes, immediately raising questions regarding the
clinical applicability of the method without an automated pre-scan.
Unlike the 2D J-resolved experiments when an in-vitro GABA threshold of 0.8mM
was detected using a 5" surface coil, GABA was only convincingly detected in
similar phantom experiments at a concentration of 1.2mM. This suggests that 2D L-
COSY is not as sensitive as 2D J-resolved MRS for in-vitro GABA measurement,
and so would only be able to detect the upper limits of normal physiological
concentration when applied in-vivo.
Of much greater concern was the poor reproducibility of 2D L-COSY when
compared to 2D J-resolved MRS and similar results in the literature. Of the high
concentration metabolites, a CV of 22.7% was obtained for the within-run, in-vitro
choline diagonal, compared to 2.2% in a corresponding reproducibility study by
Binesh et al (20). Using 2D J-resolved MRS, CVs < 10% were acquired for choline
in the J = 0Hz extracted spectrum. Such results raise questions about scanner
performance and specifically to the 2D L-COSY experiments, the operator
dependency on the manual pre-scan. The variation in pre-scan optimisation also
contributed to the larger number of 2D L-COSY spectra where in-vitro GABA
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detection failed as compared to 2D J-resolved MRS. With such poor results obtained
in a homogeneous, motionless phantom, they do not suggest that reliable GABA
measurement will be immediately forthcoming in-vivo. Further evidence for this
view was obtained when in only one of the three volunteers scanned could the F2 =
3.01ppm, F1 = 1.9ppm GABA cross-peak be identified.
10.5 Conclusion
2D GABA measurement should only be applied routinely in-vivo if it has been
shown that accurate and reproducible measurements can be made. In-vitro, 2D J-
resolved MRS is a sensitive and reliable technique for GABA measurement, but
these results were not reproduced in-vivo. In comparison, 2D L-COSY has not
shown itself to be as robust or sensitive in any of the in-vitro or in-vivo experiments,
but this may be due to the operator-dependant manual pre-scan. Thus, in their
current form, pure GABA measurement using either of these 2D techniques at 1.5T
is not suitable for routine clinical use. The absence of convincing results from the
spectral editing methods reported at 1.5T (13,14,16,19,103) would also suggest that
measurement of normal, physiological GABA levels on the current breed of clinical
scanners is not viable. However, it may be possible to identify GABA in patients
with elevated GABA concentrations (27).
10.6 Future work
In order for 2D J-resolved MRS to be successfully applied for in-vivo GABA
measurement, a stable, high-field magnet (> 1.5T) is essential. However it is not
clear to what extent the field strength needs to be increased before GABA can be
reliably identified. Despite reports ofGABA measurement at 1.5T (22-26), in an in-
vivo 2D J-resolved MRS rat study at 4.7T, no spectral assignment was made to
GABA (166). This is in spite of an assignment to taurine, which exists in-vivo at a
concentration of approximately 1.5mM (7) - a comparable level to GABA. At 3T,
conflicting results have been obtained using 2D L-COSY with in-vivo GABA
assignments reported by Thomas et al (130) yet not by Zielger and co-workers (118).
Another hardware requirement is higher order shimming to improve the linewidths of
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the in-vivo spectra is required to improve the appearance of the 2D spectra and
associated extracted rows. Application of multi-channel array coils may also
improve the SNR or allow a reduction in the scanning time (167). Post-processing
techniques may also improve the appearance of the spectra. Although a basic zero-
order phase correction algorithm reduced fi noise from the main metabolites singlets
as shown in chapter five, a first or higher order algorithm may further reduce any F1
bleed. Alternative apodization functions designed to suppress the dispersion of the
magnitude mode spectra may lead to improvement in the F1 resolution. In addition,
adaptations of other fitting programmes such as LC Model (105) or FELIX
(Accelrys, San Diego, CA) may facilitate the quantification of GABA based on
model solutions of the individual metabolites. However, careful consideration will
need to be given to the differences between in-vivo and in-vitro data as described in
chapter eight.
Similar developments may also benefit GABA detection with 2D L-COSY, although
it is expected that an immediate improvement in the reliability of the sequence would
be observed with the development of an automatic prescan.
Results from the literature suggest that more convincing GABA results may be
possible at higher fields using 2D L-COSY (133) and spectral editing techniques
(106-108,110,111). With 3T scanners becoming more commonplace in the clinical
environment, there are exciting opportunities to establish the accuracy and reliability
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